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1 
Introduction 1 
1.1 Cost-of-illness studies 
Over the past decades health economics has emerged as a new scientific discipline. 
From the very beginning the field has continued to expand and take on increasing 
significance. An important focus is on the economic evaluation of health care 
facilities withln the area of Medical Technology Assessment (MTA) or Health 
Technology Assessment (!ITA). Other topics studied by health economists regard 
among others the demand for care, the role of health insurance, the industrial 
organisation of the health care sector and the international comparison of health 
care systems. 
Cost-of-illness (COl) studies have also attracted the attention of health 
economists. Since the pioneering work of Dorothy Rice in the United States in the 
Sixties [Rice 1966], cost-of-illness data have been published for several countries. 
There is, however, some controversy about the results. Physicians and 
policymakers frequently ask what the often very large financial estimates for costs 
of specific diseases mean and how reliable, valid and useful they are. This thesis 
focuses on COl studies. We will start with a few definitions [Rice 1994]. 
1.2 Definitions 
Disease-specific and general COl studies 
Cost-of-illness studies so far can be divided into two types: disease-specific studies 
and general studies. In disease-specific COl studies, all relevant costs of one 
disease are combined to cover total costs of the disease. Disease-specific studies 
usually follow a bottom-up methodology using patient-based information on 
health care consumption and corresponding unit prices. Disease-speqfic studies 
may be cross-sectional or longitudinal. Cross-sectional studies use annual 
expenditure data from all health care sectors. Costs per disease category are 
estimated by aggregating these data for all patients in all sectors. In longitudinal 
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studies life long expenditures are estimated by following patients or patient groups 
during the course of time. 
Most COl studies belong to the disease-specific category. Examples include the 
costs of ntigraine [Osterhaus 1992, Lissovoy 1994], depression [Greenberg 1993], 
astbma [Krahn 1996], rheumatoid anhritis [Magnusson 1996], diabetes mellitus 
[Warner 1996], and neck pain [Borghouts 1999]. Marc Koopmanschap compiled 
an overview of a number of major disease-specific COl studies [Koopmanschap 
1998]. In some studies health care costs are further allocated to risk factors. These 
'cost-of-risk-factor' studies usually include all costs of diseases that are caused by 
important risk factors as smoking [Barendregr 1997, 1999] and cholesterol 
[Bonneux 2000]. In this kind of studies also the costs and possible savings of 
preventing major diseases can be studied [Bonneux 1998]. 
General cost-of-illness studies describe total health care costs for different 
diseases using a common top-down methodology. These studies usually cover the 
whole range of diseases of the International Classification of Diseases (lCD). 
Because all diseases are aggregated in major categories, general COl studies use 
much broader disease definitions than disease-specific studies that in some cases 
only regard some particular lCD codes. 
General COl studies are cross-sectional, describing the annual costs of all 
people with the disease in a certain year. The top-down methodology generally 
consists of four steps. First, total health care costs are broken down into more or 
less homogeneous sectors. Second, key variables are defined per sector, 
representing equal units of care, for instance hospital days and visits to outpatient 
clinics. In the third step, disease-specific data on health care utilisation is collected 
for each sector, for instance from national registries and surveys. The numbers are 
used for the construction of a 'probability map', which in the fourth step is applied 
to the sector costs, resulting in a distribution of costs by diagnosis. These basic 
steps of the top-down methodology will be explained further in Chapter 2 and 
appendix A. 
This thesis focuses on general COl studies. Disease-specific studies only play a 
ntinor role in highlighting the findings of general studies and their comparisons. 
Incidence-based or prevalence-based 
In epidemiology distinction is made between incidence and prevalence of a 
disease. Disease incidence relates to the new cases of the disease in a certain year. 
Disease prevalence regards all cases of the disease in a certain year irrespective 
whether the patients got the disease in that particular year or earlier. 
Cost-of-illness studies can be based on incidence or prevalence. Lifetime costs 
for a certain disease are represented by incidence-based COI figures, including all 
cases vv:ith onset of the disease in a given base year. All costs during the course of 
the disease, which might last for several years, are included and require 
longitudinal data. Prevalence-based COl studies estimate the econontic burden of 
one or more diseases during a certain period of time, usually a year, as a result of 
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the prevalence of the disease. This approach measures the value of resources used 
during a specified period of time. 
The approach adopted depends on the concept and the purpose of the study. 
General CO! studies are always cross-sectional and therefore prevalence-based. 
Disease-specific studies can be either prevalence-based or incidence-based. If the 
results are to be used for an insight in the distribution of costs or for cost 
containment "Within a limited time span, the prevalence-based method is 
appropriate, since this approach identifies the main components of current health 
expenditure. If the analysis is aimed at making decisions about the choice of 
treatment or research strategy to implement from the perspective of efficiency, the 
incidence method is more appropriate because it provides the basis for predictions 
about the likely savings from programmes that reduce incidence or improve health 
status. Only a relatively small number of disease-specific studies, however, is 
incidence based [Koopmanschap 1998]. 
Disease and comorbidity 
Another issue is whether the COl study regards only primary diagnosis or also for 
secondary diagnoses. Two categories must be distinguished. 
The first category consists of diseases that are related by a common causal 
background, but are classified separately in the disease classification. A good 
example is diabetes mellitus, which is an underlying disease for heart disease, eye 
disorders and some other diseases as renal insufficiency. Hepatitis infections, 
which can cause acute liver insufficiency and cirrhosis, are another example. The 
existence of causal morbidity and mortality pathways is the main characteristic of 
this category. In a disease-specific COl study all costs will be attributed to, for 
instance, diabetes using primary and secondary diagnoses. In a general CO! study, 
however, all diseases are included and only primary diagnoses are used in order to 
avoid double counting. As a consequence of the codification rules for morbidity, 
costs of heart diseases, for instance, are classified among heart diseases, whether 
they are caused by diabetes or not. According to the International Classification of 
Diseases (ICD), morbidity registrations are based on the diseases that are held 
responsible for the actual health care need and use. So in hospital registrations 
heart diseases or eye disorders are registered as causes of health care use, 
irrespective of underlying diseases such as diabetes. As a result cost estimates of 
general and disease-specific CO! studies can differ substantially. It is important to 
mention that mortality registrations are based on different rules. According to the 
ICD always the underlying disease must be mentioned as primary cause of death. 
So in the example of diabetes all deaths must be registered under diabetes, while 
substantial parts of health care use and costs are attributed to heart disease and 
others. 
The second category consists of diseases that are not causally related. Two 
variants can be distinguished: diseases that mutually influence the medical 
prognosis and diseases without such an interaction. In most cases this type of 
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comorbidity will increase health care needs and health care consumption. In some 
cases it is clear whether health care consumption relates to a particular disease or 
another. In other cases the distinction is less obvious. But in all cases costs are 
attributed to primary diagnosis. Hospital costs, for instance, are allocated to 
disease categories according diagnoses at discharge. In this way all costs from . 
admission until discharge are attributed to primary diagnosis, although some costs 
might be caused by comorbid conditions or complications of treatment. As a result 
the costs of, for instance, chronic ulcers of the skin, sepsis and chronic disabling 
diseases such as dementia are underestimated, while costs of more acute diseases 
are overestimated. In theory disease~specific COI studies could reckon with this 
problem using detailed data on health care consumption per patient. In practice it 
would be very difficult to disentangle the different causes of health care use from 
hospital registrations. In general CO! studies this problem can partially be solved 
by specifying some well-known complications as chronic ulcers of the skin as 
second axis for diagnosis. In general, however, COI srudies can not deal with this 
problem, and hence will always incorporate some opacity that is inherent to their 
concept and methodology. 
In this thesis comorbidity mainly refers to the second category consisting of 
diseases that coincide without a causal pathway. 
Direct and indirect costs 
Health economics theory distinguishes direct and indirect costs. Direct costs relate 
to the resources for which investments are made, whether they are paid or not. So 
direct medical costs relate to the value of all resources that are employed in the 
health care system, including informal care, because these resources are directly 
involved in the process of care-giving, such as prevention, diagnostics, treatment, 
rehabilitation and nursing. Direct costs may also include non-health care costs 
such as, for instance, travelling costs paid by patients. 
Indirect costs consist of investments indirectly related to the disease and also 
to resources that are lost or assumed to be lost due to the disease. These costs 
refer to, for instance, costs of specialised schools for children with intellectual 
disabilities and judicial costs of criminals with mental disorders. Most attention is 
given to the economic consequences of lost producti'Vity and absence from work 
due to morbidity, disability and monality. Health economists generally adopt two 
approaches to estimate these so-called 'productivity costs': the human capital 
method [Scitovsky 1987], and the friction-cost method [Koopmanschap 1995]. 
Other, less dominant approaches estimate indirect costs in terms of willingness-to-
pay [Mishan 1971] or quality-of-life [Gold 1996, Brouwer 1997]. 
Disease-specific COI srudies usually include both direct and indirect costs. In 
these srudies the human capital method is favourite for estimating indirect costs. 
Some general COI srudies, too, provide estimates of indirect costs, for instance for 
Canada [Moore 1997] and Sweden [Jacobson 1996]. Other studies only deal with 
direct medical costs, for instance for Australia [Mathers 1998], or at the most 
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specify absence from work and mortality as quantities, as has been done for the 
Netherlands [Koopmanschap 199.1, Polder 1997]. In this thesis, we focus on direct 
medical costs, ignoring direct non-health care costs and indirect costs. 
In summary this thesis regards: 1) general cost-of-illness studies that; 2) are 
prevalence based; 3) focus on primary diagnosis; and 4) only comprise direct 
medical costs. 
1.3 Overview of published COl studies 
Dorothy Rice published the first general cost-of-illness study [Rice 1966]. She 
allocated the United States' health expenditure in 1963 to 16 major disease 
categories in accordance with the International Classification of Diseases (8th 
revision, ICD-8). This pioneering study was updated and extended for the United 
States in 1972 [Cooper 1976] and in 1980 [Hodgson 1984, Rice 1985]. 
In Europe the first CO! study was performed by Bjorn Lindgren and his 
colleagues. In 1981 Lindgren published CO! estimates for Sweden in 1964-1975 
[Lindgren 1981]. The figures were updated for 1980 [Lindgren 1990] and 1991 
[Jacobson 1996]. Other countries followed. Hemminki constructed CO! figures for 
Finland in 1972 [Hemminki 1977]. In Germany, CO! estimates were published for 
1980 [Henke 1986], 1990 [Henke 1997] and 1994 [Schneider 1999]. 
In Canada, CO! figures were published for 1986 [Wigle 1991] and 1993 
[Moore 1997]. In Australia, CO! studies were performed for 1989-90 [AIHW 
1996] and 1993-94 [Mathers 1998]. COl figures for England in 1993- 94were 
published within the scope of a broader burdens-of-disease study [NHS 1996]. The 
OECD Health Data further contain COl estimates for Japan, Korea and Spain 
[OECD 1998]. 
In the Netherlands a study group in Rotterdam compiled CO! estimates for 
health expenditure in 1988 [Koopmanschap 1991, 1994]. By comparison their 
study was very comprehensive in two respects. First, total health expenditure was 
included in the CO! study. In other words: the results added up to known totals. 
Second, all costs were simultaneously and by the same methods allocated to 
diagnosis, age and sex. The study was updated and extended for 1994 [Polder 
1997, Meerding 1998]. At the time of finishing this thesis (Spring 2001), a new 
study is being performed in co-operation with the National Institute for Health and 
Environment (RIVM). In this study CO! estimates for 1999 will be constructed, 
including topics such as comorbidiry and health care costs in the last year of life. 
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1.4 Objectives of COl studies and possible applications 
The objectives of COI studies and their applications can be summarised under 
three headings: description, comparison and projection [e.g. Black 1975, Hodgson 
1989, Davey 1992, Drummond 1992, Ament 1993, Rice 1994, Roijen 1997, 
Koopmanschap 1998, Byford 2000, and Rice 2000]. 
Description 
The first and major objective is to identify and measure all costs of a disease. 
We have seen in the above that disease-specific studies focus on one or more 
particular diseases, whereas general studies assign the whole health care budget to 
disease categories and in this way provide a kind of epidemiological description of 
total health expenditure. By using monetary value as a universal numerator COI 
studies give a summarising overview of health care utilisation and provide a single 
index of the economic burden of disease (BOD) complementary to other estimates 
based on incidence or mortality. 
COI studies tell how much society is spending on one or more diseases. Some 
authors argue that COI studies by implication give an idea about the amount of 
money that would be saved if the diseases were eradicated [Byford 2000]. 
Although complete eradication of major diseases is unlikely, COl studies combined 
with information on prevention or curability of diseases can help to identify the 
main cost components of health expenditure as well as the areas where savings 
can be made. These savings, however, must be interpreted very carefully, because 
the eradication itself requires investments that can become quite high. 
Furthermore the prevention of fatal diseases likely will result in more chronic 
disabling conditions with high costs [Bonneux 1998]. 
In combination with data on effectiveness of treatment and normative views 
on health care and its objectives COl studies can also be used to justify the actual 
health care budget or expenditure on specific treatment programs for particular 
diseases. COl data thus provide a basis for health care policy and might assist 
planning of health care facilities. 
COl studies furthermore provide a kind of Pandora's box that can be used and 
misused by numerous stakeholders. Patients' associations adopt COI figures to 
advocate their interests, whereas the health care industry, especially 
pharmaceutical companies, use cor data for marketing purposes. cor figures are 
then employed to demonstrate potential benefits of new drugs that are claimed to 
replace more expensive conventional treatment. 
cor studies also provide an economic framework for program evaluation. 
Mainly incidence-base9. studies estimate baseline data that can be used to 
undertake more sophisticated and more expensive economic and clinical 
evaluations. 
It is also claimed that COl figures can help policy makers to determine 
priorities in medical research [Black 1975]. Although cost data can not be 
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substituted for important other aspects, such as a knowledge of scientific 
opportUnities, the American National Institutes of Health optimistically stated that 
'COl estimates can help decision-makers in Congress and Administration anticipate 
and respond to public interests' [Varmus 2000, Rice 2000]. 
Comparison 
Since more COI studies are available results can be compared. Comparisons can be 
made betvveen studies performed at different periods in a particular country. In 
this way trends in health care costs can be studied from an epidemiological and 
demographic perspective. Comparisons can also be made across countries trying to 
trace potential differences in the prevalence of diseases and the way they are 
treated. 
Projection 
COl figures can be employed in demographic and epidemiological scenarios to 
make projections of future health care costs. A prerequisite is that the CO! study 
distinguishes sufficient age and sex categories. In combination with population 
forecasts a demographic projection of future health care costs can be performed 
assuming no changes in epidemiology and health care technology. Epidemiological 
models such as multi-state lifetables can be used for more sophisticated 
projections that reckon vvith changes in incidence and prevalence of certain 
diseases. In these models COl figures can be used to calculate the consequences of 
the assumed developments on health expenditure. 
COl studies, in summary, are primarily aiming at describing health care costs from 
an epidemiological and demographic perspective. Insights become better if 
comparisons over time and across countries are made. COl estimates can also be 
used in a prospective way by combining estimates for one particular year with 
demographic and epidemiological forecasts to project future health care costs. The 
results of COl studies can play an important role in more normative debates on 
health care and its future. 
1.5 Objectives of this thesis 
The objectives of this thesis are: 
1. To explain the construction, application and interpretation of general cost-of-
illness studies; 
2. To discuss the advantages and limitations of general cost-of·illness studies 
with respect to the objectives of description, comparison and projection. 
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1.6 Outline of this thesis 
This thesis contains seven chapters that, vvith the exception of Chapter 7, all relate 
to the research project 'Costs of illness in the Netherlands 1994', which was 
financially supported by the Ministry of Health. 
Because the chapters in this thesis were designed as independent papers and 
are reprinted here without alterations, some overlap was inevitable, especially 
between Chapters 2 - 4 and 6. 
Outline 
This thesis consists of four pans. The focus in Pan I is on general descriptions, 
comparisons and projections. Chapter 2 summarises cost of illness in the 
Netherlands in 1994. In Chapter 3 a comparison is made with the earlier study on 
1988 [Koopmanschap 1991]. This chapter focuses on developments per disease 
category. Chapter 4 deals with the detenninants of increases in health 
expenditure, and provides a simple projection for future health care costs. 
Pan II contains more detailed studies. In Chapter 5 further comparisons 
between 1988 and 1994 are made, now focusing on age-specific trends. These 
trends are demonstrated vvith comprehensive and detailed data on hospital 
admissions, interventions and length of stay per age category. Chapter 6 deals 
with the costs of inteliecrual disability, one of the disease categories with highest 
costs. Chapter 7 reports on the costs of treatment and rehabilitation after hip 
fracture. This chapter was written within the scope of a cost-effectiveness analysis 
in which alternative discharge policies from hospital after hip fracture were 
studied. Chapter 7 contains the unabridged, original paper. The implications of 
this study for the COl field wili be discussed in Chapter 9. 
In part III the COl study for the Netherlands is compared to similar studies for 
five other countries (Chapter 8). Pan IV contains a general discussion on cost of 
illness given the objectives of this thesis and the findings in Chapters 2- 8 
(Chapter 9). 
Part I 
General descriptions, 
comparisons and projections 
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Abstract 
Objectives To determine the demands on health care resources caused 
by different types of illnesses and variation witb age and sex. 
Design Information on healtb care use was obtained from all healtb 
care sectors of the Netherlands. Most important sectors 
(hospitals, nursing homes, inpatient psychiatric care, and 
institutions for tbe mentally disabled people) have national 
registries. Total expenditures for each sector were sub-
divided into 21 age groups, sex, and 34 diagnostic groups. 
Setting The Netberlands, 1994. 
Outcome measures Proportion of health care budget spent on each category of 
disease and cost of health care per person at various ages. 
Results After the first year of life, costs per person for children were 
lowest. Costs rose slowly tbroughout adult life and increased 
exponentially from age SO onwards till tbe oldest age group 
(9S+ ). The top five areas ofhealtb care costs were mental 
retardation, musculoskeletal disease (predominantly joint 
disease and dorsopatby), dementia, a heterogeneous group 
of otber mental disorders, and ill-defined conditions. Stroke, 
all cancers combined, and coronary heart disease ranked 7, 8 
and 10, respectively. 
Conclusions The main determinants of health care use in the Netherlands 
are old age and disabling conditions, particularly mental 
disability. A large share of tbe healtb care budget is spent on 
long-term nursing care, and this cost will inevitably increase 
further in an ageing population. Non-specific cost 
containment measures may endanger the quality of care for 
tbe old and mentally disabled people. 
Key messages 
1. Little is known about demands for health care outside acute sectors. 
2. In tbe Netberlands healtb costs are strongly age dependent, increasing 
exponentially afrer age SO. 
3. The five highest healtb care costs are for mental retardation, musculoskeletal 
disease, dementia, other mental disorders and ill-defined conditions. 
4. Corona:ry heart disease, all cancers, and stroke accounted for only 9% of costs. 
5. The main health care costs are for care not cure; costs are likely to increase 
rapidly in an ageing society. 
British MedicalJournal1998;317:111-115. 
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the Netherlands 1994 
2.1 Introduction 
11 
2 
The debate on containing the cost of health care is mainly focused on the supply 
side and the financing of health care [Aaron 1990]. Little attention is given to 
changes in population health, which is another important determinant of costs. 
This may be because the relation between disease and costs is not straightforvvard 
and relevant data are often lacking. We therefore subdivided total health care 
costs in the Netherlands by health care sector, diagnosis, age and sex to determine 
which illnesses and age groups have the greatest demand for care. The Dutch 
health care budget is ideal for this rype of analysis since the countty is smal~ more 
than 99% of its population has full health insurance coverage, and, because of a 
longstanding administrative tradition, most health care sectors have excellent 
registries, of which the most important are national. The completeness of Dutch 
health care data has enabled not only acute care sectors but also those sectors that 
deliver long-term care to disabled people to be included. Long-term care is rarely 
included in other studies [Lubitz 1995, NHS 1996, Moore 1997], which 
consequently underestimate the high costs of disabling disease. 
2.2 Methods 
We performed a prevalence-based cost-of-illness study including all direct medical 
costs in the Netherlands. We used data on health care costs for each care sector 
from the Ministty of Health for 1994 (table 2.1) [Ministerie VWS 1996]. 
Additional personal expenditures, such as over the counter medication and 
spectacles (6o/o of all costs) were not included. 
We clustered the diagnoses of the International Classification of Diseases (!CD, 
9th revision) into 34 diagnostic groups, which can be regrouped into the 17 
chapters of the !CD (table 2.2) [WHO 1977]. We defined groups of diagnoses to 
minimise misclassification between diagnostic groups and so that each group 
would be large enough to describe a sufficiently large proportion of health care 
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costs. Conditions that could not be related to a specific diagnostic group but that 
are unambiguously related to a specific functional system (cardiovascular, 
respiratory, mental, etc.) were assigned to the remainder group of that specific 
!CD chapter. ill-defined conditions which could not be related to a specific !CD 
chapter were classified as 'Symptoms and ill-defined conditions' (I CD chapter 16). 
This is particularly relevant in primary health care, where patients present with 
problems, not diagnoses and physicians function as gatekeepers. To avoid double 
counting, we have considered only primary diagnoses. 
Table 2.1 Percentage of health care budget spent on different sectors of care in the 
Netherlands, 1994 
Health care sector 
Hospital care 
Nursing homes 
Homes for the elderly 
- medical costs 
- living costs 
Psychiatric care 
Institutions for mentally and physically disabled people 
Primary medical and paramedical services (excluding dental care) 
Dental care 
Pharmaceutical care 
Home care and other small sectors 
Health care administration 
% of total * 
32.1 
8.9 
3.7 
5.4 
7.1 
8.6 
5.7 
4.0 
8.8 
10.4 
5.3 
* Health care spending in 1994 was 59.5 billion guilders(£ 21.3 billion,$ 32.7 billion), 9.7% of 
gross national product. 
Of all health care costs, 8.1% could not be allocated to any diagnostic group 
because of insufficient information from some smaller health care sectors and 
5.3% are for health care administration and are not related to specific health 
problems. Together with the living costs in homes for the elderly, these costs were 
assigned to non-specific health care costs. 
For each health care sector we identified key variables that are representative 
of health care use in that sector, such as days of stay for nursing costs in hospitals 
and nursing homes, or outpatient visits for costs of outpatient hospital care. We 
divided each sector by sex, 21 age groups (0, 1 -4, 5-9, 10- 14, ... , ;,:95 years), 
and 34 diagnostic clusters to give 1428 cells. We considered the distribution of the 
costs to be the same as the distribution of the key variable for that sector. Thus, for 
each health care sector costs for each combination of age, sex and diagnostic 
group were calculated as the proportion of the key variable in the relevant cell 
times the total costs for the sector. 
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Table 2.2 Diagnostic groups used in the study and corresponding ICD-9 code 
reo chapter Diagnostic group ICD codes 
Infectious and parasitic Infections 1-139 
II Neoplasms Cancers 140-208 
Benign neoplasms 210-239 
III Endocrine, metabol!c and Diabetes 250 
nutritional diseases Other endocrine diseases 240-279 
N Blood and blood-forming Blood diseases 280-289 
v Mental disorders Dementia 290 
Schizophrenia 295 
Depression/anxiety 296, 300 
Alcohol/drugs 291-2, 303-5 
Mental retardation A 317-319, 758.0 
Other mental disorders remainder 290-316 
VIa Nervous system Neurologic diseases 320-359 
Vlb Sense organs Eye disorders 360-379 
Ear disorders 380-389 
Vli Circulatory system Hypertension 401-405 
Coronary heart diseases 410-414 
Heart failure 428-429 
Stroke 430-438 
Other circulatory diseases remainder 390-459 
VIII Respiratory system Asthma & COPD 490-496 
Other respiratory diseases 460-489, 497-519 
IX Digestive system Dental diseases 520-529 
Gastro-Intestinal diseases 531-569 
Liver, gall and pancreas dis. 570-579 
Xa Urinary system Urinary diseases 580-599 
Xb Genital organs Genital diseases 600-629 
XI Pregnancy & childbirth B Pregnancy 630-676 
XII Skin diseases Skin diseases 680-709 
XIII Musculoskeletal system Musculoskeletal diseases 710-739 
XIV/x:-1 Perinatal/congenital B Perinatal/congenital dis. 740-779 
x:-/I Symptoms, Ill-defined Ill-defined conditions 780-899 
XVII Accidents Falls E880-888 
Other accidents E800-879, 
E890-999 
Not allocated 
Non-specific c 
A. Down's syndrome is classified in ICD chapter XV. code 758.0. 
B. Hospital costs of healthy babies (boys and girls) after childbirth were assigned to pregnancy and 
childbirth (women). 
C. Costs of health care administration and living costs in homes for the elderly. 
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The probability distribution of key variables was derived from sector specific 
registries and sample surveys. Detailed information about the registries and the 
key variables used is available in a report (in Dutch) [Polder 1997] and in 
appendix A. 
2.3 Results 
Total health care costs, representing 9.7% of the Dutch gross national product, 
were£ 1381 ($ 2124) per capita in 1994, £ 1613 ($ 2481) for women and£ 1144 
($ 1760) for men. The distribution is strongly age dependent (figure 2.1). 
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Figure 2.1 Total and per capita health care costs by age and sex for hospital and long· 
term care in the Netherlands, 1994. Long-term care indudes nursing homes, 
homes for the elder(y, institutional care for disabled people, and appliances to 
assist disabled people. In 1994: $ 1 = £0.65 ($1 = £ 0.83). 
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Table 2.3 Health care costs by diagnostic group and sex, the Netherlands 1994, ranked 
by share (in % of total health care costs) 
Rank Diagnostic group A Men Women Total 
1 Mental retardation, Down's syndrome 11.0 6.0 8.1 
2 Musculoskeletal diseases 5.4 6.4 6.0 
3 Dementia 2.9 7.4 5.6 
4 Other mental disorders 5.4 4.7 5.0 
5 Ill~defined conditions 4.6 5.0 4.8 
6 Dental diseases 4.9 3.8 4.2 
7 Stroke 3.0 3.4 3.2 
8 Cancers 3.7 2.8 3.2 
9 Pregnancy 0.0 4.3 2.6 
10 Coronary heart diseases 3.9 1.5 2.5 
11 Neurologic diseases 2.6 2.3 2.4 
12 Other circulatory diseases 2.8 2.1 2.4 
13 Other respiratory diseases 2.9 1.9 2.3 
14 Other accidents 2.8 1.9 2.3 
15 Depression and anxiety 1.8 2.6 2.3 
16 Falls 1.3 2.4 2.0 
17 Gastrointestinal diseases 2.4 1.6 1.9 
18 Asthma & COPD 2.4 1.2 1.7 
19 Eye disorders 1.7 1.7 1.7 
20 Liver, gall, and pancreas diseases 1.7 1.6 1.7 
21 Skin diseases 1.7 1.6 1.6 
22 Genital diseases 0.9 1.9 1.5 
23 Schizophrenia 2.1 1.0 1.4 
24 Urinary diseases 1.3 1.3 1.3 
25 Infections 1.5 1.2 1.3 
26 Hypertension 1.3 1.3 1.3 
27 Diabetes 1.1 1.4 1.2 
28 Ear disorders 1.4 0.9 1.1 
29 Heart failure 1.1 1.1 1.1 
30 Perinatal I congenital diseases 1.4 0.9 1.1 
31 Alcohol and drugs 1.4 0.4 0.8 
32 Benign neoplasms 0.5 0.9 0.7 
33 Other endocrine diseases 0.4 0.8 0.6 
34 Blood diseases 0.3 0.3 0.3 
Not allocated 7.2 8.8 8.1 
Non-specific 6 9.1 11.7 10.7 
Total 100.0 100.0 100.0 
Share of men and women in total costs (%) 41.0 59.0 100.0 
A See table 2.2 for !CD codes of all diagnostic groups. 
B. Costs of health care administration and living costs in homes for the elderly. 
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Costs are relatively high in the first year of life, reflecting the high costs of 
perinatal care, but than drop to the lowest levels in childhood. During adulthood 
costs increase slowly, and after age 50 they start to increase exponentially up to 
the highest age group (;,95). The higher share in total costs of women (59%) is 
predominantly caused by their longer life expectancy, the higher prevalence of 
women in nursing homes and homes for elderly people, and the high costs of 
reproduction (including contra-conception and diseases of the genital organs). 
Table 2.3 shows the share in total costs of diagnostic groups by sex. A high 
proportion of health care costs are for mental disorders. Mental retardation ranks 
1, dementia ranks 3, depression and anxiety ranks 15, schizophrenia 23, alcohol 
and drug misuse 31, and the heterogeneous remainder group of mental disorders 
ranks 4. All mental disorders together cover 28.4% of the health care budget that 
could be allocated to diagnostic groups. Ill-defined conditions, which include 
many psychosomatic problems, rank 5. Musculoskeletal diseases (predominantly 
all types of arthritis) rank 2. Dental diseases (predominantly dentists' costs) rank 
6. The main causes of death -that is, stroke, all cancers combined, and coronacy 
heart disease- rank 7, 8 and 10, respectively. Among women, costs of 
reproduction rank 6. 
Table 2.4 shows the 15 diagnostic categories with the highest health care 
expenditure for five age groups. In all age groups either mental retardation or 
dementia is the main health care cost. In children cognitive disability ranks second 
but congenital diseases also cover many mentally disabling conditions. Among 
younger adults (age 15- 44) the heterogeneous remainder group of mental 
disorders is second and schizophrenia, depression, and alcohol and drug related 
problems all rank among the top 15. Musculoskeletal diseases rank among the top 
five in all age groups after age 14, and iii-defined conditions rank among the top 6 
in all age groups. In the oldest age group (;,85) stroke is second and accidental 
falls (predominantly hip fractures) third. All cancers reach the top five only in the 
65-84 age group and coronaty hean disease only in middle age (age 45- 64). 
2.4 Discussion 
In the Netherlands health care costs are dominated by old age and by disability, 
particularly mental disability and musculoskeletal diseases. The amount of the 
health care budget spent on the maln fatal diseases is relatively modest: all 
cardiovascular diseases and all cancers, which together cause 67% of all deaths, 
account for only 17% of all health care costs that can be allocated to a diagnostic 
group. 
These results have to be interpreted with caution. Less attention should be 
paid to the exact share of costs spent on each separate diagnostic group than to 
the patterns of distribution which emerge ftom this data. Firstly, the key variables 
Table 2.4 Fifteen diagnostic groups* accounting for the highest percentage of health care costs for five groups, the Netherlands 1994 
age0-14 age 15-44 age 45-64 age 65-84 age ~85 
Rank Diagnostic group % Diagnostic group % Diagnostic group % Diagnostic group % Diagnostic group % 
1 Per I natal{ cong en Ita I 10.2 f>1ental retardation 16.5 Mental retardation 9.4 Dementia 9.5 Dementia 22.2 
2 Mental retardation 9.7 Other mental dis. 8.6 Musculoskeletal dis. 8.3 Stroke 6.7 Stroke 6.6 
3 Other respiratory 6.3 Pregnancy 8.5 Dental diseases 6.3 Musculoskeletal 5.8 Falls 5.9 
4 Other mental 6.0 Dental diseases 6.6 Ill-defined conditions 5.8 Cancer 5.6 Musculoskeletal 4.3 
5 Ill-defined cond. 5.5 r-1usculoskeletal 6.3 Coronary heart dis. 5.0 Ill-defined conditions 4.6 Ill-defined cond. 3.7 
6 Ear disorders 5.2 Ill-defined conditions 4.7 Other mental disorders 4.9 Coronary heart 4.0 Heart failure 2.9 
7 Dental disorders 4.6 Schizophrenia 3.5 Cancer 4.6 Other circulatory 3.9 Cancer 2.1 
8 Infection 4.0 Depression/anxiety 3.4 Depression/anxiety 3.4 Neurologic diseases 2.9 Other respiratory 2.1 
9 Neurologic diseases 2.8 other accidents 3.1 other circulatory 3.3 Other mental dis. 2.6 Neurologic. 2.0 
10 Other accidents 2.3 Genital diseases 2.3 Gastrointestinal 2.7 Falls 2.5 Other circulatory 1.7 
11 Eye disorders 2.2 Skin diseases 2.2 Neurologic diseases 2.7 Asthma & COPD 2.5 other mental 1.5 
12 Asthma & COPO 2.3 other respiratory 2.0 Liver, gall and 2.5 Eye disorders 2.3 Liver, gall and 1.3 
diseases pancreas diseases pancreas diseases 
13 Musculoskeletal 1.9 Neurologic diseases 2.0 Hypertension 2.5 Diabetes 2.2 Eye disorders 1.2 
14 Gastrointestinal 1.6 Alcohol/drugs 1.6 Asthma & COPD 2.2 Gastrointestinal 2.2 Urinary diseases 1.2 
15 Skin diseases 1.6 Gastrointestinal 1.6 other accidents 2.2 Heart failure 2.1 other accidents 1.1 
diseases 
% share In total costs 7.9 29.3 20.7 30.6 11.6 
% share In population 18.4 46.0 22.5 11.8 1.3 
* See table 2.2 for ICD codes of all diagnostic groups. 
18 Cost of illness in the Netherlands 
used to break down costs are generally not collected for epidemiological purposes, 
but in the Netherlands there is no financial incentive to register one diagnosis 
rather tban another. We considered only primary diagnoses. It is beyond the limits 
of the method used to assign costs appropriately to the primary as well as each 
secondary diagnosis. Valld infonnation about secondary diagnoses is generally 
lacking or incomplete. As a result, costs of diagnoses that are more often 
registered as secondary or tertiary, such as diabetes, are slightly underestimated. 
However, the registered primary diagnosis is generally the more important 
diagnosis for the health care sector concerned and the main reason why health 
care is needed -for example, what the internist calls osteoporosis, is for the 
surgeon a hip fracture, for the ambulance service an accidental fall, and for the 
nursing home a demented patient. The advantage of our method is that each 
guilder is allocated to only one combination of age, sex and diagnostic group, 
avoiding double counting. 
Secondly, the key variables used to break down costs for each health care 
sector do not represent exactly equal amounts of resources. Not all days of stay in 
hospitals or nursing homes are equally expensive, some hours of care are more 
labour intensive than others, and outpatient visits or primary care consultations 
can vary in length. As a result, costs of some diagnoses may be biased. For 
example, because hospital nursing costs are broken down by bed days without any 
differentiation, costs of diagnoses for which relatively more days are spent in 
intensive care will be slightly underestimated and vice versa. These limitations, 
however, will not affect our main findings, such as the exponential increase in per 
capita costs by age or the heavy burden of mental disorders. 
2.5 Comparability 
Our study's biggest strength is its comprehensiveness. This explains why our 
results seem at variance with an American (Medicare) study that shows decreasing 
costs at the oldest ages (Lubitz 1995]. The American study did not include long· 
term home care for elderly people or in nursing and homes for the elderly. It is 
these costs which cause the exponential increase in costs in old age. Like the 
American study we found that costs for acute admissions in hospital decrease at 
the oldest ages (figure 2.1). Most of these patients are already admitted to a 
nursing home or are too old or too ill to consider hospital admission usefuL A 
Swedish study, which is older and less complete, showed the same results 
[Lindgren 1990). 
Our findings correspond to a large extent with those of our earlier study in 
1988 [Koopmanschap 1991, 1994). Studies tbat are more or less comparable have 
been published in England [NHS 1996], Australia [Mathers 1998] and Canada 
[Moore 1997). These studies show basically similar cost patterns, but with lower 
shares particularly for mental retardation and dementia (see Chapter 8). However, 
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they either did not consider all health care, particularly long-term psychiatric care, 
or could not assign these costs to diagnoses. Apart from the degree of 
comprehensiveness, many other methodological and country-specific issues may 
cause differences in cost distributions. A serious international comparison of 
distribution of cost of illness would require specifically designed cross-national 
studies. 
Our study considered only medical costs and not costs of informal care. It has 
been estimated that if informal care in the Netherlands was entirely substituted by 
professional care it would double the current costs of professional home care 
[Groenenboom 1995]. Informal care mainly substitutes for simple forms of 
professional care. If these costs had been included the total costs of chronic, 
disabling conditions such as dementia and musculoskeletal disease would have 
been even more dominant, thus strengthening our conclusions that the main 
deterntinants of health care use in the Netherlands are old age and disabling 
conditions. 
The share of costs accounted for by fatal diseases is relatively small because 
care stops at death. Disability is the main reason why people use health care. The 
pattern of epidemiological causes of costs that we found is remarkably consistent 
with Murray and Lopez's estimates of the main causes of disability in the 
developed world. [Murray 1996, 1997]. In 1990 they estimated that mental 
disorders (including dementia and hereditary disorders of the central nervous 
system) accounted for 35.5o/o of life years lived with disability. In our study, the 
same disorders, including congenital anomalies, caused 28.4% of all health care 
costs that could be allocated to diagnostic groups. Musculoskeletal diseases, 
including arthritis and dorsopathy, caused 7.3o/o of the allocated health care costs, 
while Murray and Lopez estimated that osteoarthritis covered 6.1 o/o of the life 
years lived with disability. 
The costs presented here are grouped in cross sectional figures. Each age group 
contains people with low or no costs and those with high costs due to costly 
interventions, severe disability or impending death. In higher age groups more 
people have high costs, causing costs per person to rise. The cost distribution by 
age is informative, especially for societies that face a further ageing of the 
population. Since the distribution of costs is determined by the current prevalence 
of disease and disability, future health care costs will depend (among other things) 
on the evolution of the risk of disability and death by age. 
We conclude that health care costs in the Netherlands are strongly deterntined 
by age and disability. Further ageing undoubtedly increases health care needs and 
costs. Talking about cost containment in health care one must be aware that large 
shares of the budgets are not spent on cure, but on care. Long-term care of old, 
frail and mentally disabled people will always be labour intensive and expensive 
but is the hallmark of a civilised society [Dunning 1991]. 
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Abstract 
To estimate the costs of health care in 1994, the 
development of the costs assigned to specific diseases, and 
the future costs. 
Descriptive. 
Erasmus University, Deparrment of Public Health, 
Rotterdam, the Netherlands. 
For each health care sector, costs were allocated to 62 
diagnostic groups, age and sex making maximal use of 
national registries and other sources with data on health care 
use in the Netherlands. 
More than 80% of the 60 billion Dutch guilders that were 
spent on health care in 1994 could be assigned to specific 
diseases. Most costs are made for non~fatal diseases like 
mental deficiency, dementia and musculoskeletal disease. 
Except for cardiovascular disease, the share of major causes 
of death share in the total costs was not significant. Average 
costs per inhabitant were low during youth and adulthood 
but increased exponentially with age from age 50 onwards. 
Between 1988 en 1994 health care costs experienced an 
annual growth rate of 5.2%, caused by price and wage 
increases (one half), ageing (a quaner) and other effects on 
health care costs such as epidemiological and technological 
change (a quaner). 
The main detennlnants of health care use in the Netherlands 
were old age and disabling conditions. Due to ageing and 
other influences, real health care costs in the years to come 
will increase by an average annual rate of 2.4%. 
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Developments between 
1988 and 1994 
3.1 Introduction 
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The costs of health care are usually described on the basis of the national spectrum 
of available health care sectors. A description based instead on health care use and 
underlying features such as diagnosis, age and sex could therefore offer important 
new insights. This article describes the total costs of health care, broken down 
according to these three underlying variables [Polder 1997]. A comparable 
analysis had previously been performed for the year 1988 [Koopmanschap 1991, 
1994, Roijen 1992], allowing for a comparison. In this chapter we: a) describe the 
health care costs in 1994 by diagnosis, age and sex; b) describe the cost 
development in the period 1988 -1994 from a cost-of-illness perspective; and 
c) make projections of future health care costs. 
3.2 Methods 
We performed a prevalence-based COl-study including all direct medical costs in 
the Netherlands. Health care costs were broken down according to diagnosis, age 
and sex via a top-down method, in which 22 more or less homogenous health care 
sectors were distinguished of which the total costs were either known or able to be 
calculated [Ministerie VWS 1996]. A breakdown of these costs was subsequently 
made per sector vvith the help of distributive codes containing information on 
health care use according to diagnosis, age and sex. Maximum advantage was 
taken of the data sources available in the Netherlands, the most important of 
which were national in scope. Appendix A provides a complete overview of the 
data sources used and a detailed description of the cost allocation method applied. 
The costs of nursing care provided by hospitals and nursing homes were allocated 
based on the number of days of nursing care provided, as reported in the files of 
SIG Zorginfortnatie [LMR 1994, SMS 1994]. Other distributive codes included: 
number of consultations (general practitioner, outpatient clinic) and number of 
residents at reference date (homes for the elderly). The key variables were 
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assumed to constitute a plausible estimate of the distribution of costs. Two sectors 
were subjected to a more refined method. The costs of clinical procedures in 
hospitals were calculated via the rates charged per type of procedure. The costs of 
pharmaceutical care were assigned to diagnoses via the costs and number of 
prescriptions per drug type. Combining the data of the separate sectors together 
ultimately yielded the distribution of total health care costs by diagnosis, age and 
sex. 
The division into diagnostic groups was based on the International 
Classification of Diseases (ICD-9) [WHO 1977]. The seventeen chapters of this 
classification were broken down into 62 diagnostic groups, in which death, burden 
of disease, economic consequences and expectations regarding future 
developments in epidemiology and treatment were taken as selection criteria. All 
costs were allocated to the primary diagnosis to avoid double counts between 
diagnostic groups. 
3.3 Results 
Costs of health care in 1994 by diagnosis, age and sex 
Of the 59.5 billion guilders spent on health care in 1994, over 80% could be 
attributed to specific diagnostic groups. The other 20% consisted largely of costs 
that could not be allocated to a particular disease (health care administration, 
room and board in homes for the elderly) and of costs that were not yet allocable 
due to lacking data (home help, psychosocial assistance). 
In distributing the costs across the 17 chapters of the ICD-9, a more or less 
similar spread was found for men and women (figure 3.1). Mental disorders were 
accountable by far for the highest proportion of costs, namely for 23% of the total 
costs (13.7 billion guilders). This included the costs of dementia (5.6%) and 
cognitive handicaps (8.1 %). These disorders were followed by coronary heart 
disease (11 %) and diseases of the digestive system (7.8), the latter chiefly due to 
the costs of dental care (2.4 billion). Cancer related costs (neoplasms, 3.9%) were 
surprisingly low, considering that this disease, responsible for 28% of the total 
mortality figure, was the second most important cause of death. Apparently non-
fatal diseases, with the exception of coronary heart disease, account for the bulk of 
health care costs. 
Health care use and'costs were shown to be strongly associated with age 
(figure 3.2). From the first year of life until approximately the fiftieth, the average 
per capita costs were low, and more or less stable. They then surge rapidly 
upward, to over 55,000 guilders in the highest age group. Table 3.1 shows this 
distribution of the costs over the !CD chapters for four different age groups. 
The share of men and women in the total costs amounted respectively to 41% and 
59%. The difference was caused by the costs of reproduction that were allocated 
to the mother and by the longer life expectancy of women. 
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XII Skin diseases 
Ill Endocrine and met,abolic diseases 
XI Pregnancy and childbirth 
X Urinary system and genital organs 
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Figure 3.1 Health care costs (million Dutch guilders) for the Netherlands in 1994 by chapters of the ICD-9 
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Figure 3.2 Per capita health care costs in the Netherlands by age and sex (1994) 
Disease specific development in costs 1988- 1994 
Between 1988 and 1994, health care costs increased by an average rate of 5.2% 
per year. Wage and price developments were responsible for 52% of these rising 
costs; other causes were demographic changes (26%) and other factors (22%), 
including epidemiological change and technological innovations. With the help of 
the health care cost surveys from both years, it became possible to establish the 
share contributed by the different diagnostic groups to the overall rise in health 
care costs. For the purpose of this comparison, adjustments were made for 
methodological differences between both studies. Adjustment proved impossible 
for 3 sectors (GPs, pharmaceutical aid, homes for the elderly and part of the care 
provided to the disabled). These sectors were therefore not included in the 
description of the disease-specific development in costs throughout the period 
1988-1994. 
Table 3.1 Health care costs (million Dutch guilders) for the Netherlands in 1994 by chapters of the ICD-9 and age (share in total 
costs per age categ01y between brackets) 
lCD chapter Age category In years Total 
0-14 15-44 45-74 75~ 
Infectious diseases 181 (3.8) 279 {1.6) 212 {1.0) 102 {0.6) 775 {1.3) 
II Neoplams 37 {0.8) 302 (1.7) 1/345 (6.6) 650 (3.9) 2,335 (3.9) 
III Endocrine and metabolic 30 {0.6) 144 (0.8) 504 (2.5) 430 (2.6) 1,108 {1.9) 
IV Blood 16 {0.3) 28 (0.2) 69 (0.3) 76 {0.4) 189 (0.3) 
v Mental disorders 740 (15.7) 5,907 {33.9) 3,579 (17.5) 3,503 (20.8) 13,729 (23.1) 
VI Nervous system and senses 469 (10.0) 699 (4.0) 1,153 (5.6) 790 (4.7) 3,111 (5.2) 
VII Circulatory system 15 (0.3) 342 (2.0) 3,285 (16.0) 2,573 (15.3) 6,214 (10.5) 
VIII Respiratory system 393 {8.4) 509 (2.9) 921 (4.5) 579 {3.4) 2,402 (4.0) 
IX Digestive diseases 317 (6.7) 1,641 {9.4) 2,106 {10.3) 595 {3.5) 4,658 (7.8) 
X Urinary and genital organs 70 (1.5) 560 (3.2) 733 {3.6) 311 (1.8) 1,675 (2.8) 
XI Pregnancy and childbirth 109 (2.3) 1,409 (8.1) 11 (0.1) 0 {0.0) 1,528 (2.6) 
XII Diseases of the skin 72 (1.5) 383 (2.2) 341 {1.7) 176 {1.0) 973 {1.6) 
XIII Musculoskeletal diseases 88 (1.9) 11098 (6.3) 1,583 (7. 7) 777 (4.6) 3,546 {6.0) 
XIV Congenital malformations 136 (2.9) 118 (0.7) 45 (0.2) 6 (0.0) 305 (0.5) 
XV Perinatal conditions 336 (7.2) 0 (0.0) 0 (0.0) 0 (0.0) 336 (0.6) 
XVI Symptoms 251 {5.3) 834 (4.8) 1,127 (5.5) 665 (3.9) 2,877 (4.8) 
XVII Injury and poisoning 167 (3,5) 668 {3.8) 704 (3.4) 980 (5.8) 2,519 (4.2) 
Not allocated 714 (15.2) 1,061 {6.1) 1,592 (7.8) 1,477 (8.8) 4,843 (8.1) 
Non-specific 562 (12.0) 1A28 (8.2) 1,191 (5.8) 3,159 (18.7) 6,340 {10.7) 
Total 4,703 {100.0) 17,412 (100.0) 20,502 (100.0) 16,847 {100.0) 59,463 {100.0) 
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The costs of the following diagnostic groups increased the most: dementia (9.4%), 
AIDS and HN infections (8.9%), perinatal conditions (8.7%), coronaryhean 
diseases (8.6%), diseases of the respiratory system (7.0%), stroke (7.0%) and 
colorectal cancer (7.0%). Relatively little to no increase, or even a decline, was 
seen in the costs of: diseases of the female genital tract (-0.2%), blood diseases 
(1.4%), appendicitis (1.5%), traffic accidents (1.9%), eye disorders (2.00/o) and 
inguinal hernias (2.2%). 
The cost development could be interpreted for several diagnostic groups, e.g. 
the rising costs of dementia may be ascribed to the ageing population, of coronary 
heart diseases to the increased number of cardiac operations and coronary 
angioplasry procedures performed. In the case of other diagnostic groups, 
including that of diseases of the female genital tract and that of eye disorders, no 
explanation for the development in costs was available without further research. 
Table 3.2 shows the distribution of these costs over the sectors for a number of 
important diagnostic groups. To safeguard reliability, this comparison was limited 
to major care sectors, which meant that noteworthy alterations in e.g. clinical, 
outpatient and day treatment were not able to be described. On the other hand, 
the share of the costs contributed by the hospirals as a whole underwent 
considerable growth for a number of diagnostic groups (musculoskeletal diseases, 
nervous system and senses and circulatory diseases). Conversely, care was 
provided for pregnancy and pregnancy-related disorders more frequently on an 
extramural basis. The share of the total costs for dementia accounted for by 
nursing homes increased significantly. This was pattly due to the expansion in 
capacity achieved in this sector. 
Projection of costs 1994-2035 
Using the mean health care costs by age and sex, it became possible to make a 
demographic projection of the cost of health care in the future, assuming 
epidemiological steady state per age. On the basis of the CBS population forecast 
of 1996 (the so-called medium variant), the costs (in constant prices of 1994) 
would annually increase by an average of 0. 9 - 1.0 o/o per year between 1994 and 
2015, and an average of 1.0-1.1% per year in the period 2015-2035 [CBS 
1997]. Next to this demographic projection, figure 3.3 also offers a projection of 
developments from the period 1988 -1994. The middle line indicates the 
expected cost development if costs were to continue to rise unchecked by an 
annuall.l-1.2% due to other causes. Furthermore, allowance is made in the 
upper curve for the difference in inflation in health care and the rest of the 
economy (0.3% per annum) [CBS 1996, 1996a]. 
In this projection, costs will experience an annual growth of 2.4% over the 
coming decades. This percentage is based on constant prices, to which inflation 
must still be added. 
Table 3.2 Share of health care sectors in health care costs of 15 major disease categories in 1988 and 1994 
Diagnostic group A Share of sectors in total costs per diagnostic group Share of 
Outpatient care 8 Other sectors c 
diagnostic groups 
Hospitals Nursing homes in total costs 
1988 1994 1988 1994 1988 1994 1988 1994 1988 1994 D 
Psychiatric conditions E 15.6 18.3 1.0 0.7 8.8 2.3 74.6 78.7 9.9 9.7 
Musculoskeletal diseases 50.9 55.6 29.8 25.8 13.6 13.2 5.7 5.4 7.1 6.4 
Intellectual disability 0.1 0.1 0.0 0.0 0.0 0.0 99.9 99.9 6.3 6.3 
Dental disorders 2.2 2.0 97.8 97.9 0.0 0.0 0.0 0.1 4.6 4.8 
Dementia 4.2 2.5 2.1 1.5 87.6 93.1 6.1 2.9 3.6 4.6 
Neoplasms 90.1 88.6 4.6 5.2 5.2 4.5 0.1 1.7 4.8 4.6 
Stroke 43.4 43.3 3.1 3.3 53.4 53.3 0.0 0.1 3.0 3.3 
Nervous system and senses 51.7 53.6 5.1 7.4 32.0 28.4 11.2 10.5 3.5 3.1 
Respiratory system 80.5 80.0 5.1 3.9 11.8 12.2 2.7 3.8 2.7 3.0 
Pregnancy and childbirth 70.1 67.7 29.9 32.1 0.0 0.0 0.0 0.2 3.2 3.0 
Coronary heart disease 94.3 96.2 1.7 1.3 4.0 2.3 o.o 0.2 2.1 2.5 
Other circulatory diseases 79.5 85.0 3.1 2.9 10.6 7.2 6.8 4.9 2.4 2.7 
Gastro-intestinal diseases 92.1 90.0 0.6 0.5 7.2 9.3 0.0 0.2 1.1 1.2 
Perinatal conditions 99.8 99.7 0.2 0.1 0.0 0.0 0.0 0.2 0.9 1.1 
Infectious diseases 61.1 65.5 2.5 1.9 9.1 9.7 27.2 22.8 0.8 0.8 
A. Selection from !CD chapters Wid more detailed diagnostic categories 
B. Dental care, parrunedical care, maternity sendces, psychosocial assistance, home care. General Practitioners e.xcluded 
c. Psyclliatric lwspitals, intramural services for disabled people, prevention, transportation, and health care administration. Plwnnaceutical care, homes for tile 
elderly e.-.:cluded 
D. Figures differ from table 3.1 because adjustments llad been made to allow for comparison between 1988 and 1994. 
E. Intellectual disability a11d dementia e.xcluded. 
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3.4 Discussion 
Over the past years, the economic consequences of morbidity have become the 
object of growing interest. A lot of disease-specific cost-of-illness studies were 
performed, mostly based on a bottom-up methodology. This yielded very 
substantial amounts that, when totalled, led to an overestimation of the total 
health care costs. An important cause of this is the fact that many patients, in 
particular elderly patients, suffer from more than a single disease at the same time 
(comorbidity). In tltis chapter we described the results from a general CO! study 
covering the total health care budget. We used a top-down methodology based on 
primary diagnoses only. A coherent overview of direct medical costs was outlined 
for all diseases, excluding double counts and allowing for comparison. 
The top-down method, however, has also some drawbaclrs. Because only 
primary diagnoses were looked at, no notice was taken of comorbidity, while tltis 
certainly plays a role in the older age groups. As a consequence the costs of some, 
mostly acute, diseases were overestimated while the costs for some chronic 
diseases were underestimated. The use of primary diagnoses further results in an 
underestimation of costs for diseases as for instance diabetes that are causally 
related to other diseases. According to the registration principles of the 
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International Classification of Diseases the health care use for these distant 
diseases is coded separately from the underlying disease. 
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Moreover, for the sake of completeness it was necessary, due to the fact that 
certain data were lacking, to make a number of crucial assumptions. In the 
analysis of the costs of care provided by GPs in 1994, for example, use was made 
of a very small data source that, lacking better data, was assumed to be 
representative for the Netherlands. Furthermore, when allocating the costs of 
outpatient care use was made of the 'Polikliniek Informatiesysteem (PO US)' 
developed by SIG Zorginformatie. As this contains no diagnostic information, the 
consultation data per treating specialisation were allocated to the diagnostic 
groups on the basis of the GP referral data from 1988. It was assumed that the 
referral pattern for specific diagnoses of GPs to the various medical specialists had 
remained uncbanged between 1988 and 1994. The costs of clinical nursing care in 
hospitals were allocated to diagnostic groups on the basis of the national medical 
register (LMR). This meant that no account was taken of the higher costs of 
intensive care (!C), as the data from the LMR did not permit this to be done. As a 
result the costs of particular diagnostic groups were more or less underestimated. 
Nor did the data on pharmaceutical drug use in 1994 provide information about 
the diagnosis. The costs were allocated to diagnoses by coupling data from the 
Drug Information Project (GIP) via the anatomical therapeutical cbemical (ATC) 
code to the prescription data of general practitioners in 1988. It was assumed that 
the distribution of the number of prescriptions per type of drug over the different 
diagnostic groups had remained unchanged between 1988 and 1994. 
The results of this study are important for analyses of the relation between 
health care and public health and for compiling future scenarios for expected care 
use. Simple projections indicate that demographic developments alone (the ageing 
population) w_ill cause costs to increase around 1% annually over the corning 
decades. If other cost increasing factors, such as epidemiological and technological 
developments, are also considered, the projected real cost increase is 2.4% per 
year. Due to the extrapolation of historic trends and the inherent assumptions this 
figure is less reliable than the demographic growth rate. Even so there are no 
conceivable reasons for this percentage to drop markedly lower over the decades 
to come. Afrer all, this growth was realised during a period in which a plethora of 
extensive cost control measures were implemented. If the government should 
nonetheless strive for an increase in health care costs of significantly less than 
2.4% per year, this implies resorting to considerably more drastic measures than 
the cost-cutting measures hitheno taken. 
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Abstract 
During the past decades health care costs in all Western 
countries have continuously increased. An adequate health care 
policy must be based on realistic expectations about the 
development of health care costs in the years to come. In this 
paper some projections of future health care costs in the 
Netherlands are made, using cost-of-illness data for 1994, 
population forecasts and quantitative insight in the cost 
development in the past. It is concluded that Dutch health care 
costs will increase in future decades by an annual rate of 2.4%. 
This projected cost increase consists of increasing health care 
use due to demographic change (0.9- 1.0%), developments in 
epidemiology and technology (1.1 - 1.2%) and of price and 
wage developments in health care which exceed general 
inflation by 0.3%. 
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4.1 Introduction 
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During the past decades health care costs in all Western countries have 
continuously increased. In almost all countries government has tried to halt this 
development by cost containment measures. In the Netherlands, official 
governmental health policy has shifted from national planning to managed 
competition and from managed competition to a stepwise change of the health 
care system. However, sectoral budgeting is still the primary governance structure. 
In the middle of the nineties, health care costs were limited to an annual real 
increase of approximately 1.3%. This tight budget constraint was heavily discussed 
and questions raised about its assumptions. In this chapter projections of future 
health care costs are made using cost-of-illness data for the Netherlands in 1994 as 
presented in the previous chapters to contribute to a realistic growth rate 
considering the ageing of the population and the historical cost development. 
4.2 Causes of cost increase in health care 
From 1985 to 1995 Dutch health care costs increased by 40% from approximately 
US$ 23,000 million to US$ 33,000 million (1 US$ = f 1.82, exchange rate 1994). 
In the same period, the share of health care costs in the Gross Domestic Product 
(GDP) dropped from 9.7% to 9.5% due to an economic growth that exceeded the 
growth of health expenditures. Figure 4.1 shows the annual fluctuations around 
this average development. 
Increasing volumes as well as an increasing average price of delivered care 
determine the development of health care costs. The volume of health care 
consumption increases by demographic and epidemiological changes and 
developments in health care provision and technological change. Prices in health 
care are closely related to the general price level but also have their own dynamics 
because increases in average wages have a greater impact due to the labour 
intensive nature of care giving [Baumol1993]. 
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Figure 4.1 Health care costs in the Netherlands 1985-1995 (total costs in US$ 1 
million (current prices) and share in Gross Domestic Product in%) 
4.3 Cost of illness in the Netherlands in 1994 
Projections of future health care costs require detailed information about the 
disnibution of health expenditures by the main dimensions of health care use. 
General cost-of-illness (COl) studies, in which health care costs for all diseases are 
reported, provide this information [Rice 1994]. The projections in this paper are 
based on a CO! study for the Netherlands in 1994 in which health care costs were 
subdivided according to health care sector, disease, age and sex [Polder 1997, 
Meerding 1998] 
In 1994, total health care costs in the Netherlands amounted to US$ 32,672 
million. With a population numbering 15.4 million, this amounts per capita to 
US$ 2,150 spent on health care. This average, however, conceals a wide variation 
between the different age groups. Average costs are low in youth and during 
adulthood but show a sharp increase from age 55 onwards toward an average of 
US$ 20,000 for women in the oldest age group (table 4.1). 
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Table 4.1 Average health care costs per inhabitant in the Netherlands in 1994 by age 
and sex (US$) 
Age group Men Women 
0 2,930 2,670 
1- 14 839 706 
15-24 1,043 1,169 
25-44 1,238 1,688 
45-64 1,842 2,068 
65-74 3,862 3,836 
75-84 7,129 9,130 
85+ 15,171 20,190 
Average 1,759 2,481 
Exchcmge rate (1994): US$ 1 ~ f 1.82. 
The distribution of costs by disease category also shows a large dispersion. 
Table 4.2 summarises the results for the 17 chapters of the International 
Classification of Diseases (ICD-9) [WHO 1977]. Most costs relate to mental 
disorders (23% of national health care costs) in which, according to the ICD-9, 
dementia (5.6%) and mental disabilities (8.1%) are included. The share of 
circulatory diseases and diseases of the digestive system in health care costs 
amounted to 10.5% and 7.8% respectively. The latter category mainly consists of 
the costs of dental care (US$ 1,300 million). Musculoskeletal dlseases and diseases 
of the nervous system and the sense organs rank 4 and 5 respectively, followed by 
symptoms and ill-defined conditions (4.8%), injuries and poisoning (4.2%) and 
neoplasms (cancer, 3.9%). Most costs relate to non-fatal, chronic diseases. The 
major causes of death have only modest implications for health care costs, 
circulatory dlseases excluded due to survivals from stroke and myocardial 
infarctions. The share of all cancers in total mortality amounts to 28% while the 
share in national health care costs is less than 4%. 
4.4 Demography and health care costs 
Demographic developments consist of changes in size and composition of the 
population. According to recent population forecasts the Dutch population will 
grow until 2035. After that year the number of inhabitants slowly will diminish 
[CBS 1996]. Based on an average cost of US$ 2,150 per inhabitant, the lowest 
curve in figure 4.2 represents the corresponding projection of total health care 
costs (in 1994 prices). 
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Table 4.2 Health care costs in the Netherlands in 1994 by disease category 
(US$ 1 million, share in total health care costs (%), male/female ratio (%)) 
Disease category Health care costs 
(Chapters of ICD-9) 
US$ 1 min* Share male/female 
(%) ratio(%) 
Infectious and parasitic diseases 426 1.3 46/54 
Neoplasms 1,283 3.9 44/56 
Endocrine diseases 609 1.9 33/67 
Diseases of the blood 104 0.3 39/61 
Mental disorders 7,544 23.1 44/56 
Nervous system and sense organs 1,709 5.2 45/55 
Diseases of the circulatory system 3,414 10.5 47/53 
Diseases of the respiratory system 1,320 4.0 54/46 
Diseases of the digestive system 2,559 7.8 47/53 
Diseases of the genitourinary system 920 2.8 33/67 
Pregnancy and child birth 840 2.6 0/100 
Diseases of the skin 535 1.6 41/59 
Diseases of the musculoskeletal system 1,948 6.0 37/63 
Congenital abnormalities 168 0.5 50/50 
Perinatal diseases 185 0.6 53/47 
Symptoms and ill-defined conditions 1,581 4.8 39/61 
Injury and poisoning 1,384 4.2 40/60 
Not allocated 6,144 18.8 35/65 
Total 32,672 100.0 41/59 
*Exchange rate (1994): US$ 1 = f 1.82. 
Population ageing rather than population growth will determine the development 
of health care expenditures in the coming decade. The large post-war birth cohorts 
are getting older, which coincides with the lower birth-rate since the end of the 
sixties (figure 4.3). Given the steep rise of health care costs with age (table 4.1), 
this development has major consequences for the national health care costs 
(figure 4.2, second curve). This projection shows total health care costs rising to 
US$ 40,000 million in 2015 and to approximately US$ 50,000 in 2035 (in 1994 
prices). The corresponding annual growth rate is 0.9 -1.0% for 1994-2015 and 
1.0- 1.1 o/o for 2015-2035. 
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Figure 4.4 shows the impact of the demographic change on the total costs per age 
group. For the age group 20- 40 total costs will decrease, while from age 40 
onwards the projected costs increase steeply. 
The demographic cost projection is based on two important assumptions. First, 
the middle variant of the population forecasts is used. Although this forecast can 
be seen as the most likely variant, a high and a low variant are also distinguished 
in the Dutch population forecasts. Taking these variants into account1 the 
projected annual growth rate of future health care costs may vary from 0.6% to 
1.2% in the period 1994-2015 and from 0.6% to 1.5% in 2015- 2035. 
Second, average costs per inhabitant are assumed to remain constant within 
each age group in the future. Because the population forecast is based on the 
assumption of decreasing monality, the assumption of constant average costs is 
not entirely correct [Beer 1997]. Some authors demonstrated that the highest 
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health care costs per unit time occur in the last year of life [Lubitz 1995, WRR 
1997]. A decline of mortality in each age group, except the highest, will result in 
lower average costs per age group but the effect on total costs, however, is 
presently still unclear because average lifetime costs and costs in the last year of 
life are only partly available. Furthermore the costs of attaining the expected 
mortality reduction are not knovv:n at all. 
4.5 Epidemiology and health care costs 
Demographic projections are based on the assumption that the incidence and 
prevalence of all diseases remain constant within each age and sex group. For 
some diseases, however, incidence and prevalence per age group will change over 
the course of time. These epidemiological developments can have an enormous 
impact on total health care costs due to large cost differences betvveen disease 
groups (table 4.2). Unfortunately, this influence can not easily be calculated. 
Epidemiological developments are quite uncertain in the long run. In the 
seventies, for instance, a surprising epidemic of heart diseases occurred that could 
not be fully explained until now [Mheen 1997]. Although epidemiological 
forecasts have been published for some diseases, the information available for 
epidemiological projections of health care costs is still insufficient [Ruwaard 
1997]. 
4.6 Technology and health care costs 
The relation between technological change and health care costs is complex. Cost 
reductions are possible by utilisation of more efficient interventions. Hip 
replacements and some vaccinations are the main examples. Costs can also 
decrease by the application of technologies that improve labour productivity and 
reduce the relative utilisation of highly trained expensive personnel. Day-care 
treatment is a good example here. In spite of these examples, however, the overall 
impact of technological change in health care will increase rather than decrease 
costs. Three major influences can be distinguished [Mheen 1997]. 
First, many new health care technologies can be characterised as 1half-way 
technologies' that reduce age specific mortality but do not cure the patients. The 
resulting transition from mortality to morbidity will increase costs due to the 
higher average lifetime costs per inhabitant [Weisbrod 1983]. The successes of 
treating myocardial infarctions resulted in declining mortality from coronary heart 
disease, but simultaneously in increasing numbers of patients with heart failure 
and stroke. 
Second, costs increase when the patient categories that are eligible for that 
intervention increase. Due to refined technologies complications will decrease and 
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people will be treated who before would be rejected on medical indications. A 
well~ known example concerns the transition from conventional to laparoscopic 
removal of the gallbladder. Because the new technology is less invasive, more 
patients are treated [Legoretta 1993]. The same holds for other minimal invasive 
treatments and especially for the decreasing numbers of contra~indications due to 
improvements in anaesthetic technology. As a result more people with a lower 
health status and relatively high health care needs survive causing a further cost 
increase. 
Third, diagnostic improvements go faster than effective therapeutic advances. 
The average number of medical procedures per patient increases, resulting in 
higher average and total costs. 
Technological change and epidemiological developments are partly correlated. 
Successful treannent generally leads to a better survival but often also to replacing 
one disease for another. Even in the case of decreasing average treatment costs 
total costs are likely to increase due to increasing average lifetime costs. In our 
projections we estimated the simultaneous influence of technology and 
epidemiology on health care costs using trends from the past. This was possible 
because cost-of-illness data were available for 1994 as well as for 1988 
[Koopmanschap 1991, 1994]. 
4.7 Epidemiology, technology and health care costs in 1988- 1994 
Health care costs in the Netherlands increased by an average annual rate of 5.3% 
in the period 1988- 1994. After correction for demographic change and 
developments in prices and wages a residual average overall growth rate of 1.1 -
1.2% represents the combined influence of epidemiological and technological 
change. The growth rates differed substantially between diseases. Costs of 
dementia increased more than average due to changes in health care supply. The 
costs of AIDS and HIV-infections increased due to expansion of the disease and the 
development of new expensive drugs. Costs of perinatal diseases increased due to 
technological change and increased treatment possibilities of children in neonatal 
care. New and expensive treatment options in cardiology caused a more than 
average increase in costs of circulatory diseases. Diseases of the female genital 
tract, traffic accidents and disorders of the eye experienced a less than average 
cost increase. The latter development was probably caused by a transition from 
inpatient to outpatient ophthalmic care. 
Figure 4.2 (third curve) shows an estimated 1.1 - 1.2% growth rate projected 
on top of the demographic projection. 
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4.8 Wages, prices and health care costs 
Until now, we have described cost projections based on developments in the 
volume of care. Yet developments in wages and prices also have a large impact on 
health care costs. About half of total cost increase in the period 1988 - 1994 was 
due to wages and prices. In projections of future costs, inflation is usually left out 
of because it is determined by the macro~econornic development that can not 
easily be predicted. By formulating the projections in constant prices this problem 
is avoided. One must, however, take into account sectoral differences in inflation. 
In health care and other sectors where personal services are delivered prices and 
wages increase more than average. According to Baumel's law average costs in the 
service industry increase more steeply compared to other sectors in the economy 
because the possibilities for labour saving technologies and improvement of labour 
productivity are small while average wages keep more or less pace with wages in 
industrial sectors [Baumol1993]. The difference between general and sectoral 
inflation must be incorporated in the projection of future health care costs. After 
all constant prices relate to current dollars and not to 'health care dollars'. The 
additional wage and price development for the Dutch health care sector can be 
calculated from national accounts and price surveys published by Statistics 
Netherlands [CBS 1996, 1996a]. Between 1988 and 1994, inflation was 
0.3 percent points higher than the annual general inflation. The upper line in 
figure 4.2 represents the corresponding projection of health care costs. We opted 
for the trend in the period 1988 - 1994 because the other developments were also 
derived from this period. If a longer period is cbosen, health care prices will 
diverge even more from average inflation (0.4 percent points for 1975 -1995). 
4.9 Concluding remarks 
Changes in health care costs have many determinants. With cost·of·illness data as 
collected in this study, population forecasts and cost developments from the past, 
it is possible to make robust projections. According to these projections, Dutch 
health care costs will increase in future decades by an annual rate of 2.4%, apart 
from general inflation. This projected cost increase consists of increasing health 
care use due to demographic change (0.9- 1.0%) and developments in 
epidemiology and technology (1.1 -1.2%) and of price and wage developments in 
health care which depart by 0.3% from general inflation. 
The projected cost increase is mucb higher than the budget allocated at the 
time of this study by the Dutch government (1.3% annual growth). Only an 
extremely stringent health policy both regarding the volume and price of health 
care might succeed in containing the costs within the proposed budget. One may 
doubt, however, the feasibility and desirability of such a policy in an affluent 
society sucb as the Netherlands at present. A more ample health care budget 
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would seem a more appropriate policy, especially in a humane society that cares 
for the old, disabled and care dependent inhabitants. 
Part II 
More detailed descriptions, 
comparisons and projections 
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Abstract 
Background The escalating costs of health care raise questions about 
demographic, epidemiological and technological 
determinants and future projections. The objectives of this 
paper are to describe the age pattern of health care costs, to 
analyse the age-specific cost changes and to project future 
health care costs in an ageing population. 
Methods Comprehensive cost-of-illness data for the Netherlands in 
1988 and 1994 are compared by age and type of care. 
National data on all hospital admissions, nursing days and 
clinical interventions for the period 1988 - 1994 are used to 
describe trends in hospital care. Population forecasts are 
used to project the age distribution of future health care 
costs. 
Results The distribution of health care costs per capita depends 
strongly on age. The growth rate of per capita costs increases 
by age for acute care but decreases by age for long-term 
care. Both combined cause an average annual growth rate of 
4.6%, nearly constant with age. 
Conclusions Ageing will result in increasing health care demands and 
costs. Secular trends in acute and long-term care indicate 
major shifts in costs from younger to older people and from 
long-term to acute care. 
European Journal of Public Health (tn press). 
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Age-specific increases 
in health care costs 
5.1 Introduction 
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The rapid growth in health care expenditure is of increasing concern for 
governments and health authorities in the industrialised countries. Many factors 
contribute to rising health care costs: ageing of the population, the development of 
new therapeutic and diagnostic modalities, and the inflation of provider costs in 
relation to average price levels in the economy [Schneider 1990, Polder 1995, 
Scitovsky 1985]. 
Per capita health care costs are strongly age dependent [Gibson 1979, 
Mendelson 1993, Meerding 1998, Lubitz 1995]. Demographic increases in the 
number of elderly people result in higher total costs. This total cost increase is 
reinforced by increasing age~specific per capita costs for the elderly, resulting from 
the growing survival rate of frail elderly, augmenting medical technologies and 
expanding per capita demands [Bonneux 1998, Scitovsky 1994]. 
These influences are interrelated. A decline in acute coronary heart disease 
mortality resulting from the introduction of thrombolysis, for instance, yields a 
higher number of patients at risk of chronic cardiovascular disease such as 
congestive heart failure or stroke [Bonneux 1994, Niessen 1993]. Other 
improvements in medical science enlarge the potential therapeutic options for 
these and other elderly patients. In earlier days, general anaesthesia was a major 
hazard to elderly persons; nowadays major complications or death from this cause 
are rare events. This has opened up a whole vista of surgical possibilities, which 
further increases the chance of survivaL Because absolute risks of disease are high 
among the elderly, they will potentially benefit most from risk reduction. Long-
term preventive pharmacotherapy, such as antihypertensive or cholesterol 
lowering drug therapy, is expensive and its use among elderly persons is rapidly 
increasing, at least in the Netherlands [ZFR 1998]. 
The cycle of intertwined technological and epidentiological changes suggests 
that developments in health care costs depend on age, and that average per capita 
costs in the course of time diverge between younger and older people. Our 
objective is to describe the age pattern of health care costs in 1994, to analyse the 
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age-specific cost changes in the period 1988-1994, and to project future health 
care costs in an ageing population by the year 2015. 
5.2 Data and methods 
We used comprehensive data on cost of illness in the Netherlands in 1988 and 
1994 [Meerding 1998, Koopmanschap 1994) In these studies health care costs are 
split into health care sector, gender, age and diagnosis. Data on health care costs 
in both years for each sector were obtained from the Ministry of Health [Ministerie 
WVC 1993, Ministerie VWS 1996). Use was made of the 17 chapters of the 
International Classification of Diseases (lCD, 9th revision) subdivided into 62 
diagnoses, and clustered age into 18 gtoups (0- 4, 5-9, ... , 80- 84, 85+) [WHO 
1977). For each health care sector, key variables were identified that were 
representative of health care use in that sector, such as days of stay for nursing 
costs in hospitals and nursing homes, and costs per procedure for diagnostic and 
therapeutic interventions in clinical and day-care settings. The probability 
distribution of key variables was derived from sector specific registries and sample 
surveys, of which the most imponant have national coverage of 95% and over. 
These studies have been described in more detail previously [Meerding 1998, 
Koopmanschap 1994, Koopmanschap 1991, Polder 1997], and more details are 
also available in appendix A. 
The Dutch health care budget is particularly suitable for this type of analysis 
since the country is small, the health system is comprehensive, and more than 99% 
of the population has full health insurance coverage with registration of nearly all 
utilisation. 
To avoid bias caused by data soUtces and methodological differences between 
both time periods and studies, only sectors with national coverage and identical 
methods of registration in 1988 and 1994 were compared. The present study 
includes acute care (general and academic hospitals) and long-term care 
(psychiatric hospitals, nursing homes, elderly homes and institutions for disabled 
people). These accounted for 60.1 o/o of all costs in 1988 and 60.0% in 1994. It 
excludes general practitioners, pharmaceutical care, physical therapy, maternity 
services and home care. Here, the study performed for 1988 and that regarding 
1994 had to use smaller samples or regional registries with vatying coverage. Day-
care in hospitals was partially excluded because no reliable data on 1988 were 
available. In 1988, however, day-care was rare, and therefore we could use 1994 
data to indicate some major transitions of clinical treatment to day-care 
interventions. Hence, acute hospital care and long-term institutional care can 
reliably be compared in both periods. 
We calculated average health care costs per inhabitant for both sectors (acute 
care and long-term care) using data on the Dutch population in 1988 and 1994 
[CBS 1997). The cost figures were corrected for inflation using the national price 
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indices [CBS 1996]. Changes in per capita costs were calculated as absolute 
differences and rates. The cost development in acute care (hospitals) was analysed 
in more detail using comprehensive data on all hospital admissions and 
interventions in 1988 and 1994 by age, sex and type of intervention. These figures 
were age-and sex-standardised using the sum of the 1988 and 1994 populations as 
reference population. 
We combined Dutch population forecasts with the observed levels and growth 
rates for per capita costs to make projections for total health care costs in 2015 
[Beer 1997]. A demographic projection was made in which per capita costs per 
age and sex group were multiplied by the population forecasts per age and sex 
group. For each age group the observed annual growth rates for acute and long· 
term care in 1988- 1994 were added to make a projection that also includes the 
age~specific trends in health care use. All projections were based on the 
assumption of a constant epidemiological burden per age-sex category. 
5.3 Results 
Per capita health care expenditure in the Netherlands amounted to Euro 1,362 and 
1,786 in 1988 and 1994, respectively (table 5.1). Total costs in current prices 
increased by 36.6% between 1988 and 1994. The inflation between both periods 
was 16.6%. The annual growth rate corrected for inflation was 2.6%. 
Table 5.1 Per capita health care costs by age and type of care, 1988- 1994 (£), and 
cost increase between both years (€, index (1988=1.0)) 
Per capita costs (€) Cost increase 
1988 1994 absolute rate 
difference (€) (1988 = 1.0) 
Total health care 1,362 1,786 424 1.31 
men 1,139 1,494 356 1.31 
women 1,580 2,071 491 1.31 
Acute care 413 540 127 1.31 
men 375 497 122 1.33 
women 451 582 131 1.29 
Long-term care 413 532 119 1.29 
men 296 383 87 1.29 
women 528 677 150 1.28 
Other types of care 536 714 178 1.33 
men 468 614 147 1.31 
women 602 812 210 1.35 
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Figure 5.1 Per capita health care costs in 1988 and 1994 by age (acute care costs and the 
sum of acute and long-term care in € (other types of care (see table 1) 
excluded)) 
Table 5.1 shows changes by sex and health care sector. Sex differences in growth 
rates are small. Nominal cost increase of women is higher than for men due to 
more utilisation growth of institutionalised care, especially in the long-term care 
sector (nursing homes and homes for the elderly) and other care (maternity 
services). Unfortunately it was not possible to include the other care in the age-
specific comparisons. Higher growth rates for acute care costs were seen in men. 
Figure 5.1 shows the age pattern of total costs per inhabitant for acute and 
long-term care. Total costs are high at birth and drop to their lowest levels in 
youth and young adulthood. From age 55 onwards, per capita health care costs 
increase exponentially. The high costs at birth consist almost entirely of acute care 
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and both (--), corrected for inflation. 
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costs. In childhood acute care costs are very low, thereafter they gradually 
increase with age. Acute care costs reach their maximum in the age group 80 - 84, 
after which they decline slightly [see also Lubitz 1995, Perls 1996, Peds 1997]. 
Long-term care costs are concentrated in population groups with chronic 
conditions and disabilities, particularly people from age 75 onwards. 
Figure 5.2 shows the age-specific grovvth rate of acute and long-term care. 
While the total growth rate is nearly identical for all ages, the growth rate for 
acute care increases vvith age whereas the growth rate for long-term care 
decreases by age. A balancing effect was observed betvveen trends in acute care 
and long-term care, A lower growth rate for acute care among younger people was 
compensated by a higher rate of long-term care. Among the elderly, the opposite 
was observed. Both phenomena together resulted in a nearly stable growth rate 
for total costs across all ages. Depending on the absolute cost levels (figure 5.1) 
the importance of these trends increases by age. 
The growth rate for long-term care results from higher expenditures in chronic 
care for younger people with disabilities and mental disorders and from relatively 
smaller investments in nursing home care for older people [Ministerie VWS 1996]. 
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The investments in long-term care for disabled children most likely resulted from 
catching up backlogs in this sector in combination with the development of a more 
individualistic provision of care rather than increasing health care needs among 
these children. 
The lower growth rate for long-term care with the older age groups results 
from societal choices to postpone chronic institutionalisation of the elderly for as 
long as possible. More disabled elderly are now cared for at lower costs in homes 
for the elderly or at home [Schreurs 1995]. Unfortunately home care was 
excluded from this comparison. Due to the observed trend, the severity of health 
care needs among the population in nursing homes and homes for the elderly 
increased on average as did the intensity of care. Furthermore a part of former 
professional care shifted on to informal care-givers. 
The age pattern in the growth rate of acute care is mainly caused by increasing 
numbers of interventions at older ages (figure 5.3). At age 0-24 the number of 
clinical interventions declined by 0.7: from 4.4 to 3.7 interventions per 100 
inhabitants (age standardised). The intervention rates for the age groups 25-44 
and 45 - 64 changed only slightly. The older age groups experienced a substantial 
growth in clinical interventions, especially in the age group 75 - 84, where 
intervention rates increased from 17.5 per 100 inhabitants per year to 22 per 100 
inhabitants per year (annual growth rate 3.8%). 
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Figure 5.3 Clinical intervention rates per 100 inhabitants by age, 1988 -1994 
(age standardised). 
Table 5.2 Characteristics of 15 intervention groups: intervention rates in 1994 (number per 100,000 inhabitants and%), changes in 
intervention ~·ates in 1988~ 1994 (number per 100,000 inhabitants and index (1988= 1)), share of clinical interventions in total of 
clinical and day-care intelYentions in 1994 (%), average duration per admission 1988-1994 (hospital days), average costs per 
intervention in 1994 (€, weighed by numbers of different interventions within each group) 
Intervention group Clln!callntervent!on rate (age standardised per 100,000 Inhabitants) Average number of 
Number In (%) Changes In 1988-1994 Share of clinical Inpatient hospital days 
1994 Interventions In per admission 
total of clinical and Number Index day~care 1988 1994 (1988~1) Interventions(%) 
Group A 
Ophthalmic surgery 402 (5.1) 82 1.26 75 6.1 3.6 
Cardiovascular surgery 181 (2.3) 26 1.17 100 13.4 12.9 
Gall bladder removal 168 (2.1) 43 1.34 97 15.5 10.1 
Hlp fractures repair 156 (2.0) 34 1.28 100 26.5 20.9 
Orthopaedic Interventions 879 (11.0) -1 1.00 72 12.0 9.9 
Peripheral vascular surgery 312 (3.9) -1 1.00 85 14.7 12.8 
Female breast surgery 192 (2.4) -16 0.92 83 8.2 6.6 
Skin 258 (3.2) -37 0.88 71 11.2 10.1 
Ears 122 (1.5) -52 0.70 20 6.6 4.7 
Group B 
Childbirth 490 (6.2) 75 1.18 97 7.3 6.0 
Tonsillectomy 135 (1.7) -37 0.79 27 3.6 3.4 
Male genital tract 215 (2.7) -58 0.79 60 9.2 7.4 
Female genital tract 374 (4.7) -172 0.68 67 8.0 7.9 
Appendectomy 112 (1.4) -21 0.84 100 7.9 6.4 
All other 3,962 (49.8) 400 1.11 71 11.9 10.1 
Total 7,958 (100.0) 266 1.03 70 11.3 9.6 
Group A. Interventions tliat contribute to {1iglier intelwntions rates and costs at older ages and/or lower rates and costs at younger ages. 
Group B. lntelwntions wit11 decreasing raies at all ages or increasing rates at younger ages. 
Cost per 
Intervention 
(weighed average 
In €, nursing days 
excluded) 
516 
3J15 
829 
1,207 
614 
885 
769 
241 
698 
461 
115 
586 
718 
466 
484 
625 
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A Interventions that contribute to higher intervention rates and costs at older 
ages and/or lower rates and costs at younger ages 
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Figure 5.4 Change in clinical intervention rates per 100 inhabitants by age and 
intervention group, 1988-1994 (age standardised, index (1988=1)) 
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Figure 5.4 and table 5.2 show the characteristics of the 14 most frequent 
intervention groups, which represent 502% of the total number of clinical 
interventions in 1994, and 60.4% of total intervention costs. The interventions can 
be divided into two groups. Interventions in the first group contributed to the 
pattern of increasing intervention rates and costs at older ages and decreasing 
rates and costs at younger ages in the period 1988- 1994. Interventions in the 
second group do not contribute to this pattern. The first category represents 33.6% 
of all interventions (66.8% of the selected interventions). The intervention rates 
for ophthalmic surgery, cardiac interventions (CABG, PTCA and other), gall 
bladder surgery, and hip fracture interventions showed the strongest growth (table 
5.2). With the exception of ophthalmic surgery these interve.J.tion groups belong 
to those medical services with the highest average treatment costs, the largest 
number of hospital days per admission and hardly any possibilities for day-care 
(table 5.2). The strong increase in ophthalmic interventions among the oldest old 
is caused by cataract extraction, which shifted partly to day-care. Total clinical 
intervention rates for peripheral vascular disease and orthopaedic conditions 
remained the same, vvith a small shift from younger to older ages. Day-care 
increased. Clinical costs and hospital days are average (orthopaedic surgery) or 
higher (vascular disease). Diseases of the skin showed a 12% decline in the total 
clinical intervention rate, mainly due to increased day-care treannent. Female 
breast surgery decreased by 8%. Figure 5.4 shows a slightly different age-pattern 
compared to other interventions. Due to the Dutch breast cancer-screening 
program for women in the age group 50 - 70 intervention rates increased most 
sharply in this age group (Koning 1995]. The age standardised number of clinical 
ear interventions declined by 30%, mainly due to myringotomy, which shifted to 
day-care and was partially substituted by antibiotic treatment. The resulting cost 
reduction among younger persons increased the slope of the age-specific acute 
care costs curve. 
The second group consists of interventions that do not contribute to the 
sharper increase .of interventions and costs among the elderly. This group 
represents 16.7% of the total number of interventions (33.2% of selected 
interventions). Two subcategories can be distinguished. Interventions in the first 
subcategory are strongly bound to younger people: childbirth and tonsillectomy. 
Both interventions show the same pattern of decreasing rates among the youngest 
age group and increasing rates among people of age 24- 44. The number of 
interventions related to childbirth increased sharply (18%). The impact on total 
costs is substantial due to the large number of interventions in combination with 
moderate average costs and number of inpatient days of hospital stay. 
Tonsillectomy saw a strong shift to day-care, especially among the youngest age 
group (Wasowicz 1998]. Clinical interventions in the second subcategory 
decreased at all ages. Important groups are the operations on male and female 
genital organs. The number of clinical prostatectomies declined because 
transurethral prostate resections were partially replaced by day-care surgery. In 
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the Netherlands, the number of hysterectomies dwmdled. Clinical appendectomies 
declined by 16% in the observed period. This development was not associated 
with a transition to day-care. Although the average duration of hospital admissions 
also declined, the cost effects remained rather modest, mainly due to the relatively 
low rate of appendectomies compared to other interventions. 
We combined the age patterns in average costs and age-specific growth rates 
with population forecasts to project future health care costs in constant prices 
[CBS 1995, Beer 1997]. Table 5.3 shows national costs of acute and long-term 
care in 1994 and two projections for 2015. In the demographic projection, per 
capita costs of 1994 are multiplied by the population forecasts per age and sex 
group. ~n this constant-per-capita-costs scenario, national costs will increase by 
1.1 o/o per year, mainly due to the increasing number of elderly with high long-term 
costs. In this projection, costs will shift from the younger to the older age groups. 
In 1994 some 53.3% were accounted for by the age group 65+, a percentage that 
will rise to 59.6% in 2015. 
Assuming the age-specific 1988 -1994 trends in acute and long-term costs 
persist in future decades, total costs will increase by an annual rate of 2.7%, 
mainly due to the increasing average acute care costs among the elderly, and the 
increasing average long-term costs among the younger population. 
Table 5.3 National health care costs in 1994 and projections for 2015 by age and health 
care sector (£ 1 million, share of age groups in %, annual growth rate) 
Age group Total Annual 
0-64 65+ growth 
€ 1 min (%) € 1 min (%) € 1 min (%) rate 
1994 
Acute care 4,560 (54.9) 3,742 (45.1) 8,302 (100) 
Long-term care 3,129 (38.3) 5,051 (61. 7) 8,180 (100) 
Total 7,689 (46.7) 8,793 (53.3) 16,482 (100) 
2015- I 
Acute care 5,105 (49.4) 5,232 (50.6) 10,337 (100) 1.1% 
Long-term care 3,298 (31.5) 7,175 (68.5) 10,473 (100) 1.2% 
Total 8,402 (40.4) 12,408 (59.6) 20,810 (100) 1.1% 
2015- II 
Acute care 6,101 (40.5) 8,977 (59.5) 15,078 (100) 2.9% 
Long-term care 7,058 (51.2) 6,724 (48.8) 13,781 (100) 2.5% 
Total 13,158 (45.6) 15,701 (54.4) 28,859 (100) 2.7% 
2015 -I Demographic projection 
2015 -II Demographic projection and age-spedfic trends 
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Figure 5.5 National costs for total care and acute care by age in 1994 and projected costs 
in 2015 using the 1996 population forecasts and the age-specific growth rates 
of figure 2 (costs in£ 1 million, constant prices of 1994). 
In this projection the distribution of total costs over age groups will change 
sligbtly, due to the balancing effect of the age-specific trends (figure 5.5). Of the 
total costs, 54.4% will be spent on the group aged 65+, due to an increasing share 
in acute care costs (from 45.1% in 1994 to 59.5% in 2015) and a decreasing share 
in long-term costs (from 61.7% in 1994 to 48.8% in 2015, table 5.3). 
Because the projection of future health care costs is in constant 1994 prices, 
the actual monetary value in 2015 will be much higher than the figures in table 
5.3. Over the period 1988-1994 increasing prices were responsible for more than 
a half of the cost increase in current prices. More important than general inflation, 
however, is the increase of health care specific prices. As Baumol has argued, 
prices in labour intensive sectors such as health care and education will rise more 
rapidly compared to general price levels (Chapter 4) [Baumol 1993]. This effect 
renders the figures in table 5.3 conservative estimates of real costs, ceteris paribus 
the population forecasts and the age-specific trends in intervention rates and 
technology utilisation. 
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5.4 Discussion 
We described age-specific developments in per capita health care costs of acute 
and long-term care in the Netherlands. Our data support the idea of diverging 
average costs between younger and older people. A nearly constant growth rate at 
all ages, consisting of an increasing growth rate for acute care and a decreasing 
rate for long-term care is the driver for this split. Effective medical interventions 
apparently have different consequences at different age groups. Assuming a 
constant epidemiological burden by age an sex in the observed period, 
technological change causes a relative reduction in costs at younger age groups, 
which is offset by additional care for people with disabilities and psychiatric 
conditions. In the older age groups, technological change causes increasing 
numbers of interventions and a more than average growth rate for acute care, 
which is compensated by a less than average growth rate for long-term care. 
In future decades, total health care costs will increase. Given the age pattern of 
per capita costs, total costs will increase due to the expansion of the elderly 
population. This development is reinforced by increasing health care needs of the 
elderly, resulting from the growing survival rate of frail elderly, augmenting 
medical technologies and expanding per capita demands. 
The changes in the age pattern are caused by high levels of long-term care 
costs with a low growth rate, and the high growth rate of expensive clinical 
interventions particularly in cardiovascular diseases. Health care costs will not 
only expand but will also shift from younger to older ages and from care to cure. 
The validity of these findings may be considered high, in the light of a number 
of important characreristics of the Dutch health care system. First, the health care 
system covers nearly all medical services and sectors, including homes for the 
elderly. Second, the sector definitions were identical for 1988 and 1994. Third. the 
same registry and the same case definitions were used for each sector to allocate 
costs in both years. Fourth, the main registries have national coverage of about 
95% and higher. Fifth, the same methodology was used for the cost calculations in 
both years. 
Because of the relatively short period of six years, no major changes are 
expected in the codification of medical care in either year. Because the 
retrospective remuneration of all health services the codification is not biased by 
financial incentives, as for instance DRG~based health systems are. 
Notwithstanding these advantages two aspects may hamper interpretation. 
First, the intervention rates relate only to clinical treaonent. Day-care 
interventions were excluded because of incomplete data for 1988, making 
comparison impossible. However, in 1988 day-care was rare, and the 1994 data 
supports the plausibility of the age-pattern found (table 5.2). Second, the analysis 
was based on 60% of total health care costs. General practitioners, 
pharmaceuticals, physical therapy and home care among some smaller sectors 
were excluded. Although age-specific trends could not be quantified for these 
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sectors, there are indications that the differences with the included sectors are 
rather smalL The trend in long-term care costs, however, might be somewhat 
underestimated due to the exclusion of home care. This trend indicates a 
transition of institutionalised care to home care and informal care. 
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The age-specific trends reflect the influence of governmental health care 
policies. In the observed period large investments in institutionalised care for the 
elderly were withheld, while in psychianic care and instirutions for disabled 
people backlogs were removed by additional investment. The influence of health 
care policy on the calculated growth rate, therefore, seems to be relatively large, 
especially for long· term care where costs are contained by fixed budget 
constraints. In acute care, the Dutch government also contains costs by budget 
constraints, but these constraints do not apply to physicians. The physicians, 
therefore, have much more possibilities to influence the volume of care and the 
application of interventions. As a result the distribution of acute care costs is much 
more driven by epidemiological and technological developments. 
In the Eighties the health care system left some possibilities for a more rational 
and frugal management, but after the cost containment policies of 1988-1994 
much of the proliferation has been stopped and left little budgetary elbowroom. 
The projections, therefore, must be understood to be a conservative estimate of 
future costs, which can be used as a rationale for new health care policies. 
It is concluded that ageing as well as technological and epidemiological 
changes reinforce the age pattern in health care costs. In future decades the share 
of the elderly in total health care costs will increase, imposing a strong 
responsibility on government and society for an appropriate allocation of sufficient 
resources. 
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Abstract 
Background 'Health care costs are continuously increasing and impose a 
strong responsibility on governments for an adequate 
allocation of resources among health care provisions and 
patients. 
Objectives To describe the health care costs of intellectual disability and 
other mental disorders in the context of total costs of all 
other diseases. To determinate the future need of health care 
resources especially for intellectual disability and mental 
disorders. 
Methods We performed a top-down cost of illness study comprising all 
health care costs of the Netherlands in 1994. For all22 
health care sectors data on health care use were obtained 
and used to ascribe costs to disease (62 groups), age (21 
groups) and sex. 
Results Costs of mental disorders are by far the largest in the Dutch 
health care system. 25.8% of total disease specific costs 
could be ascribed to mental disorders (psychiatric conditions 
10.6%, intellectual disability 9.0o/o, dementia 6.2%). There 
are large differences betvveen age-sex groups. Costs of 
intellectual disability and schizophrenia are higher among 
men; costs of dementia and depression are higher among 
women. The age pattern shows tvvo peaks. The first at age 
25-35 (intellectual disability and psychiatric conditions), 
the second at age 75-85 (dementia). Time trends between 
1988 and 1994 show an average annual growth rate of 5.2% 
for total health care costs (psychiatric conditions 4.8%, 
intellectual disability 5.4%, dementia 9.4%). Demographic 
projections suggest a less than average cost increase for 
intellectual disability and psychiatric diseases (annual 
growth rate of 0.2% and 0.4% respectively) compared to 
costs of dementia and total health care (annual rate of 1.6% 
and 0.9% respectively). 
Conclu.sion.s Intellectual disability and mental disorders represent a large 
part of health care use in the Netherlands. The costs will 
inevitably increase due to the ageing of the population and 
increasing life expectancy among disabled people. Non-
specific cost containment measures may endanger the quality 
of care for vulnerable people at younger and older ages. 
Health care costs of 
intellectual disability 
6.1 Introduction 
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The care provided to people with intellectual disabilities* has received an 
increasing amount of attention in the past decades [Aspray 1999]. Whereas long-
term residential care used to be predominant , nowadays community oriented 
services running on 'ordinary life' principles are gaining ground. This transition 
caused benefits in all areas of functioning. Social abilities, social networks and 
oppottunities for integrated activities all increased [May 2000]. The repotted costs 
were comparable to the costs of residential care [Howe 1998], higher [Felce 1998, 
Dockrelll995] or slightly lower [Knobbe 1995, Stancliffe 1998] mainly depending 
on the case-mix and the levels of staffing [Davies 1991, Shiell1993]. 
The past decades also saw the start of the ongoing debate on cost containment. 
Governments in western countries were confronted with rising health care costs 
that in most periods exceeded economic growth. The need for cost containment 
gave rise to several policies to allocate health care resources in a more rational 
and efficient way. The debate and the policy measures focussed on the supply side 
of health care and their finance systems and the scope was mainly limited to 
specific health care sectors. However, an adequate health care policy for future 
decades must also have attention for the demand side and the perspective of 
population health. Until now, however, little note has been taken of the 
demographic and epidemiological detettninants of health care costs. This may be 
because the relation beMeen disease and costs is not straightfo:rvvard, and 
relevant data are often lacking. We performed a cost-of-illness study for the 
Netherlands in 1994 and repotted the results elsewhere (Chapter 2) [Meerding 
1998]. The present chapter highlights the costs of intellectual disability from the 
perspective of total costs of all diseases and makes specific comparisons with other 
areas of mental health care. 
* In this chapter 'intellectual disability' refers to 'mental handicap', 'mental retardation' or 
'learning disability' (code 317-319 and 758.0 in the ICD-9) according to the tenninology 
used by psychiatrists in the United Kingdom and the Journal of Intellectual Disability. 
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In this cost-of-illness study we divided total health care costs in the Netherlands by 
health care sector; diagnosis, age and sex, to detem1ine the illnesses and age 
groups in which the demand for care is the highest. We performed our study from 
a health care perspective: only direct medical costs were included. The Dutch 
health care system is ideal for this type of analysis since the system is very 
comprehensive and more than 99% of the population has full insurance coverage. 
Furthermore, as a result of a longstanding administrative tradition most health 
sectors have excellent patient-based registries, most of which are national. Thus 
acute care but also long-term care to disabled people could be analysed. As 
intellectual disabilities predominantly are associated with lifelong diseases with 
little room for treatment, we are happy to present its costs from the perspective of 
population health and total health care. 
6.2 Materials and methods 
We used data on health care costs for each sector from the Dutch Ministry of 
Health for 1994 [Ministerie VWS 1996]. We clustered the diagnoses of the 
International Classification of Diseases (I CD, 9th revision) into 5 categories of 
mental disorders (intellectual disability, dementia, depression, schizophrenia and 
other psychiatric conditions) and 15 categories of soma ric diseases (mainly 
chapters of the ICD-9). We defined groups of diagnoses to minimise 
misclassification between diagnostic groups and to ensure that each group would 
be large enough to describe a sufficiently large proportion of health care costs. To 
avoid double counting, only primary diagnoses were taken into account. 
For each health care sector, we identified key variables representing equal 
units of health care use, such as days of stay for nursing costs in hospitals and 
inpatient care for disabled and elderly people, or outpatient visits for costs of 
outpatient care. We divided each sector by diagnoses, sex and age (5-year gmups). 
The distribution of the costs were considered to be the same as the distribution of 
the key variable for that sector. Thus, for each health care sector costs for all 
combinations of age, sex and diagnostic group were calculated as the proportion 
of the key variable times the total sector costs. For some sectors with a 
heterogeneous health care supply, more sophisticated methods were employed, 
using additional variables that related costs to different types of care. 
The probability distribution of key variables was derived from sector-specific 
registries and sample surveys. Detailed information about the registries and the 
key variables used is available in appendix A. 
Our top-down approach and the use of cross-sectional data have some 
drawbacks. Without advanced modelling it is impossible to estimate costs at 
individual level, and the use of only primary diagnoses will resnlt in an 
underestimation of underlying diseases and comorbid conditions. Furthermore our 
figures exclude the costs of family, informal care-givers and specialised schools. 
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6.3 Results 
Costs by sector 
The Dutch health care system is extremely comprehensive. Total health care costs 
in 1994 amounted to € 26,983 million, representing 9.7% of the gross national 
product. Average per capita costs were € 1,453 for men and € 2,049 for women. 
Table 6.1 summarises the distribution of costs among the different health care 
sectors. Hospitals represent the largest share, accounting for 32.1 o/o of total health 
care costs, and 39.2% when psychiatric care is included. The costs for long-term 
care are also substantial. Care for people with disabilities represents 8.6% of the 
total budget. Several types can be distinguished. Most costs relate to the care 
provided to persons with intellectual disabilities and within this group the major 
item is that of permanent residential care. 
Table 6.1 Health care costs in the Netherlands by sector (1994). Costs in£ 1 million, 
share in total costs(%). Capacity of major fadlities in number of beds/places 
(absolute numbers and rate per 1,000 inhabitants (rounded to thousands). 
Health care sector 
Care for disabled people 
Intellectual disabilities 
- institutions for 24 hours care 
-activity centres (9 a.m. - 5 p.m.) 
-family homes (5 p.m. - 9 a.m.) 
- home care and other 
Physical and sensory disabilities 
Psychiatric care 
Nursing care 
Nursing homes 
Homes for the elderly 
Home care 
Other health care sectors 
Hospital care 
Primary care 
Pharmaceutical care 
All other care and administration 
Total 
Costs in 1994 Capacity 
------·······----·------------------
€ 1 min % 
(2,324) (8.6) 
1,430 5.3 
266 1.0 
364 1.3 
64 0.2 
199 0.7 
1,910 7.1 
(6,308) (23.4) 
2,409 8.9 
2,445 9.1 
1,454 5.4 
8,658 32.1 
2,940 10.9 
2,386 8.8 
2,458 9.1 
26,983 100.0 
Absolute 
number of 
beds/places 
34,000 
16,000 
17,000 
50,000 
6,000 
33,000 
55,000 
114,000 
Rate 
(per 1,000 
inhabitants) 
2,1 
1,0 
1,1 
3,1 
0,4 
2,1 
3,4 
7,1 
61,000 3,8 
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Activity centres (day care from 9 a.m.- 5 p.m.) and family homes (5 p.m.- 9 a.m.) 
are relatively modest in cost, namely 1.0% and respectively 1.3% of total health 
care costs. Costs for home care and other facilities for people with intellectual 
disabilities are low (0.2% of total costs), in absolute levels, but also in relation to 
the number of people that is cared for. 
The figures must be interpreted with caution. In line with the transition from 
residential care to community care as mentioned in the introduction, the Dutch 
government allowed providers of disability care to substitute some provisions by 
other within the existing budget system. So institutions for residential care could 
provide ambulatory support and home care to people living at home. Hence the 
care for disabled people was more community oriented than the institutional cost 
figures suggest. 
Unlike the system in most other countries, homes for the elderly in the 
Netherlands are included in the health care system. The total costs of these homes 
amount to 9.1 o/o of health care costs, which is slightly higher than nursing home 
costs (8.9%). The population of the homes for the elderly consists mainly of frail 
elderly people, which by assumption have the same distribution of diseases and 
impairments as people in nursing homes, but less severe. Together vv:ith home care 
(district nursing) total nursing care represents 23.4% of Dutch health care costs in 
1994. Primazy care, pharmaceutical care and a group of all other provisions 
represent each about one tenth of total health care costs, and are relatively small 
compared to hospital care and long-term care. 
Costs by diagnosis 
Figure 6.1 shows the distribution of health care costs among the 17 chapters of the 
ICD-9. Mental disorders represent by far the largest share in total costs, at great 
distance followed circulatory, digestive and musculoskeletal diseases. Costs of 
cancer are relatively low, despite interventions with high per item costs such as 
surgery, radiation and chemotherapy. The main reason for these low costs is the 
short period of clinical care compared to the long-term nature and residential care 
of mental disorders. Costs for congenital diseases are low, because major groups 
such as Down's syndrome and fragile.X are classified as intellectual disabilities 
within the lCD chapter of mental disorders. As a result of the top-down character 
of the study using only primary diagnoses, however, the relatively high costs of 
heart disease among people with Dovv:n's syndrome are attributed to the I CO-
chapter 'circulatory diseases'. 
Table 6.2 distingulshes 20 disease categories. Compared to figure 6.1 the 
mental disorders have been split up into five categories (intellectual disability, 
dementia, depression, schizophrenia and other psychiatric conditions) while some 
other !CD chapters have been combined. Symptoms, ill-defined conditions and 
costs that could not be assigned to specific categories due to data problems were 
classified as 'other'. The category 'non-specific costs' consists of health expenditure 
without any relation to diagnosis such as expenditure on health care 
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administration and living costs in homes for the elderly. The disease categories are 
ranked from highest to lowest shares in total costs. Intellectual disabilities rank 
first with a share of 9.0% in total disease-specific costs. Large differences betvveen 
age and sex groups exist (rank 1 among age group 0 - 64; rank 16 among the 
elderly). Focusing upon mental disorders, dementia ranks 5 (only ;,65, mainly 
women), depression has nearly the same share in total costs as all diseases of the 
nervous system together, and costs for schizophrenia are higher than total costs of 
all infectious diseases. These categories also reveal interesting sex differences: 
costs of depression are high among women while men have more costs for 
schizophrenia. This finding cotresponds to epidemiological data on the prevalence 
of diseases [Bijl1998, Mutray 1994]. All other psychiatric diseases together rank 
4, accounting for 6.7% of total costs mainly among age group 0- 64 (rank 2). 
Costs of men are higher due to addiction of drugs and alcohol. From the other 
categories we mention musculoskeletal diseases (the only disease that appears in 
the top 5 of both age groups), stroke (that ranks 3 among elderly), dental 
abnormalities (ranks 4 among age group 0- 64), accidents (ranks 5 among 
elderly, mainly consisting of falls ) and respiratory diseases (nearly the same 
ranking across age groups, higher costs for men due to smoking-related chronic 
pulmonary diseases). 
Blood diseases - IV-
Congeni1al malformations- XIV-) 
Perinatal conditions- XV- ~ 
Infectious diseases- I -~ 
Skin diseases- XII-
Endocrine and metabolic diseases -Ill-
Pregnancy and childbirth- XI-
Urinary system and genital organs- X-: 
Neoplasms- ll - , 
Respiratory system- VI !I -
Injury and poisoning- XVII-
Symptoms and ill-defined conditions -XVI-
Nervous system and senses- VI-
Musculoskeletal diseases- Xlli-
Digestive system- IX - \ 
Circulatory diseases- VII-, 
Mental disorders- V-
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Figure 6.1 Dutch health care costs by ICD-9 chapter and sex (1994, £ 1 million, not 
allocated costs excluded). 
Table 6.2 Disease specific health care costs by diagnosis, age and se.x-. Share in total disease specific costs per age-sex group (%), ranking from 
high to low costs, ranking numbers for age groups 0- 64 and 2==65 
Diagnostic groups {lCD chapter and codes) Whole Age 0-64 Age <:::65 
population 
---- ----------------- --------------Share In f'.1en Women Total Men Women Total total costs 
(%) % % % Rank % % % Rank 
1. Intellectual disability (V: 317-319, 758.0) 9.0 17.2 11.6 14.2 (1) 1.9 1.1 1.3 (16) 
2. Heart and vessels (VII: 390-429, 440-459) 8.1 7.0 4.0 5.4 (5) 16.3 10.0 12.1 (2) 
3. f'.-1usculoskeleta1 (XIII: 710-739) 6.7 6.9 7.0 7.0 (3) 4.0 7.4 6.2 (4) 
4. other psychiatric (V: 291-316, excl. 295-6, 300.4) 6.5 10.0 8.0 8.9 (2) 2.6 3.0 2.9 (11) 
5. Dementia (V: 290) 6.2 0.2 0.2 0.2 (20) 9.2 18.2 15.1 (1) 
6. Dental (IX: 520-529) 4.7 6.7 6.9 6.8 (4) 2.8 1.1 1.7 (13) 
7. Accidents (XVII: 800-999) 4.7 4.7 3.0 3.8 (9) 4.1 7.2 6.1 (5) 
8. Respiratory (VIII: 460-519) 4.5 4.9 3.9 4.4 (7) 7.7 3.2 4.7 (7) 
9. Cancer (II: 140-239) 4.4 2.7 3.9 3.3 (11) 8.6 4.6 6.0 (6) 
10. Digestive (IX: 531-579) 4.0 4.4 3.5 3.9 (8) 4.9 3.9 4.2 (8) 
11. Stroke (VII: 430-438) 3.6 0.9 0.6 0.8 (19) 8.0 7.7 7.8 (3) 
12. Urinary and genital (X: 580-629) 3.2 1.8 4.8 3.4 (10) 3.8 2.2 2.7 (12) 
13. Sense organs (VI: 360-389) 3.1 3.6 2.9 3.2 (13) 3.1 2.9 3.0 (10) 
14. Pregnancy (XI: 630-676) 2.9 o.o 9.0 4.8 (6) 0.0 0.0 0.0 (20) 
15. Nervous system (VI: 320-359) 2.7 2.6 2.5 2.5 (14) 3.6 2.8 3.1 (9) 
16. Depression (V: 296, 300.4) 2.5 2.4 4.0 3.2 (12) 1.1 1.7 1.5 (14) 
17. Skin (XII: 680-709) 1.8 2.1 2.2 2.1 (16) 1.3 1.4 1.4 (15) 
18. Schizophrenia (V: 295) 1.6 3.3 1.8 2.5 (15) 0.2 0.2 0.2 (18) 
19. Infectious (I: 001-139) 1.5 2.0 1.8 1.9 (18) 0.8 0.8 0.8 (17) 
20. Perinatal I congenital (XIV, XV: 740-779, excl. 758.0) 1.2 2.2 1.8 2.0 (17) 0.1 0.1 0.1 (19) 
All other 16.9 14.4 16.6 15.6 16.0 20.6 19.0 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Total disease specific costs (€ 1 m!Hlon) 24,106 6,700 7,693 14,393 3,321 6,393 9,714 
Non-specific costs 2,877 644 589 1,233 389 1,255 1,644 
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Costs of mental disorders by age and sex 
Table 6.2 shows that mental disorders (lCD chapter V) represent 25.8% of total 
disease specific costs, with a substantial difference among large age groups (age 
0-64: 29%, age '<65: 21 %). Figure 6.2 shows the whole age-sex picture of this 
!CD chapter. The costs of mental disorders are expressed as the fraction of total 
costs per age-sex group. The curve shows a mountain-like pattern with peaks at 
age 20-25 and 85-94, and the lowest point at age 70- 74. In men aged 15-
39, the costs of mental disorders represent more than 40% of the total costs in this 
group. Compared to men, the costs of mental disorders (as a fraction of the total 
costs) in women are 10%-15% points lower in this age group. There are tvvo 
main causes: lower costs among women for intellectual disabilities and higher 
total costs. Costs in 15 - 39 year women are dominated by high costs for 
pregnancy and childbirth 
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Figure 6.2 Costs of mental disorders (ICD chapter V) by age and sex (share in total 
health care costs per age-sex group in %) 
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sex ( £ 1 million) 
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which also revert the peak into a local minimum for women aged 25 - 34. Figure 
6.2 reveals one more interesting difference: bervveen the age of 0- 49 the 
proportion of mental disorders is higher for men compared to women, while from 
SO onwards the opposite holds. There are four reasons: 1) the prevalence of 
intellectual disability is higher in men; 2) women fall pregnant (high other costs at 
younger ages); 3) the incidence of circulatory diseases is high among men 
compared to women (high 'other' cost for men at age SO -74); 4) women get old 
(high costs for dementia). 
Figure 6.3 gives the age-sex distribution for four specific mental disorders and 
a group of other psychiatric conditions. The curves affirm the higher costs for 
intellectual disability among men, and higher costs for dementia among women, 
as well as the age patterns of both diseases. The figure also shows that the higher 
costs for schizophrenia among men are mainly visible in early adulthood, while 
higher costs for depression in women show a more proportional age pattern with 
costs more evenly distributed among the age groups form young to old. Lastly, the 
curve for other psychiatric conditions shows an upward shift in costs for men at 
age 1S - 24 which is caused by addiction related health care. 
Trends and projections 
Health care costs change in the course of time. Several influences can be 
distinguished, related to demographic, epidemiological, technological and 
economic changes (Chapter 4). Between 1988 and 1994 Dutch health care costs 
increased by an average annual rate of S.2o/o (table 6.3). The growth rate for 
intellectual disabilities was slightly higher (S.4o/o) and for psychiatric conditions 
slightly lower (4.8%). Dementia experienced the sharpest increase (9.4%). This 
growth could partly be assigned to demographic change. The annual cost increase 
resulting from population growth and ageing amounted to l.So/o for all diseases, 
with notable differences for mental disorders. The demographic growth rate for 
intellectual disability was lowest (0.6%) and for dementia the highest (2.4%). 
Compared to all other diseases the non-demographic cost increase of intellectual 
disabilities and dementia was quite large. This was caused by relatively large 
investments in care for the disabled and an increasing share of demented elderly 
in the nursing homes (ChapterS). 
Cost-of-illness data can be used in combination with population forecasts for 
projections of future health care costs [Beer 1997]. We made a demographic 
projection for 201S. In the period 1994- 201S costs are expected to increase by 
an annual rate of 0.9% due to demographic changes (constant prices and all other 
trends excluded, table 6.3). Due to the ageing of the population, the costs of 
diseases that are prevalent at older ages will increase more, and those of diseases 
at younger ages will increase less. Our projections show an annual increase of 
1.6% for dementia and 0.2% for intellectual disability. For psychiatric diseases, we 
projected an annual cost increase of 0.4% which is also lower than for the somatic 
diseases (1.0%). As a result, the share of dementia in total cost of illness will 
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increase, while the amounts accounted for by intellectual disabilities and 
psychiatric conditions are expected to decrease. The sex distribution changes 
slightly to higher costs for men. 
Our demographic projections neglect increasing life expectancy. We assumed 
that costs for each combination of age, sex and disease group remain constant and 
multiplied these figures with changing cohorts in the population forecasts. As 
result of this method, future costs are underestimated. The costs of intellectual 
disability, in particular, are underestimated because life expectancy in this group 
continues to rise relative to the remainder of the population. The effects of 
longevity could be analysed using specific life-tables for this population. The cross-
sectional static character of the cost data, however, likely causes problems here. 
Given the high prevalence of heart diseases in elderly people with Down's 
syndrome, the static costs data would underestimate the real costs also in a 
scenario with increasing life expectancy. In fact, longitudinal data for the costs in 
the last year of life are needed. 
Table 6.3 Cost increase of mental disorders and all other diseases. Nominal and · 
demographic development between 1988 and 1994, projection for 2015 
(annual growth rate in%) 
Annual growth rate (%) Share in total costs 
(%) 
1988- 1994 1994- 2015 
total demo* demo* 1994 2015 
Intellectual disability 5.4 0.6 0.2 9.0 7.8 
Men 5.5 0.6 0.2 (55.9) (55.8) 
Women 5.1 0.7 0.2 (44.1) (44.2) 
Psychiatric diseases 4.8 1.3 0.4 10.6 9.6 
Men 5.3 1.2 0.4 (46.2) (45.4) 
Women 4.4 1.3 0.5 (53.8) (54.6) 
Dementia 9.4 2.4 1.6 6.2 7.2 
Men 10.2 1.6 2.3 (21.5) (25.0) 
Women 9.2 2.6 1.4 (78.5) (75.0) 
All other diseases 5.0 1.6 1.0 74.2 75.4 
Men 5.1 1.3 1.3 (41.0) (43.3) 
Women 5.0 1.7 0.8 (59.0) (56.7) 
Total health care 5.2 1.5 0.9 100.0 100.0 
Men 5.3 1.3 1.1 ( 41. 7) (43.2) 
Women 5.2 1.7 0.8 (58.3) (56.8) 
*demo = demographic 
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6.4 Discussion 
In the Netherlands a large share of toral health care costs deals with mental health 
care (25.8%). Five groups can be distinguished: intellectual disability, depression, 
schizophrenia and other psychiatric conditions (all at younger ages), and dementia 
(at old age). 
The Dutch health care system is very comprehensive and due to the availability 
of national registries containing data on health care use, all medical costs were 
included in our study and nearly all costs could be assigned to disease categories. 
This is important for the mental disorders which have much lower costs in other 
studies, partly because the specific types of care does not exist at all, are not seen 
as a part of the health care system, or are excluded from van cost-of-illness 
analysis due to data problems [Lubitz 1995, Moore 1997, Mathers, 1998]. As a 
result, international comparisons of cost-of-illness data, especially for mental 
disorders, are difficult to interpret. An advantage of our data is that costs are 
incorporated, which are more or less hidden in other countries. In an international 
context, therefore, our figures can be interpreted as an estimate of the share of 
mental disorders in total health care costs if the system is as comprehensive as the 
Dutch is. 
We performed our study from a health care perspective. Only direct medical 
costs were included. From a societal perspective, costs of informal care and 
indirect costs are also important [Drummond 1997]. Indirect costs relate to 
expenditure on specific schools as well as to productivity losses due to illness and 
disability. For mental disorders, especially intellectual disability and some 
psychiatric conditions, these costs will be very high, especially if the estimates are 
based on the human capiral approach. Although the appropriateness of calculating 
productivity losses for people who are not expected to have paid work during their 
whole life is dispurable, it is clear that the social burden of intellectual disability 
exceeds the cost estimates in this paper, particularly when non-economic aspects 
are included. 
General cost-of-illness studies are based on a top-down methodology using 
cross-sectional data on primary diagnoses. There are several problems here. First, 
it is difficult to detect some kinds of intellectual disabilities as for instance fragile X 
and Turner syndromes. Costs can be underestimated if diagnoses are not properly 
classified. Second, many people with Down's syndrome develop serious heart and 
renal diseases as well as dementia caused by vascular disorders. Due to the top-
down approach hospital costs for Down's syndrome are underestimated since these 
costs are allocated to the somatic diseases that were responsible for the hospital 
admission. Third, more in general mental disorders are classified as secondary 
diagnosis if people also suffer from somatic diseases. As a result all costs are 
allocated to the somatic disease. Fourth, menral disorders can delay the recovery 
from somatic diseases. In these cases health care costs increase, but are still 
attributed to the somatic disease according to primary diagnosis. 
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Due to the cross-sectional approach, costs can not be related to individual persons, 
but only to all persons within a specific disease-age-sex group. Altbougb lifetime 
costs can be estimated using the figures per age-sex combination in life-tables, a 
real dynamic analysis of, for instance, the costs in the last year of life is not 
possible. Such analyses require longitudinal data on individual persons. 
Our study is also static in another way. We used data on health care use in one 
particular year. In demographic projections, the cost-of-illness figures are 
extrapolated according to population forecasts. These projections are based on tvvo 
important assumptions. First life expectancy is assumed to be constant over time. 
The future costs for intellectual disability are underestimated because life 
expectancy among this population continues to rise more. Second, health care use 
per individual in a particular disease-age-sex group is assumed to remain the 
same. This is a bold assumption. A detailed analysis of the changes in cost of 
iliness in tbe period 1988 -1994 revealed major trends in healtb care costs tbat 
could be attributed to developments in healtb technology and healtb care policy 
(Chapter 5). These developments will, in some way or another, also influence 
future healtb care costs. If tbe trends in long-term care persist, tbe costs of 
intellectual disabilicy will increase above average rather than below average, as 
was indicated in the demographic cost projection. The care for the intellectually 
disabled, however, is undergoing fundamental change. Each cost projection, using 
either static figures from a certain year, or trends from a period in the past, must 
therefore be interpreted with care. 
We conclude that costs for mental disorders in general and intellectual 
disability in particular, represent a large share in tbe healtb care cost of civilised 
countries. In times of rapidly changing healtb care services tbe scarcity of 
resources imposes a strong responsibility upon sociecy for an efficient and fair 
distribution of resources among health care services and patients. Long-term care 
for disabled and old people will always be labour intensive and tbus expensive. It 
is also tbe hallmark of a civilised country. 
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Abstract 
It is widely assumed that health care costs can be reduced 
considerably by providing care in appropriate health care 
institutions without unnecessary technological overhead. This 
assumption has been tested in a prospective study. Conventional 
discharge after hip ftacture surgery was compared with an early 
discharge policy in which patients were discharged to a nursing 
home with specialised facilities for rehabilitation. We compared 
costs for both strategies from a societal perspective, using 
comprehensive and detailed data on type of residence and all 
kinds of medical consumption during a 4-month follow-up 
period. 
As expected, early discharge reduced the hospital stay (with 
13 days, p=0.001). More patients were discharged to a nursing 
home (76% versus 53%). Total medical costs during follow-up 
were reduced ftom an average of € 15,338 to € 14,281, 
representing relatively small and not significant savings 
(p = 0.3). There are two explanations for this unexpected result. 
First, hip ftacture patients were relatively cheap while in 
hospital. Hence nursing home costs almost equalled hospital 
costs per admission day. Second, compared to the 
conventionally discharged group early discharged patients 
received more medical procedures during the first post-operative 
days. We conclude that: 1) early discharge shifted rather than 
reduced costs; 2) the details of costing have a 
major influence on the cost-effectiveness of alternative discharge 
policies. 
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Costs after hip fracture 7 
7.1 Introduction 
Health technology assessment (HTA) is employed to optimise medical treatment in 
an economic way. Distinction is made bervveen cost~effectiveness analysis (CEA) 
and cost-minimisation analysis (CMA). CEAs deal with the question whether new 
or additional treatment provides value for money compared to conventional 
treatment. CEAs have been applied in the fields of prevention and treatment by 
comparing costs and effects for alternative medical procedures and 
pharmaceuticals. In CMAs it is studied to what extent less intensive treatment is 
worthwhile regarding medical outcomes. It is assumed that optimising the chain of 
care can reduce health care costs, for instance by replacing more expensive health 
care institutions with cheaper ones, without worsening medical outcomes. We 
performed a prospective study to compare the societal costs of a conventional 
discharge policy after hip fracture repair with the costs of an early discharge policy 
in which patients were rehabilitated in a specialised nursing home as example of a 
CMA.* 
Hip fracture incidence rises exponentially with age. All over the world ageing 
has important consequences for costs of treatment and rehabilitation [Melton 
1993, 1996, Boyce 1985, Laet 1996, Johnell1996, Hollingworth 1995]. The 
rehabilitation process is focussed in the first 4 months after hip fracture repair 
with estimated costs of around US$ 11,000 per patient [Cameron 1994, Berquist 
1991]. Since a substantial part of these costs (SO%) is made in the orthopaedic 
department of the hospital several strategies have been described to shorten 
hospital stay [Berquist 1991]. These strategies include joint orthopaedic-geriatric 
rehabilitation [Murphy 1987, Kennie 1988] and hospital-at-home schemes [Pryor 
"I,· This chapter is based on the paper 'Early discharge from hospital after hip fracture does not 
reduce societal costs' and belongs to a set of publications based on a clinical trial in which 
the benefits and costs of early discharge after hip replacement were assessed. The present 
chapter highlights the main findings of that study from a general economic perspective. In 
Chapter 9 the meaning and implications of these findings for cost-of-illness studies will be 
discussed. 
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1988]. Because functional outcome is expected to be similar, cost-effectiveness of 
early discharge depends on costs, and boils down to cost-minimisation. 
Shortening the length of the hospital stay could be expected to generate 
substantial cost savings, even with a similar total stay within institutions such as 
nursing homes and homes for the elderly, because of the higher costs per hospital 
day. Early discharge is also attractive because it provides possibilities for reducing 
backlogs and the waiting period for hip surgery. Potential drawbacks of early 
discharge, apart from medical outcomes, regard an unjustifiable shift to informal 
care and high capaciry costs for the continuous availabiliry of nursing home beds. 
Although several prospective studies reported the costs of hip fracture, few 
described the consequences of a change in treatment program [Cameron 1994, 
Farnworth 1995, Hollingworth 1993, and Stromberg 1997]. We compared the 
costs between a conventional discharge policy and a strategy in which patients 
were dlscharged earlier to a nursing home after day five of admission, if medicaliy 
possible. We checked for equivalence of medical outcome in terms of functional 
status and cognitive performance. Costs were studied in detail, since there are 
indications that costs are highest during the first post-operative days, and decrease 
thereafter [French 1995]. Using average charges or even average costs per hospital 
day would lead to an overestimate of the real costs per hospital admission, and by 
consequence to an overestimation of potential cost savings. 
7.2 Data and methods 
We performed a prospective study in a universit:Y and a general hospital in 
Rotterdam, the Netherlands. A ''before and after" study design was chosen. 
Randomisation of patients was not considered feasible since the change from 
conventional discharge to early discharge arrangements required such 
organisational adjustments that both service models could not be offered 
simultaneously. 
Patients, procedures and medical outcomes 
Between October 1996 and October 1998 we invited for participation in both 
hospitals ali patients, aged 65 years and older, with a ftesh hip ftacture. Excluded 
were patients vv:ith a hip fracture due to metastatic cancer or as part of a multi-
trauma. The first 130 eligible patients formed the conventional discharge group of 
which 102 patients (78%) consented to participate in the study. Early discharge 
was proposed to the next 124 eligible patients, of whom 106 (85%) consented to 
participate. There were no clear differences in age and sex between participants 
and non-participants although slightly more non-participants lived at home before 
admission (85% versus 60%). 
Patients with conventional discharge stayed in hospital till rehabilitation was 
finished. The treatment consisted of physical therapy, which was given two times 
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per day by the hospitals' physical therapists under supervision of the ward 
physicians. Early discharge was implemented by a discharge protocol that started 
five days postoperatively. Administrative procedures were speeded up and the 
number of beds available on the rehabilitation ward of the participating nursing 
home was increased. Physical therapists, occupational therapists and social 
workers were involved in the rehabilitation process, supervised by a physician 
trained in geriatric medicine. 
Clinical equivalence was checked for functional outcome and cognitive status 
using the Rehabilitation Activities Profile (RAP) and the Mini Mental State 
Examination (MMSE) [Bennekom 1995, Folstein 1975]. The RAP is based on the 
International Classification of Impairments, Disabilities and Handicaps (ICIDH) 
and measures disabilities in communication, mobility and personal care. 
Costs: methods 
Costs were studied from a societal perspective using a bottom-up methodology 
[Drummond 1997]. First, real costs were estimated based on a detailed 
measurement of investments in manpower, equipment, materials, housing and 
overhead. Fees and charges were only used in case of uncommon interventions 
and standard laboratory analyses. Second, all medical costs were included as well 
as the costs borne by the patient and the family, for instance costs of informal care 
and travelling. Costs of absence from work and related productivity losses were 
not taken into account, because all patients were old and retired from work. 
Costs were calculated for the participating centres only. Hospital costs were 
estimated separately for a general and an academic hospital. Only one nursing 
home participated in the study. This nursing home had the disposal of a 
specialised rehabilitation ward with 30 beds. Because this ward existed already 
when our study started, we did not consider the invesrrnent costs of such a 
specialised rehabilitation ward. All capacity related costs were allocated to bed 
days using the real invesonents in the past and annual production figures. These 
figures included the occupation of nursing home beds. So the availability costs of 
these beds were discounted in the average costs per inpatient day. 
We calculated integral costs per patient. All medical costs during a certain 
period were included, although from a differential point of view- comparison of 
the two discharge strategies- some items were not relevant. For these items, 
including the hip replacement itself, we used charges instead of real cost 
estimates. 
We distinguished six categories of care (table 7.1): 1) inpatient days (in 
hospitals, nursing homes and elderly homes); 2) nursing (in hospitals, nursing 
homes and at home); 3) health practitioner activities (physicians, therapists and 
other); 4) medical procedures (therapeutic, diagnostic and laboratoty); 5) 
travelling (ambulance, taxi and other); and 6) informal care and other costs as 
meal service at home and adjusrrnent of the housing conditions. 
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Table 7.1 Cost categories and data used in cost calculations 
Cost category Parameter Data collection Cost 
volume of care* estimate 
H 5 Q 
(unit price) 
Inpatient days 
Hospital days * real costs 
Nursing home days * real costs 
Home for the elderly days * real costs 
Care 
Hospital minutes * real costs 
Nursing home minutes * real costs 
Home care minutes * real costs 
Health practitioners 
Physician (inpatient) minutes * real costs 
Physician (outpatient) visits * real costs 
General practitioner visits * fees 
Physical therapist minutes * real costs 
Psychologist/social worker visits * * real costs 
Other health professionals visits * * fees 
Medical procedures 
Hip replacement number by type (3) * charges 
Other therapy number by type (30) * charges 
X-ray hip number * charge 
X-ray thorax number * charge 
Other radiology number by type (30) * charges 
Laboratory number by type (125) * charges 
Travelling 
Ambulance rides * charge 
Taxi rides * charge 
Other rides * real costs 
Informal care and other 
costs 
Informal care minutes * shadow 
price 
Day care (hospital) number * charge 
Day care (nursing home) number * charge 
Other costs various * various 
* H = hospital registry, S = study registry, Q = questionnaire 
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Costs were estimated for a 7-month period, 3 months pre-operatively and 4 
months post-operatively. We distinguished seven periods based on the location of 
the patient: 1) before hospital admission; 2) from admission to day five after hip 
surgery; 3) from day 6 until discharge form hospital; 4) nursing home; 5) elderly 
home; 6) home; 7) readmission to hospital or nursing home. For each period we 
calculated total costs per patient for the six categories mentioned before. 
Costs were calculated by multiplying the volumes of health care use with the 
corresponding unit prices and are reported in 1998 Euros. Discounting was not 
relevant because of the limited time horizon. 
Costs: volume of health care use 
The volume of health care was observed in much detail. A research assistant 
registered for each patient the number of inpatient days, the time needed for 
nursing, care and therapy as well as the time spent by physicians and other health 
practitioners per admitted patient. Nursing time was registered in the patient files 
by the nurses in the hospitals and the nursing home. The research assistant took 
care of the completeness of the data. She also interviewed all caregivers about 
their time investments per patient and furthermore registered the type of hip 
surgery, the number ofX-rays and the number of outpatient visits to physicians 
and general practitioners. Detailed information on medical consumption in 
hospital was derived from the hospital information systems of the participating 
hospitals. These data included medical interventions other than hip replacement 
(30 categories), radiology (30 categories) and laboratory analyses (125 types). 
Data on nursing time and costs of home care were obtained from the largest 
provider covering 65% of the included patients. Data on outpatient care were 
collected by questionnaires. 
Medical consumption in hospital and nursing home was registered on a daily 
basis. Discharged patients were visited by the research assistant one month after 
inclusion and at the end of the follow-up period. She assisted the patients with 
questionnaires on medical consumption. If needed, for instance because demented 
people could not answer the questions, the research assistant gathered 
information from personnel in the nursing home or elderly home in which the 
patients lived, or otherwise from the relatives of patients at home. 
Costs: unit prices and cost calculation 
Unit prices for inpatient days were estimated as real, basic costs per day using 
detailed information from the financial accounts of the hospitals, nursing home 
and elderly home that participated in the study. These estimates included 
overhead and indirect costs but excluded all direct costs that were analysed 
separately. Hence nursing costs and cost of all diagnostic and therapeutic 
interventions and laboratory examinations, as well as all costs of health 
practitioners that are normally included in average day prices were calculated 
separately. We calculated average costs per hospital day for each patient in the 
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study population by summing up all costs per category of health care use. For 
readmissions in hospitals and nursing homes, partly not participating in the study, 
no detailed data on health care use per inpatient day were available. For these 
readmissions we therefore used ali-in average prices per inpatient day. 
The salary schemes of hospitals and other health care suppliers were used to 
estimate costs per hour for each type of care giver. Taxes, social securities and 
vacations were all included, as well as the costs for the time that could not be 
assigned to individual patients. 
In the Netherlands a detailed 'fee for service' system is used for the 
remuneration of medical intexventions and diagnostic procedures. For these 
categories we used the fees as a proxy of real costs. There are several reasons for 
not calculating real costs. First, the hip replacement as such was not the focus of 
our study but the discharge strategy after surgery. Second, the llst of diagnostic 
procedures is long, but total costs are relatively small and the Dutch charges for 
laboratory procedures can be seen as a good proxy of real cost [Oostenbrink 
2000]. 
Bottom-up cost estimates were made. In this chapter we will reverse the order 
of presentation. First, estimates on average costs at aggregate level are presented, 
and the cost differences between conventional and early clischarge analysed (using 
the Mann·Whitney U test). Second, we show detailed figures for different periods 
and categories. 
Explanatory factors 
This chapter will also deal with a number of explanatory factors, including age, 
number of comorbidities, cognitive status, functioning before fracture, residence 
before admission and costs before admission. These factors were tabulated to 
indicate the major determinants of health care costs within this population. These 
factors were further analysed with multiple linear regression. 
7.3 Results 
Patient characteristics 
The baseline characteristics of the two groups of patients were sintilar (table 7.2). 
Patients averaged 83 years of age, were predominantly female (79%) and most of 
them were living without partner (74%). All patients could walk before fracture, 
most of them without assistance or walking aids. The RAP score averaged 9.6 for 
all patients with small, not statistically significant differences between 
conventionally and early discharged patients. Many patients (41 %) were 
institutionalised before fracture, and 94% had one or more comorbid conditions at 
time of hospital admission. 
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Table 7.2 Characteristics of conventionally and early discharged hip fracture patients 
Discharge policy Total 
conventional early 
(n=102) (n=106) (n=208) 
Demography 
Mean age (years) 83 84 83 
Median age (years) 83 84 84 
25th- 75th percentile (years) 77-88 79-90 78-89 
Men/women 16/84% 26/74% 21/79% 
With/without partner 24/76% 27/73% 26/74% 
Residence before fracture 
Nursing home 16% 14% 15% 
Home for the elderly 27% 25% 26% 
Own home 57% 61% 59% 
Walking ability 
Not 0% 0% 0% 
With help 3% 5% 4% 
With walking frame 26% 23% 24% 
With crutches 8% 17% 12% 
Without walking aids 64% 56% 60% 
RAP score (0 - 36) 9.3 9.9 9.6 
Fracture type 
Cervical 43% 51% 47% 
Trochanteric 49% 47% 48% 
Sub-trochanteric 8% 2% 5% 
Number of comorbidities 
0 6% 6% 6% 
1 27% 24% 25% 
2 20% 29% 25% 
3 30% 26% 28% 
4 and more 17% 15% 16% 
Average number 2.4 2.2 2.3 
Medical outcomes 
Medical outcomes at 4 months after hip fractUre repair were equivalent for 
conventionally and early discharged patients. Nearly 20% of all patients died, with 
no difference between both groups (table 7.3). Differences in residence (nursing 
home, home for the elderly and own home), walking ability, RAP score and MMSE 
were small and not statistically significant (p < 0,05 Mann Whitney U test). 
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Table 7.3 Medical outcomes at 4 months after hip fracture repair 
Discharge policy Total 
conventional early 
Status at 4 months (n~102) (n~106) (n~208) 
Died 20% 19% 20% 
Hospital 0% 0% 0% 
Nursing home 28% 26% 27% 
Home for the elderly 17% 14% 15% 
Own home 36% 41% 38% 
Walking ability (n~82) (n~86) (n~168) 
Not 15% 21% 19% 
With help 10% 8% 9% 
With walking frame 42% 37% 
With crutches 7% 14% 
Without walking aids 27% 20% 
RAP score (0- 36) 14.5 14.9 
MMSE score (0- 29) 20.8 20.6 
RAP = Rehabilitation Activities Profile (higher figures indicate worse health status) 
MMSE = Mini-Mental State (higher figures indicate better cognitive status) 
Inpatients days and type of residence during +month follow-up 
39% 
10% 
23% 
14.7 
20.7 
Early discharged patienrs stayed an average of 13.5 days less in hospital than 
conventionally discharged patienrs (12.7 versus 26.2 days, table 7.4). The total 
time spent in a health care institution, however, was the same for both groups 
(75.7 days for early discharged and 79.3 days for conventionally discharged 
patients). The main cause was the longer average stay in nursing homes of the 
early discharged group ( 46.4 versus 34.7 days). 
Table 7.4 also shows the destination of patienrs at discharge from hospital. 
Most patients in the early group were discharged to a nursing home for 
rehabilitation (76%). Conventionally discharged patienrs were rehabilitated in 
hospital and discharged after their (longer) hospital stay, relatively more 
' . frequently to the1r own home or an home for the elderly compared to early 
discharged patienrs (42% versus 23%). Nevertheless, a good 53% of the patienrs 
in the conventional group were discharged to a nursing home, which is high given 
that before fracture only 16% of these patienrs lived in a nursing home. 
At four months afrer hip fracture, these differences in residence had completely 
disappeared. Most patienrs lived in their own homes (36% and 41 o/o among the 
conventionally and early discharged group, respectively, table 7.3), although the 
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number remained low compared to the living situation before fracture (57% and 
61% respectively, table 7.2). 
Table 7.4 Average number of inpatient days in hospil:a~ nursing home and elderly home, 
and discharge arrangements for conventionally and early discharged patients 
Inpatient days 
Hospital 
Nursing home 
Home for the elderly 
Readmission to hospital I nursing home 
Total days in institutions 
Destination at discharge 
Died in hospital 
Nursing home 
Home for the elderly 
Own home 
Costs per patient 
Discharge policy 
conventional 
(n=102) 
26.2 
34.7 
16.5 
1.9 
79.3 
6% 
53% 
17% 
25% 
early 
(n=106) 
12.7 
46.4 
12.2 
4.4 
75.7 
0% 
76% 
9% 
14% 
Average costs during the 4 months after incidence of hip fractUre amounted to 
€ 14,281 for early discharged patients, which is € 1,057less compared to 
conventionally discharged patients (€ 15,338, table 7.5). There was a wide 
variation in costs vvithin both groups. Among conventionally discharged patients 
costs at 25th -75th percentiles were € 3,511- € 18,144. The variation among 
early discharged patients was somewhat smaller (€ 3,986- € 16,968). Due to the 
large variation the difference in cost between the two discharge strategies failed to 
reach statistical significance (p = 0.3). 
Table 7.5 shows that early discharge causes a shift in costs from hospital to 
nursing home. Hospital costs were reduced by € 2,812 (p<.01), nursing home 
costs increased on average by€ 1,290 (p<.001). The conventionally discharged 
patients incurred 47% of costs in the hospital, 33% in the nursing home, 12% in 
the home for the elderly and 6% at home. For early discharged patients these 
figure~ were respectively 31%, 44%, 10% and 5%. These figures exclude 
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readmissions in hospital or nursing home. Because early discharged patients have 
a greater chance of readmission, this can bias the results in favour of early 
discharge. Table 7.5 shows a cost difference of € 952, resulting almost entirely 
from readmissions to hospital. When these costs are included the savings in 
hospital costs per early discharged patient decrease to around € 1,800. A second 
important shift in costs shown in table 7.5 regards an increase of hospital costs 
during the first days after surgery among early discharged patients. Compared to 
the conventionally discharged group, average costs increased by€ 399 (p<.01). 
Apparently the prospect of a short hospital stay cause physicians to speed up 
diagnostic and laboratory procedures. More or less substantial differences existed 
for the periods outside hospital and nursing home. These differences, however, 
neither reached statistical significance nor changed the general finding that the 
cost savings achievable with early discharge were llmited. 
Costs up to 3 months before admission amounted to € 4,517 in the 
conventional group and € 4,705 in the early group. After correcting for this pre· 
admission costs, the adjusted costs difference after hip fracture increased slightly 
to € 1,162 (p ; 0.25). The costs caused by hip fracture in addition to the costs of 
care the patients received before the fracture, were estimated at € 9,316 for 
conventionally discharged and € 8,008 for early discharged patients. 
Table 7.5 Average costs (£, 1998) per patient by period and discharge policy, cost 
difference between early and conventional discharge 
Period 
Before fracture (3 months) 
Hospital 
(S 5 days after surgery) 
c~ from day 6 until discharge) 
Nursing home 
Home for the elderly 
Home 
Readmission in hospital or nursing 
home 
Total costs after fracture 
* p < .05 ** p < .01 *** p < .001 
n.s. = not statistically significant 
Discharge policy 
conventional early 
(n=102) (n=106) 
c 4,517 € 4,705 
7,235 4,423 
(2,665) (3,064) 
(4,570) (1,359) 
4,990 6,280 
1,767 1,436 
847 692 
498 1,450 
15,338 14,281 
Difference 
(early-
conventional) 
€ 188 n.s. 
·2,812 ** 
(399) ** 
(·3,211) *** 
1,290 * 
·331 n.s. 
·155 n.s. 
952 n.s. 
-1,057 n.s. 
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Costs per inpatient dey 
Average costs per inpatient day are shown in Table 7.6. These figures are based on 
the real medical consumption as registered in the study. The first 5 hospital days 
immediately after surgery were more expensive than later days due to more 
nursing time, more supervision by physicians and additional diagnostic and 
laboratory procedures. Average hospital costs for early discharged patients were 
higher than for conventionally discharged patients, as explained before. Average 
costs per inpatient day in nursing homes (about € 140) and homes for the elderly 
(about € 100) were substantially lower in comparison with hospitals. 
In the Dutch health care system inpatient days are remunerated on daily basis 
by charges that represent average costs over all patients. These charges do not 
differentiate between types of care other than IC-units versus corrunon nursing 
wards. Charges per hospital day vary among general and university hospitals from 
€ 235 until € 350 [Oostenbrink 2000]. Our detalled cost estimates show higher 
costs for the first post-operative days and lower costs for the remainder of the 
hospital stay. Hence, early discharge seems unprofitable from the perspective of 
hospital financing. It must be noted, however, that most of the included 
interventions and examinations can be charged separately. So also the first days 
after surgery will not cause a financial loss for hospitals. 
Table 7.6 Average costs and charges paid by the health care system (£, 1998) per 
inpatient day in hospital and nursing home 
Real costs in study population* Charges in the 
Dutch health 
Conventional Early discharge care system 
discharge 
AC (SD) AC (SD) 
Hospital 235- 350 
:S day 5 after surgery 422 (110) 456 (186) 
~from day 6 until discharge 237 (128) 264 (105) 
Nursing home 143 (36) 134 (30) 130 
Home for the elderly 101 (26) 119 (35) 60 
~· AC =Average costs, SD = Standard deviation 
Costs by categories 
Table 7.7 shows the average costs per patient by category, period and discharge 
policy. Costs before fracture were mainly incurred in the categories inpatient days, 
care, informal care and other costs, with only slight differences between both 
Table 7.7 Average costs (€, 1998) per patient by period, cost categmy and discharge policy (conventional versus early) 
Period Inpatient Nursing Health Medical Travelling Informal Total costs per patient 
days practitioners procedures care 
and other 
conv early conv early conv early conv early conv early conv early conventional early 
Before fracture 2,516 2,492 1,115 1,261 73 85 0 0 0 4 812 863 4,517 4,705 
Hospital 
:S 5 days after surgery 763 821 505 479 107 124 1,268 1,615 23 25 0 0 2,665 17% 3,064 21% 
2 day 6 until discharge 2,330 675 1,350 293 212 74 566 150 113 169 0 0 4,570 30% 1,359 10% 
Nursing home 2,518 3,414 2,008 2,163 421 633 0 0 28 62 15 8 4,990 33% 6,281 44% 
Home for the elderly 1,125 829 571 529 45 40 0 0 14 3 12 35 1,767 12% 1,436 10% 
Home 0 0 285 324 73 104 0 0 18 27 472 237 847 6% 692 5% 
Readmission 477 1,437 21 13 0 0 498 3% 1,449 10% 
Total after fracture 7,213 7,176 4,717 3,787 858 975 1,833 1,765 217 299 499 280 15,338 100% 14,281 100% 
(Share) 47% 50% 31% 27% 6% 7% 12% 12% 1% 2% 3% 2% 100% 100% 
~ Not available (costs included in inpatient days). 
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discharge groups. Total cosrs after hip fracture could mainly be attributed to 
inpatient days (50%, € 7,200) and nursing (30%, € 4,000). 
Cosrs for health practitioners (physicians, physical therapisrs and other) were 
limited to only 6 - 7% of total cosrs. This figure excludes hip surgery and all other 
medical procedures including diagnostic and laboratory assessment, that 
represented 12% of total cosrs. Cosrs· of travelling were modest (1 - 2%). Informal 
care and other cosrs represented 2 - 3% of total cosrs. On aggregate level 
differences between both discharge policies were rather limited. Major differences 
were only observed in average cosrs from day 6 until discharge for inpatient days 
in hospital (lower cosrs for early discharge) and nursing home (higher cosrs for 
early discharge). The shoner stay in hospital and longer stay in nursing home 
explain this finding. Cosrs of medical procedures shifted to the first 5 days after 
surgery in the early discharge group, as mentioned before. Readmissions were 
more frequent in the early discharge group (16 versus 8 patients), but most were 
not directly related to the hip fracture. If these cosrs were excluded, a somewhat 
larger difference between both groups was observed, with borderline statistical 
significance (€ 2,008, p=0.06). 
Volumes of health care use 
Duting the 4 month follow-up period, patienrs stayed on average a sintilar time in 
a health care institution (hospital, nursing home or elderly home): 79 days when 
conventionally discharged and 76 days when discharged early (table 7.8). 
Table 7.8 Average number of inpatient days, hours of care and time invested by health 
practitioners, number of medical procedures per patient by period and 
discharge policy 
Period Inpatient Nursing Health Medical 
days (hours) practitioners procedures 
(number) 
------------------
(hours) 
---(~~~~~!) ---
conv early conv early conv early conv early 
Before fracture 36.2 34.7 43.2 48.9 1.6 1.9 0.0 0.0 
Hospital 
:s; 5 days after surgery 6.5 7.0 11.1 10.5 2.2 2.6 54.0 74.1 
;:: day 6 until discharge 19.7 5.7 29.7 6.4 5.7 2.1 61.5 17.5 
Nursing home 34.7 46.4 61.4 66.1 13.2 19.8 0.0 0.0 
Home for the elderly 16.5 12.2 17.5 16.0 1.2 1.1 0.0 0.0 
Home 0.0 0.0 11.0 12.5 1.8 2.8 0.0 0.0 
Readmission 1.9 4.4 
Total after fracture 79.4 75.7 130.7 111.6 24.0 28.4 115.6 91.6 
-Not available 
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Nurses spent around 131 hours caring for patients in the conventional discharge 
group and 112 hours for early discharged patients. The difference is wholly 
attributable to the longer hospital stay in the conventional group. All health 
practitioners together- physicians (supervision only, medical procedures 
excluded), physical therapists and other- spent a total of 24 hours on each 
conventionally discharged patient and 28 hours on each early discharged patient. 
Most time was invested in physical therapy. The number of medical procedures 
differed between the two discharge groups, mainly due to additional diagnostic 
and laboratory assessments among early discharge patients in the days 
immediately after surgery. 
Explanatory factors 
Relationships betvveen several variables and average costs per patient are shown 
in Table 7.9. The difference between patients admitted to the general or to the 
university hospital was € 1,219 (p = 0.26) with higher costs for the university 
hospital. A larger number of co-morbid conditions, diminished cognitive status, 
deteriorated functioning before fracture, increased costs before admission, the 
presence of diagnosis dementia and the pre-fracture residency in a home for the 
elderly or nursing home were all associated with increased costs (table 7.9). In a 
multivariable analysis, the pre-fracture residency in an elderly home (p = 0.005), 
the number of comorbidities (p = 0.04), functioning before fracture (RAP-score, 
p = 0.06) and dementia (p= 0.06) were the most important explanatory factors 
for costs after fracture. 
7.4 Discussion 
We compared t\N"o discharge policies after hip fracture repair. Because the patients 
in both groups had on average the same characteristics before fracture and 
medical outcomes were equivalent, it was possible to perform a cost-minimisation 
analysis (CMA). We found that early discharge of hip fracture patients from 
hospital led to a limited, statistically non-significant reduction of total costs. We 
used a detailed calculation method to estimate real costs from a societal 
perspective. Therefore we were able to present estimates of costs in different 
categories and for different periods after hip fracture. Hence it was possible to 
observe some imponant shifts in costs. Finally, we identified a number of 
explanatory factors for costs after fracture. 
Total costs: early discharge versus conventional discharge 
Contrary to our expectations, early discharge did not significantly reduce costs. 
This was mainly due to the shift of costs from hospital to the nursing home. The 
total number of inpatient days in all institutions together was almost the same 
within both groups, and costs per day in a nursing home differed little from costs 
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Table 7.9 Average costs (£, rounded to hundreds, 1998) per patient according to 
explanatory factors 
Explanatory factor Costs pe~ patient Number of Significance 
patients of difference 
Euros SD 
Hospital 
General hospital 14,100 7,100 90 n.s 
University hospital 15,300 8,100 118 
Age in years 
65-79 14,100 8,400 67 n.s 
so- 89 14,900 7,900 101 
<?:90 15,800 5,900 40 
Number of comorbidities 
0 6,700 4,200 12 ** 
1 13,600 7,800 53 
2 15,200 7,100 51 
3 17,000 8,100 59 
4 and more 15,000 6,600 33 
MMSE score after 1 week 
Missing 15,500 6,400 18 *** 
0-12 18,300 8,000 48 
13- 18 15,400 6,300 30 
19- 22 16,300 7,100 31 
23-29 11,700 7,500 81 
Dementia 
No 13,900 7,400 166 ** 
Yes 18,400 7,900 42 
RAP score before fracture 
0-4 12,200 7,500 78 *** 
5- 14 15,100 6,900 68 
15- 36 17,800 7,800 62 
Residence before fracture 
Home 12,900 7,500 124 
Home for the elderly 17,700 5,800 53 ** 
Nursing home 17,300 9,200 31 ** 
Costs before fracture 
< €4,540 12,800 7,400 116 *** 
> €4,540 17,400 7,300 92 
Discharge policy 
Conventional discharge 15,300 7,800 102 n.s 
Early discharge 14,300 7,600 106 
** p <.01 ***p < .001 
n.s.: not statistically significant 
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in hospital after the first 5 days post-operative. During the first days in hospital, 
the costs were initially high due to hip surgery, diagnostic and other medical 
procedures and intensive postwoperative care, but subsequently decreased 
substantially [Stromberg 1997]. 
Although the reduction in hospital stay by the early discharge programme was 
larger than in some Australian studies [Cameron 1994, Hollingworth 1993, and 
Sikorsky 1993], we did not observe significant cost savings. Adjustment for costs 
incurred before hip fracture did not change this outcome. 
Cost savings in the Australian studies resulted from a shorter hospital stay and 
were relatively modest (about € 650 per patient [Cameron 1994, Hollingworth 
1993)) or only reached statistical significance when costs per recovered patient 
were calculated separately [Cameron 1994]. We found a difference of € 1.057 per 
patient in favour of the early discharge programme but due to a wide variation in 
costs the cost savings were not statistically significant. Another cost-cutting 
strategy was early discharge of patients to a 'hospital-at-home' scheme [StrOmberg 
1997]. Again, the savings resulted from shorter stays in orthopaedic and geriatric 
wards, while costs at home did not increase substantially. The hospital-at-home 
scheme, however, was only suitable for about 40% of total patients in this study, 
while in another pan of England only 18% of patients fitted the selection criteria 
[Cathain 1994]. 
In Sweden, the substitution of hospital care by geriatric care resulted in a cost 
decrease of 12% [French 1995]. In that study, the number of hospital days was 
approximately halved by earlier discharge to geriatric wards. 
Hospital and incremental costs 
Hospital costs in our study (€ 7,235 for conventionally discharged patients and 
€ 4,432 for early discharged patients) fitted well within the range of costs reported 
by others. These range from € 3,600-8,400 in Great Britain [Farnworth 1994, 
Stromberg 1997, Parker 1992], € 5,300-8,700 in Sweden [Borquist 1991, French 
1995, Sembo 1993] to € 10,300 in the United States [Bralnsky 1997]. Costs 
during the 4-month follow-up are more difficult to compare. Our estimate of 
€ 15,000 is high compared to Berquist's estimate for Sweden (€ 10,700) [Borquist 
1991], which, however, only included patients coming from home. 
We estimated costs in the three months before fracture at € 4,600. Incremental 
costs atrtibutable to hip fracture were therefore € 9,300 for conventionally 
discharged and € 8,000 for early discharged patients. These figures are in line with 
the € 8,600 of additional costs during the first year after hip fracture reported by 
De Laet for the Netherlands [Laet 1999] and with the estimate of € 8,910 by 
Cameron eta!. [Cameron 1994]. Others, however, found much higher figures: 
€ 12,000-14,000 "for the United States in 1993 [Brainsky 1997] and € 17,000 in 
Sweden in 1994 [Zethraeus 1997]. This difference may partly be explained by 
higher hospital costs and more admissions to geriatric departments and nursing 
homes in the latter two studies. 
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Explanatory factors 
The most important explanatory factors were the prewfracture residency, the 
number of comorbidities, level of functioning (RAP score) before fracture and 
dementia. These factors also explain survival, which influences the cost estimates. 
For example, patients with dementia incurred higher costs, while their survival 
was worse compared to non-demented patients. On average, for surviving and 
deceased patients we estimated costs at € 15,300 and € 12,700 respectively. 
The higher costs among institutionalised patients are in line with data from 
Sweden [Zethraeus 1997] but were not demonstrated in Scotland [Farnworth 
1995]. We could not confirm the relation with type of fracture or gender that was 
reported by Borquist [Borquist 1991]. 
Explanations for the disappointing cost savings 
Owing to the detailed cost analyses available, we are able to provide some 
explanations for the disappointing cost reduction. First, comorbidity played an 
important role in our study population. People were old and had multiple diseases 
(table 7.2). Comorbidity was an important explanatory factor for high costs 
(table 7.9). The large variation in costs between patients within both groups also 
indicate that hip fracture is but one cause of health care costs. People were old 
and needed care for different diseases and disorders. The total number of 
inpatient days was on average the same for both groups, irrespective whether the 
care was supplied by a hospital or a nursing home. 
Second, in hospital the number and costs of medical interventions and 
examinations was higher among the early discharged group. Apparently hip 
fracture patients need a certain amount of medical procedures, mainly diagnostic 
and laboratory, which can not simply be skipped. Early discharge resulted in a 
concentration of medical procedures during the first post-operative days, which 
partially cancelled out its potential benefits. In addition the early discharged 
patients received more physical therapy in nursing home than the conventionally 
discharged received in hospital. This also decreased the cost difference betvveen 
both groups. 
Third, we confirmed that hospital costs per inpatient day decrease after day 
five [Hollingworth 1995, Farnworth 1994]. Shortening the hospital stay will 
always save the less costly days. Calculations that do not reckon with this 
phenomenon will overestimate the potential savings. The use of charges would 
even increase the difference, since for hip fracture patients the Dutch charges 
exceed real hospital costs but remain under real costs in nursing homes and homes 
for the elderly (table 7.6). 
Real costs in the real world 
We estimated real costs in the setting of the study. In the real world things might 
be different. It is assumed that early discharge causes a shift from fortnal to 
informal care. We could not confirm this assumption. Costs of informal care were 
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relatively low. Costs among early discharged patients were rather lower than 
higher, although the difference reached not statistical significance. The large 
number of inpatient days plays an important role here. On average patients, 
whether early discharged or not, remained more than half of the 4-month study 
period in a health care institution. At the end of this period 54% of all patients 
stayed in a nursing home or elderly home, an increase of one third compared to 
the situation before fracture. 
In our study the investment and capacity costs of a specialised rehabilitation 
ward in a nursing home were rather low. The ward already existed at onset of 
study, and due to an efficient planning of patients the occupation of these ward 
was high. Investment costs and capacity costs were integrated in the average costs 
per admission day. In real life, costs will be higher if specialised wards must be 
newly built. Capacity costs can also become high, if the ward is too large for an 
efficient occupation of beds, or too small for an efficient employment of physical 
therapists and other personnel. National application of early discharge would 
therefore require a careful planning of rehabilitation wards. 
Limitations of the study 
Our study has some limitations. First, the sample size was relatively small (1 02 
and 106 patients). The difference in hospital stay (13 days), however, should have 
been large enough to show any clear economic advantage of the early discharge 
programme. Second, the design was not randomised and it is possible that some 
variables such as the duration of hospital stay and discharge destination changed 
during the study independently from the intervention. Third, it is difficult to 
generalise the results for patients living in other countries because geriatric 
rehabilitation and long-term care of the elderly differ between countries. The 
rehabilitation ward of a Dutch nursing home probably compares best with a 
geriatric rehabilitation ward in a hospital or a Skilled Nursing Facility in the US. 
7.5 Conclusions 
This study shows that the details of costing highly influence the outcomes in a 
cost-minimisation analysis. Costs shifted from hospital to the nursing home 
because total institutional length of stay was similar and there was only a small 
difference in costs per inpatient day between hospital and nursing home. This 
latter phenomenon was caused by the relatively less intensive care of hip fracture 
patients among the hospital population and relatively more intensive care 
compared to other people in nursing and elderly homes. Furthermore, the early 
discharge regime evoked a concentration of diagnostic procedures in the few days 
prior to discharge, resulting in higher average costs that cancelled out some of the 
potential savings. 
Chapter 7. Costs after hip fracture 89 
Our study emphasises the importance of a detailed cost analysis based on real 
resource use. Standard charges or average all-in prices would raise expectations 
about cost savings that can not be realised. This conclusion is not limited to our 
study or other early discharge studies but has relevance for the whole field of cost 
analysis in health care. The implications for cost-of-illness studies will be discussed 
in Chapter 9. 
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Part III 
International comparison 
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Abstract 
Since 1998 the OECD Health Data contain figures on cost of 
illness (CO!). The large clifferences between countries are 
striking. We compared a Dutch CO! study with similar data for 
Australia, Canada, England, Germany and Sweden. The 
distribution of health care costs over major disease categories 
shows similar patterns for all countries as well as some 
remarkable clifferences, mainly caused by health care systems. 
Comparisons for hospitals and pharmaceutical care showed 
differences that could in part be related to epidemiological and 
methodological factors. We concluded that the current scope of 
COI studies is more or less limited to national levels, because 
health care systems dominate the magnitude and disttibution of 
health care costs. Cross-national comparisons might be possible 
if data and methods are standardised and COI estimates are 
made for a common comparable package. 
8.1 Introduction 
A cross-national 
perspective on 
cost of illness 
93 
8 
In the decades after the pioneering work of Dorothy Rice several cost-of-illness 
(COl) studies have been published, for the United States as well as for other 
countries [Rice 1966, Cooper 1976, Rice 1985, Lindgren 1981, Kooprnanschap 
1991, Wigle 1991, Henke 1997]. Recently some countries updated their COl 
estimates while others launched their first contribution in this field [Mathers 1998, 
Moore 1997, Jacobson 1996, NHS 1996, Schneider 1999, and Polder 1997]. Since 
1998 the key figures of most COl studies are summarised in the OECD Health Data 
[OECD 1998]. These figures, however, show a wide variation that can not easily 
be explained. 
This paper addresses the question of cross-national comparability of COl data. 
Our objectives are: 1) to construct a comparable dataset; and 2) to explain major 
cross-national differences in cost of illness. 
8.2 Methods 
We selected six countries according to the following criteria: a) the study should 
report on one of the years in the period 1991- 1995; b) a background report with 
detailed infonnation on data and methods should be available, since the OECD 
Health Data only contained data with a small glossary. The countries were: 
Australia, Canada, Netherlands, Sweden, United Kingdom and Gennany [Mathers 
1998, Moore 1997, Polder 1997, Jacobson 1996, NHS 1996, Schneider 1999]. 
We distinguished six explanatory factors for cross-national differences. First, 
health care supply differs between countries. The Dutch homes for the elderly, for 
instance, have no equivalent in other countries. Another example regards the 
German 'Kurorte' from which this 'Kurort-argument' derived its name. Second, 
given health care supply the definition of health expenditure differs between 
countries. In Australia, for instance, care for disabled people belongs to the 
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welfare services while in most other countries it is included in the health care 
system. Third, total cost-of-illness deviates from total health expenditure, while in 
addition the extent of this deviation differs per country. Fourth, data and methods 
employed in the COl studies differ. Fifth, health care utilisation and costs differ 
due to differences in health status and health care needs caused by 
epidemiological and demographic variables. Sixth, cross-national variations in 
medical practice cause differences in costs. 
The ranking of these factors is not arbitrarily chosen. Epidemiological and 
demographic explanations are only interesting or even possible if the definitions of 
health care, health expenditure and total COl are the same. Before looking at real 
causes of difference it is also needed to investigate whether differences might be 
caused by the characteristics of the COl studies. Due to the ranking of these 
arguments the analysis of cross-national differences should start with studying 
differences in health care and health expenditure. This has been done in the 
common comparable package literature [Mosseveld 1998, OECD 2000a]. From a 
CO! perspective, however, it was unfortunately not possible to Start the analysis 
here, since published COl data did not fit into the definitions of a common 
comparable package. 
We therefore started with published COl data and with help of additional data 
on health care systems and health expenditures we cancelled out all differences 
betvveen health care expenditure and total COL The resulting dataset, however, 
still incorporated differences in health care and differences in COl methodology, 
while in addition the variation in not allocated costs was large. We therefore 
disaggregated the national COl data to sectoral figures. Five sectors were 
distinguished: hospitals and physicians, other health practitioners, pharmaceutical 
care, institutional care and all other care. The COl studies of four countries 
allowed for a sectoral breakdown. We tried to explain the differences by COl 
methodology, epidemiology and demography, and medical practice variations 
using data from COl reports and medical literature. 
8.3 Cost of illness and national health expenditure in 6 countries 
OECD Health Data 
Table 8.1 shows the COl figures for these countries as reported by the OECD 
[OECD 1998, 2000]. The cross-national differences within disease categories are 
expressed by the coefficient of variation (standard deviation relative to the mean). 
At least five issues attract attention: 1) The overall pattern was roughly the same: 
high costs for mental disorders, circulatory, digestive and musculoskeletal 
diseases; low costs for congenital malformations, perinatal conditions and 
infectious diseases; 2) There were remarkable differences for some major disease 
categories, especially mental disorders, circulatory diseases, digestive diseases and 
musculoskeletal diseases; 3) Some lCD chapters were missing for the UK; 4) The 
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percentage of non-allocated costs differed substantially; 5) The Canadian and UK 
figures totalled 93.8% and 95.3% in stead of 100% as in the other countries. 
Table 8.1 Cost of illness in six countries according to OECD Health Data (Share of ICD 
chapters in total costs and coefficient of variation. Total costs in billions of 
national currency units (NCU)) 
Chapters ICD-9 AUS * CAN UK GER NETH SWE Coeff. of 
1993 1993 1993 1994 1994 1991 variation 
Infectious 2.7 1.8 3.7 1.9 1.3 2.0 36% 
Neoplasms 6.1 7.3 8.3 5.2 3.9 5.6 26% 
Endocrinal 3.1 3.0 2.9 3.9 1.9 3.4 23% 
Blood 0.6 0.6 1.6 0.6 0.3 0.5 71% 
Menta! 8.4 11.4 14.4 10.9 23.1 18.4 38% 
Nervous 7.4 5.1 3.4 8.4 5.2 5.8 31% 
Circulatory 11.7 16.7 25.7 12.4 10.5 16.9 36% 
Respiratory 8.0 8.6 9.8 5.2 4.0 7.7 30% 
Digestive 11.8 7.5 8.3 15.9 7.8 4.6 43% 
Genito-urinary 5.3 5.1 6.8 5.0 2.8 3.8 29% 
Pregnancy 3.3 4.6 2.5 2.6 1.6 38% 
Skin 3.0 2.0 3.1 2.3 1.6 2.0 26% 
Musculoskeletal 9.5 5.6 7.3 12.6 6.0 5.4 36% 
Congenital 0.6 0.7 0.4 0.5 1.2 44% 
Perinatal 0.8 1.2 0.3 0.6 0.6 43% 
Symptoms 4.3 4.2 4.7 4.8 5.6 13% 
Accidents 8.3 7.1 7.9 4.2 5.6 26% 
Not allocated 5.1 1.2 0.0 18.8 9.2 111% 
Total costs 100.0 93.8 95.3 100.0 100.0 100.0 
NCU (billion) 31.4 41.4 18.0 344.7 59.5 104.4 
* AUS =Australia, CAN= Canada, UK= United Kingdom, GER = Gennany, NETH = Netherlands, 
SVVE = Sweden, SD = standard deviation. 
Cost of illness and national health care expenditure 
Table 8.2 provides some characteristics of the COl studies based on the 
background reports and shows the relation between national health expenditure 
and cost of illness. 
All COl studies employed a top-down methodology using provider data to 
allocate costs to diseases. Disease categories were in all studies based on the 9th 
edition of the International Classification of Diseases (ICD-9) [WHO 1977]. The 
Swedish study distinguished 18 groups including one rest category for costs that 
could not be allocated to the 17 chapters of the !CD-9. The other studies also 
distinguished more detailed disease categories (table 8.2). 
Table 8.2 Health expenditures and cost of illness in five countries 
Country Australia Canada England Germany Netherlands Sweden 
Year 1993 1993 1993 1994 1994 1991 
National health expenditure 
National currency units (NCU) 36,495 71,743 32,731 344,618 59,463 125,215 
US$ a 24,882 55,615 48,852 208,859 32,672 20,697 
Share In gross domestic product 8.5% 10.2% 6.9% b 10.0% 9.7% 8.7% 
Average per Inhabitant (US$) 1,395 1,824 1,112 b 2.350 2,124 2,402 
Direct cost of Illness 
Direct medical costs (NCU) 31,397 51,062 27,821 344,618 59,463 104,443 
US$ 21,359 39,583 41,524 208,859 32,672 17,263 
% of health expenditure Included 86% 71% 85% 100% 100% 83% 
Number of health sectors 13 7 6 1 22 3 
A. Diagnosis 
Classification of diseases ICD-9 ICD-9 ICD-9 ICD-9 JCD-9 ICD-9 
Number of diagnostic groups 21 25 36- 108 c 47 62 18 
% of included expenditure allocated 95% 94% 94% 92% 81% 91% 
% of total expenditure allocated 81% 67% 80% 92% 81% 76% 
B. Age and sex 
Number of age groups 7 4' 0 0 21 0 
% of included expenditure allocated 100% 100% 0% 0% 100% 0% 
% of total expenditure allocated 86% 71% 0% 0% 100% 0% 
Male/Female ratio In total costs 43/57 44/56 n.a. n.a. 41/59 n.a. 
Indirect cost of Illness (US$) n.a. 65,987 n.a. 157,640 n.a. 27,339 
% allocated to diseases 93% 0% 98% 
n.a. = not available 
1. US$ 1 ~ AUS$ 1.47; CAN$ 1.29; UK£ 0.67; DM 1.65; NLf 1.82; SEK 6.05. 
2. United Kingdom. 
3. The number of diagnostic categories varies per sector, from 36 to 108 categories for p11Cumaceutical care and hospital costs, respectively. 
4. In tlw Canadian study costs were not simultaneously allocated to diagnosis and age as in tire Australian and Dutch stlldies. 
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Some studies also included demographic variables. In the Dutcb and Australian 
study, health care costs were simultaneously broken down according to diagnosis, 
age and sex. The Canadian study provided estimates for age and sex without 
disease specific information. 
Some COl studies further estimated indirect costs. These costs relate to 
absence from work (productivity costs) due to morbidity (morbidity costs) and life 
years lost (mortality costs). These costs were included in the Canadian and 
Swedish study, while the German study provided an estimate of total indirect costs 
without any allocation to diseases. In this paper, we focus on direct medical costs 
and do not compare indirect costs. 
Despite the common cbaracteristics of a top-down approacb using the ICD-9, 
the cor studies can not easily be compared, because in most countries total cor 
did not match with total health expenditure. Only in Germany and the 
Netherlands total COl equalled national health expenditure. In the other countries, 
some parts of health care costs were excluded from the CO! study. Compared to 
table 8.1 total CO! in Canada, United Kingdom and Germany cbanged. Based on 
the original researcb.report [Moore 1997] we adjusted the Canadian figures for: 
a) an additional category of not-allocated costs ('well patient care', all V-codes of 
the ICD-9); and b) an additional CAN$ 7 billion that could be allocated to speclfic 
ICD chapters such as mental disorders (treatment in institutions), digestive 
diseases (dental care) and nervous system and sense organs (eye care and hearing 
aids). Afrer these corrections total CO! amounted to CAN$ 51.1 billion (71% of 
national health care costs). 
The OECD figures for CO! in the UK (total£ 18.0 billion, table 8.1) were quite 
different from the estimates in the burden~of-disease report, in which an amount 
of£ 32.7 bllllon (table 8.2) was given for England alone [NHS 1996]. Our further 
comparisons were based on these latter estimates. 
The German figures cbanged slightly. In the OECD data all costs were 
allocated to disease categories (table 8.1), including the costs of health 
administration (8.1 o/o). In the other countries these costs were assigned to the 
category 'not-allocated'. We adjusted the German figures in a similar way using 
the background document [Scbneider 1999]. Table 8.2, therefore, shows that 92% 
of the costs included could be allocated to diseases. 
Afrer fitting total cost of illness to national health expenditure we calculated 
the share of total expenditure that was assigned to diseases. Table 8.2 shows a 
large variation (67%- 92%), mainly due to the inclusion or exclusion of major 
health care facilities. 
National COI figures adjusted to national health expenditure 
Table 8.3 shows the recalculated CO! figures on the aggregate level. Compared to 
table 8.1, a new category 'not included' has been added in order to fit total cost of 
illness to total health expenditure. The adjustments improved comparability. The 
coefficient of variation decreased in 11 disease categories bervveen the countries 
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(table 8.3, last column), especially for circulatory diseases due to rbe better 
(lower) estimates for rbe UK. Alrbough rbe orber disease groups experienced a 
modest increase in variation the overall pattern is more homogeneous than in the 
OECD figures (table 8.1). Even so, rbere were some important differences. 
For some disease categories rbere is a reasonable epidemiological explanation. 
The higher costs of cancer and skin diseases in Australia were likely caused by a 
higher prevalence [Mathers 1998a]. Higher costs for endocrine diseases in 
Germany could be explained by a higher prevalence of diabetes [OECD 1998, 
Eurostat 2000]. The costs of accidents were high in Australia and Germany, 
mainly due to the higher number of road accidents in both countries. However, for 
most other cross-national differences no clear disease- or demography-related 
explanations were available. 
Table 8.3 Recalculated cost of illness in six countries (Share of !CD chapters in total 
costs. Change in coefficient of variation compared to table 8.1. Total costs in 
billions of national currency units (NCU). 
Chapters !CD-9 AUS* CAN ENG GER NETH SWE Coefficient of 
1993 1993 1993 1994 1994 1991 variation 
% change 
Infectious 2.3 1.1 0.9 1.7 1.3 1.7 34% -4 
Neoplasms 5.2 4.5 3.9 4.8 3.9 4.7 12% -14 
Endocrinal 2.6 1.9 1.5 3.6 1.9 2.9 32% 11 
Blood 0.5 0.4 0.5 0.6 0.3 0.4 23% -42 
Mental 7.1 8.2 15.8 10.0 23.1 15.3 45% 8 
Nervous 6.4 5.1 8.0 7.7 5.2 4.9 22% -8 
Circulatory 10.2 10.3 11.5 11.4 10.5 14.1 13% -23 
Respiratory 6.9 5.3 5.9 4.8 4.0 6.5 19% -11 
Digestive 10.2 11.2 7.9 14.6 7.8 3.8 40% -3 
Genito-urinary 4.5 3.1 3.4 4.6 2.8 3.2 21% -7 
Pregnancy 2.9 2.8 3.1 2.3 2.6 1.4 24% -14 
Skin 2.6 1.2 1.6 2.1 1.6 1.7 27% 1 
Musculoskeletal 8.2 3.4 7.4 11.5 6.0 4.5 42% 6 
Congenital 0.4 0.4 0.4 0.4 0.5 1.0 46% 1 
Perinatal 0.7 0.8 0.7 0.3 0.6 0.5 30% -18 
Symptoms 3.6 2.6 3.9 4.3 4.8 4.6 20% 8 
Accidents 7.1 4.4 3.6 7.2 4.2 4.6 30% 4 
Not allocated 4.4 4.6 5.0 8.1 18.8 7.7 68% -43 
Not included 14.2 28.8 15.0 0.0 0.0 16.6 88% 
Total costs 100.0 100.0 100.0 100.0 100.0 100.0 
NCU (billion) 36.6 71.7 32.7 344.7 59.5 125.2 
~· AUS =Australia, CAN= Canada, ENG =England, GER = Germany~ NEfH = Netherlands~ 
SWE = Sweden~ SD = standard deviation. 
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There are three reasons for the still disappointing comparability. First, the large 
differences in notMincluded and not-allocated costs cause also a large variation in 
the costs per ICD chapter. In Canada, for instance, the costs of mental disorders 
and musculoskeletal diseases were relatively low because most health care 
institutions, physical therapists and other allied health professionals were not 
included in the cost-of-illness study. 
Second, the definitions of health expenditure differ. So the cosrs of the nervous 
system and the senses were relatively low in the Netherlands because the high co-
payments for ophthalmic services· and hearing aids were not included in 
expenditure data. In Australia costs for mental disorders were relatively low 
because institutions for people with intellectual disabilities did not belong to the 
health care system. In the Netherlands these diseases ranked highest because not 
only nursing homes were included in the health care system but also homes for the 
elderly. By consequence of these differences there was a large variation in per 
capita health expenditure (table 8.2). Figure 8.1 shows the age distribution of per 
capita cosrs for the three countries that provided age-specific cor figures, and 
confirms the role of included and excluded sectors, mainly for the elderly in the 
Netherlands. 
Third, the comparability of aggregate cor figures could be hampered by 
differences in data and methods employed in the different countries. 
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Figure 8.1 Health care costs attributed to age groups in Australia, Canada and the 
Netherlands 1993- 1994 (costs per capita in US$) 
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These problems can partially be solved by disaggregating national CO! to more-or 
less homogeneous sectors. Per sector insight in methodological differences can 
help to determine whether the remaining differences in cor can be explained by 
health status and health care needs in the population or by medical practice 
variations. 
8.4 Data and methods of COl studies in 4 countries 
COI and a common comparable package 
Four CO! studies, the Swedish and German excluded, provided detailed figures for 
different health care sectors (6 - 22, table 8.2) that allowed for regrouping the 
COI data into more or less comparable sectors. Unfortunately it was not possible to 
construct a common comparable package [Mosseveld 1998], nor to fit the figures 
into the System of Health Accounts (SHA) propcsed by the OECD [OECD 2000a]. 
When breaking down COl data for Australia, Canada, England and the 
Netherlands we distinguished five sectors: hospitals and physicians, other health 
practitioners, pharmaceutical care, institutional care and all other care. 
Data and methods in cost-of-illness studies 
Table 8.4 shows some details about data and methods in the four CO! studies for 
which a sector breakdown was possible. Total costs of hospitals and physicians 
varied from 42.5o/o of national health expenditure in the Netherlands to 58.0% in 
Canada. The Dutch share is low because of the comprehensive nature of the health 
care system and because costs per inhabitant were highest (table 8.2). In all 
countries the majority of costs could be allocated to diseases (84.5% - 97.4%, 
table 8.4). All studies used a top-down methodology mainly based on the number 
of inpatient days and outpatient visits. However, some major differences were 
revealed. In the Canadian study all hospital costs were allocated by the number of 
bed-days, weighed by resource intensities, while in Australia and the Netherlands 
medical services and ambulatory care were allocated separately from nursing days. 
The Australian study was based on diagnostic related groups (DRGs). The Dutch 
study used detailed information on medical interventions (> 1,000 categories) that 
were weighed by individual fees and charges. Only the English study did not 
adjust the number of hospital days for differences in resource costs. Expenditure 
on physicians was allocated in nearly the same manner in all countries. 
Pharmaceutical·care represented around 10% of total health care costs in the 
four countries (table 8.4). The share in total costs was higher in Australia and 
Canada, while per capita costs were higher in the Netherlands. In Australia and 
the Netherlands respectively 97.0% and 93.2% of pharmaceutical expenditures 
were allocated to !CD chapters. This percentage was substantially lower for 
Canada and England. In England, expert opinions were used for the attribution of 
costs to diagnoses. The other studies used the diagnoses for groups of drugs as 
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prescribed by physicians. Australia and Canada used therapeutic groups weighed 
by expenditures. In the Dutcb study, 250 groups and their expenditures were used 
based on the ATC-classification and retail prices per drug [WHO 1994]. 
The costs of health practitioners varied substantiaily (7.6 -11.7%, table 8.4). 
This was mainly caused by differences 'in the number of practitioners and the 
classification in the health system, especially for England. This sector includes 
dentists, physical therapists, midwives and other professionals, such as speech 
therapists. Costs of dental care were allocated to digestive diseases in all countries, 
and to age and sex in the Netherlands and Australia by the number of visits. Costs 
of other therapists were ailocated using diagnoses from registries of paramedical 
care (Netherlands) or referral diagnoses (Australia). Expert opinions were used in 
England, while in Canada the costs were excluded from the cor study. In both 
countries, the percentage of costs that could be allocated to !CD chapters was 
relatively low. 
International differences were largest for institutional care. In the Netherlands, 
nursing homes and homes for the elderly were included as well as institutions for 
people vvith intellectual and physical disabilities. In the other countries, homes for 
the elderly did not exist or were excluded from the cor study. In Australia 
institutions for people with intellectual disabilities did not belong to the health 
care system. In England nursing homes were included in the CO! study, but the 
definition and service provision was quite different from the Netherlands. This 
heterogeneity rendered COI comparisons next to useless, especially in the light of 
the large differences in the methods of allocation costs to diseases. 
All other costs were classified as other care. The differences betvveen the 
countries, regarding both the item included and the methods used to allocate costs 
(table 8.4) were considerable. In the Canadian study, only the costs of hearing 
aids and ophthalmic services were included. These costs were allocated to diseases 
of the nervous system and the senses. The English study used disability surveys to 
allocate a mucb wider range of expenditure. In the Netherlands, epidemiological 
data and results from other studies were used, such as cost-effectiveness analyses 
on cancer screening. The Australian COI study also used data from cancer 
screening programmes. Due to the heterogeneity in data and methods, all further 
cost comparisons were irrelevant. 
Table 8.4 Main categories of health care costs (% of total expenditure), costs included in cost-of-illness study (% of total expenditure) and 
data and methods used for allocation of costs to disease (and demographic) categories 
1. Hospitals and physicians A 
Costs(% of total expenditure) 
Allocated to diseases 
Allocation 
- Medical services 
- Hospital stay and day care 
- Ambulatory care 
- General practitioners 
2. Pharmaceutical care 
Costs (% of total expenditure) 
Allocated to diseases 
Allocation 
3. Other health practitioners 
Costs (% of total expenditure) 
Allocated to diseases 
Allocation 
- Dentists 
- other practitioners 
Australia 
58.0% 
86.5% 
Number weighed 
by DRG costs c 
Number of days weighed 
by DRG costs 
Number of visits 
Weighed number of visits 
11.1% 
97.0% 
Prescriptions weighed for 
therapeutic groups by 
relative utilisation and 
costs 
8.9% 
93.0% 
Number of visits 
Number of visits by 
referral diagnosis 
Canada 
50.8% 
92.2% 
Number of days weighed 
by resource Intensity 
Fee-for-service expenditure 
13.8% 
69.8% 
Prescription diagnoses 
and expenditures by 
therapeutic class 
8.4% 
77.6% 
Expert opinion 
England 
54.4% 
84.5% 
Number of days 
Number of referrals 
from GP's 
Weighed number of visits 
9.3% 
66.4% 
Expert opinion 
11.70/o B 
79.30/o 
Expert opinion 
Disability surveys and 
expert oplfllons 
Netherlands 
42.5% 
97.4% 
Number by type (1.000) 
and charge 
Number of days 
Number of visits by 
referral diagnosis 
Weighed number of visits 
10.2% 
93.2% 
Prescription diagnoses 
and expenditures by ATe-
code {250 groups) 
7.6% 
94.9% 
Weighed number of visits 
Number of visits 
by diagnosis 
Table 8.4 <continued> 
4. Institutional care 
Costs (% of total expenditure) 
Allocated to diseases 
Allocation 
- Disability homes 
- Nursing homes 
- Home for the elderly 
5. Other health services 
Costs(% of total expenditure) 
Allocated to diseases 
Allocation 
Total allocated to diseases 
n.a. Not available. 
Not separately allocated. 
A. Psychiatric hospitals included. 
Australia 
8.1% 
89.4% 
Number of residents 
13.9% 
36.4% 
Various, Including 
data on screening 
programmes 
81.4% 
B. Including community health services. 
C. DRG = Diagnostic Related Group. 
Canada 
9.8% 
11.1% 
Expert opinion 
17.2% 
11.3% 
Expert opinion 
for ophthalmic services 
and hearing aids 
66.6% 
England 
8.9% 
95.5% 
Number of days 
Expenditure on 
Income support 
15.7% 
60.0% 
Disability surveys 
80.0% 
Netherlands 
26.7% 
79.4% 
Number of days 
Number of days 
Number of Residents 
13.1% 
17.5% 
Various, Including surveys 
on prevalence of 
Impairments and data on 
screening programmes and 
use of home nursing and 
ambulance services 
81.2% 
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8.5 Cost of illness in 4 countries according to sector, revised data 
Hospitals and physicians 
The variation in CO! for hospitals and physicians (table 8.5) decreased further 
compared to the aggregate figures (table 8.3). The variation declined for mental 
disorders, digestive and musculoskeletal diseases due to the more homogeneous 
sector definition. However, for some diseases, differences remained or even 
increased. 
Although sector differences betvveen COI studies were eliminated as much as 
possible, the remaining differences in cost shares per ICD category still had to do 
with characteristics of the health care systems and COl studies. The high costs of 
nervous diseases in the Netherlands were caused by specialised hospitals for 
people with epileptic disorders. The high costs of mental disorders in the 
Netherlands resulted from the comprehensive services provided by psychiatric 
hospitals. The lower costs for cancer in England were caused by the English CO! 
methodology, which failed tot take resource intensities for hospital care into 
account. Probably also undemeatrnent plays a role here. 
There was some evidence for the influence of epidemiological factors on the 
costs of infectious diseases (Australia), respiratory diseases (England and Canada), 
musculoskeletal diseases (Canada) and accidents (Australia and Canada) [OECD 
1998]. 
Other differences were likely caused by variations in health care practice. The 
lower hospital costs for pregnancy and childbirth in the Netherlands were at least 
partially caused by the typical Dutch practice of childbirth at home, assisted by 
midwifes and nurses instead of physicians. In England and the Netherlands, the 
costs of digestive and cardiovascular diseases were relatively low compared to 
Canada which probably resulted from substitution of hospital care by 
pharmaceutical care (table 8.5, right panel) and relatively low costs per 
intervention for CABG and PTCA. 
Pharmaceutical care 
The variation in CO! for pharmaceutical care (table 8.5) increased compared to 
aggregate cost of illness (table 8.3). A problem here, is that pharmaceutical prices 
differ enormously over the world. Furthermore methodological differences played 
a role. The English estimates, for instance, were based on expert opinions instead 
of prescription data, and underestimated the costs of diseases for which generic 
medicines are usually prescribed. Another methodological difference regards the 
allocation of contraceptive medicine. In the Dutch COI study, these costs were 
allocated to pregnancy and childbirth causing relatively high costs for this lCD 
chapter. In the other countries these costs were not-included or not-allocated to a 
specific disease category. The low pharmaceutical costs of cancer were striking in 
view of the costly chemical and hormonal therapies invoked. These therapies, 
Table 8.5 Costs of hospitals and physicians and of pharmaceutical care by diagnosis in four countries. Share of ICD chapters ill total costs per 
sector(%) 
Chapters ICD-9 Hospitals and physicians Pharmaceutical care 
AUS CAN ENG NETH Coeff. of AUS CAN ENG NETH Coeff. of 
Variation Variation 
Infectious 2.6 1.4 1.5 1.7 35% 4.8 2.3 1.4 3.7 55% 
Neoplasms 7.5 8.0 6.2 7.6 13% 1.3 2.4 2.9 1.8 38% 
Endocrinal 2.2 2.2 1.4 1.9 23% 7.6 5.1 3.0 5.3 41% 
Blood 0.7 0.6 0.8 0.6 17% 0.6 0.3 0.4 44% 
Mental 6.8 12.2 11.5 20.1 49% 4.9 6.1 5.2 7.8 26% 
Nervous 5.6 4.8 5.4 7.2 21% 6.1 4.5 4.3 5.0 19°/o 
Circulatory 10.2 15.7 12.3 12.8 21% 17.7 15.9 18.4 20.9 14% 
Respiratory 6.9 7.7 7.8 5.2 21% 19.4 9.8 11.8 13.1 36% 
Digestive 6.4 7.5 5.4 5.9 17% 6.8 5.9 14.0 12.7 47% 
Genito-urinary 6.5 5.1 4.9 4.6 19% 3.5 4.0 3.7 3.3 10% 
Pregnancy 4.6 5.4 5.0 3.3 24% 0.3 0.4 2.8 116% 
Skin 2.7 1.7 2.4 2.9 26% 6.4 2.8 2.3 2.8 59% 
Musculoskeletal 8.1 5.4 6.4 7.8 22% 6.8 5.0 4.9 24% 
Congenital 0.6 0.8 0.7 1.0 27% 0.0 0.1 0.5 118% 
Perinatal 1.0 1.5 1.2 1.3 20% 0.0 0.1 0.0 231% 
Symptoms 4.3 4.2 5.5 7.2 31% 7.5 3.4 0.8 7.0 72% 
Accidents 9.7 8.0 6.0 6.4 27% 3.1 1.9 1.1 57% 
Not allocated 6.4 7.8 5.6 2.6 45% 3.0 2.8 33.6 6.8 121% 
Not included 7.1 0.0 9.9 0.0 114% 0.0 27.4 0.0 0.0 159% 
Total costs 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
* AUS =Australia~ CAN = Canada, ENG = Englillld, GER = Germany, NRTH = Netherlands, SWE = Sweden, SD = stillldard deviation. 
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however, were applied in hospitals and therefore all CO! studies reported the costs 
as part of hospital costs. 
For the three remaining countries (England excluded), the overall distribution 
among lCD chapters was roughly the same. Some major epidentiological-based 
differences regarded infectious diseases, diabetes, respiratory diseases and 
diseases of the skin [Looper 1998]. Other differences were caused by variations in 
medical practice, as for instance the lower costs for digestive diseases (acid 
inhibitors) and circulatory diseases (anti-hypertensive and cholesterol lowering 
medicine) in Australia and Canada likely due to cost containment policies. 
Health practitioners 
Among health practitioners international variations in health systems and COI 
studies played a major role (table 8.6). In the Canadian study, costs of digestive 
diseases were hlgh because only dental care was allocated. In England, costs for 
mental disorders, nervous system and senses and circulatoxy diseases were high 
because of expenditure on psychiatrists, ophthalmologists and cardiologists which 
in other countries was included in hospital costs. 
As a result only a bilateral comparison between Australia and the Netherlands 
was reasonable. The overall pattern for both countries was almost the same. Some 
imponant differences regarded diseases of the nervous system, pregnancy, 
musculoskeletal diseases and symptoms and were caused respectively by more 
outpatient ophthalmic care in Australia, childbearing at home assisted by 
midwives in the Netherlands, a substantial number of Cesar and Mensendieck 
therapists in the Netherlands, and a high frequency of symptoms registered by 
physical therapists in the Netherlands. So most differences were caused by 
differences in the health care systems. 
The costs for endocrine diseases were high in Australia and probably resulted 
from a higher prevalence of diabetes among the aboriginal population. In this 
sector it was the only disease for which a possible epidentiological cause could be 
distinguished. 
Institutional care 
Cross~ national differences were largest for institutional care and all could be 
explained by differences in health systems (table 8.6). Due to the comprehensive 
sector of health institutions, the costs of mental disorders (intellectual disability 
and dementia) and circulatory diseases (stroke) were high in the Netherlands. The 
costs of musculoskeletal diseases and diseases of the nervous system were low in 
the Netherlands, mainly due to the specialised institutions for rehabilitative care 
and people with epileptic disorders that belong to the hospital sector. The high 
share of unallocated costs in the Dutch study regarded living costs in homes for 
the elderly. 
Table 8.6 Costs of health professionals (physicians excluded) and institutions by diagnosis in four countries. Share of ICD chapters in total 
costs per sector (%) 
Chapters ICD-9 Health professionals Institutional care 
AU5 CAN ENG NETH Coeff. of AU5 CAN ENG NETH Coeff. of 
Variation Variation 
Infectious 0.5 0.0 0.1 132% 0.4 0.1 0.4 63% 
Neoplasms 0.4 0.5 0.1 69% 1.1 0.8 0.9 20% 
Endocrina\ 1.7 0.4 0.1 113% 1.6 1.7 0.9 38% 
Blood 0.0 0.0 0.0 0.2 0.4 0.1 76% 
Mental 2.5 15.5 0.9 119% 24.2 11.9 48.7 50.4 61% 
Nervous 7.0 10.4 1.1 81% 17.0 12.5 4.8 61% 
Circulatory 1.2 9.8 0.5 124% 19.8 8.4 10.3 55% 
Respiratory 1.1 0.8 0.8 24% 3.6 2.0 1.7 49% 
Digestive 56.8 77.6 27.4 53.3 44% 1.2 1.9 0.5 65% 
Genito-urinary 0.5 0.1 0.1 92% 1.1 1.8 0.4 70% 
Pregnancy 0.2 3.7 11.0 108% 0.0 0.0 0.0 
Skin 1.7 0.2 0.1 124% 0.2 0.4 0.2 51% 
Musculoskeletal 12.8 7.9 16.5 42% 14.5 12.9 2.1 75% 
Congenital 0.0 0.1 0.1 115% 0.4 0.1 0.2 68% 
Perinatal 0.0 0.0 0.0 0.1 o.o 0.0 115% 
Symptoms 1.8 1.3 6.3 90% 0.2 2.6 2.0 82% 
Accidents 4.9 0.5 3.9 80% 3.8 1.3 3.6 55% 
Not allocated 1.4 0.0 15.0 5.1 119% 0.0 4.5 21.6 118% 
Not included 5.6 22.4 6.7 0.0 108% 10.6 88.1 0.0 0.0 151% 
Total costs 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
* AUS =Australia, CAN = Cruwda, ENG = EnglaJld, GBR = Gennmty, NETH =Netherlands, SWE = Sweden, SD = stmzdard deviation. 
108 Cost of illness in the Netherlands 
8.6 Discussion 
Reponed cost-of-illness figures showed a wide variation in costs for different 
diseases. We distinguished six explanatory factors for cross-national differences: 
1) health care services; 2) the definition of health expenditure; 3) deviations 
between cost-of-illness and health expenditure; 4) data and methods employed in 
the COl studies; 5) health care utilisation due to differences in health status and 
health care needs caused by epidemiological and demographic variables; 
6) variations in medical practice. Unfortunately it was not possible to correct for 
factors 1 - 4 and to explain remaining differences completely by factors 5 - 6, 
since CO! figures could not be adjusted to a common comparable package. In fact, 
such a package had not been defined for the six countries in our study. Although 
the comparability increased a lot by adjusting CO! data to national health 
expenditures, it was only possible to indicate some major epidemiological 
explanations for the remaining differences. 
For four countries further improvements could be made by disaggregating CO! 
figures to more or less comparable health care sectors, especially hospitals and 
physicians and pharmaceutical care. Due to differences in health system as well as 
in the data and methods employed in the CO! studies, several unexpected 
variations in CO! figures remained. The differences in CO! methodology did not 
regard the overall top-down method that was used in all studies, but the more 
detailed properties of, for instance, the use of resource intensity weights and 
expert opinions. As a result, also at disaggregate level only major epidemiological 
explanations could be distinguished. Differences in health care systems, health 
care provision and COl methods provided more satisfactory explanations. 
In the Dutch and Australian study, health expenditure was simultaneously 
allocated to age and sex, while in the Canadian study estimates for age and sex 
separated from the allocation to diseases. Demographic cost estimates are useful 
for the projection of future health care costs. Within the scope of cross-country 
comparisons there is additional benefit. The cost estimates per age and sex 
category provide a framework with borderline statistics for the interpretation of 
differences betvveen health care sectors and disease categories. Moreover a 
simultaneous breakdown allows for the adjustment of cor estimates to differences 
in the age structure of the populations involved. 
Recommendations 
CO! studies are primarily designed for national purposes. Hence the significance of 
a crude comparison of costs per !CD chapter as in the OECD Health Data is very 
limited. The findings of such comparisons are weak and the major conclusions 
only regard obvious aspects. At present, for a real insight into cross-national 
differences, it is much better to study either health care systems or epidemiology 
instead of their interaction in COI studies. 
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If, nevertheless, COl comparisons are desired, it would be better to compare 
disease specific studies. Such comparisons should contain detailed data on 
epidemiology of the disease and cross-national variations in the provision of health 
care. Given the differences in cost estimates for different diseases [Koopmanschap 
1998], this approach would in fact require international collaboration from onset 
of the study. 
If a comparison of general CO! studies is what is wanted, some major 
conditions for success can be mentioned: 1) uniform sector definitions should be 
used [Mosseveld 1998, OECD 2000a, Eurostat 2000]; 2) many subsectors should 
be distinguished to allow for detalled adjustments of national data to international 
definitions; 3) a distinction should be made between sectors with multiple 
diagnoses (mainly hospitals, physicians, pharmaceutical care and probably nursing 
homes) and sectors which costs can be attributed to oniy one diagnosis (dental 
care, care for people with intellectual disabilities or psychiatric conditions); 4) a 
further standardisation of methods is necessary; 5) the inclusion of age and sex in 
the CO! estimates would be very usefuL In our opinion only a joint research 
project can fulfil these conditions. 
8. 7 Conclusions 
We concluded that the scope of COl studies barely extents beyond national levels. 
Published CO! studies could oniy be compared at a high level of aggregation. At 
this level, the overall distribution of costs among lCD chapters was roughly the 
same. There were, however, major deviations that in most cases could not solely 
be explained by epidemiological factors, the health care systems involved or 
characteristics of the study. Cross-national comparisons, therefore, should start 
with health care systems or epidemiology rather than COl studies. In the long run, 
CO! comparisons might be successful if the scope is limited to sectors in which 
multiple diseases play a role, if methods are standardised at detailed level and the 
CO! figures regard a common comparable package or any other international 
standard of health care supply. 
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9.1 Introduction 
This thesis deals with general cost~of-illness studies. In the previous chapters we 
demonstrated the construction, application and interpretation of COl studies (the 
first objective of this thesis, see 1.5). In this cbapter we discuss the advantages and 
limitations of general COl studies (the second objective). First, the theoretical 
debate on COI studies is summarised and discussed. Second, the implications of 
more practical issues for the COl field will be discussed regarding the objectives of 
description, comparison and projection. We will finish with come conclusions and 
recommendations. 
9.2 The cost-of-illness debate 
In the literature, there has been some debate about the usefulness of cost-of-illness 
studies. Some criticisms regard the methods by whicb indirect or productivity costs 
are estimated. Because this thesis focuses on medical costs alone, we refrain from 
participating in that discussion, and instead concentrate on the qualities of general 
COl studies that include only medical costs. 
Objectives of cost·ofillness studies and possible applications 
The objectives and applications of COI studies mentioned in the literature can be 
summarised under three headings: description, comparison and projection (see 
1.4) [e.g. Ament 1993, Black 1975, Byford 2000, Davey 1992, Drummond 1992, 
Hodgson 1989, Koopmanscbap 1998, Rice 1994, Rice 2000, Roijen 1997]. 
114 Cost of illness in the Netherlands 
General cost-of-illness studies are assumed: 
Description 
L to provide a single index of the burden of illness; 
2. to tell how much society is spending on one or more diseases, and by 
implication the amount that would be saved if the diseases were eradicated; 
3. to raise cost-consciousness among policy-makers; 
4. to identify the main components of health expenditure and areas where 
savings can be made; 
5. to justify the present and future health care budget or the amount on specific 
intervention programs; 
6. to assist in the allocation of research dollars on specific diseases. 
7. to provide baseline data on which more detailed economic evaluations can be 
undertaken. 
Comparison 
8. to explain trends in health expenditure by comparing different years within a 
particular country; 
9. to explain differences in health expenditure across countries. 
Projection 
10. to be employed in demographic and epidemiological scenatios to project 
future developments in health expenditure. 
Criticisms on cost-of-illness studies 
The above mentioned objectives have been criticised by some authors. The most 
firm and concise ctitique was described by Shiell eta!., who stated that COl 
studies 'only confuse, mask and mislead' [Shiell1987]. Their arguments and the 
criticisms of others regard objecrives 1-6 and 10. 
1. General concept and use as index for burden of illness 
COl studies rest on a fundamental misunderstanding of economic cost. In 
economics costs are defined as opportunity costs which measure the value of 
forgone benefits of the most favourable alternative use of the resources. In 
health care these opportunity costs should be measured in terms of quality-
adjusted-life years (QALYs) [Shiell1987]. 
COl studies do not capture the whole burden of diseases, since they do not 
reckon with the consequences of the diseases for quality of life [Drummond 
1992]. 
COl estimates are difficult to interpret. Does the ranking of diseases according 
to costs yield a ranking according to disease severity or something else? Based 
on the Canadian CO! study, in which the costs of coronary hean disease were 
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estimated at CAN$ 7.4 billion, compared to CAN$ 1.9 billion for motor 
vehicle traffic injuries [Moore 1997], it was questioned whether these data 
'demonstrate that coronary heart disease is a ''bigger'' problem than motor 
vehicle traffic injuries, by a factor of four times, or mean that four times the 
resources ought to be allocated to coronary heart disease?' [Currie 2000]. 
2. Savings resulting from eradication of diseases 
In a policy context, total COl estimates are not appropriate, since they only 
indicate the benefits of totally eradicating the disease in question. As few 
diseases can be eradicated, at least in the short run to which cor estimates 
relate, potential cost savings are to a large extent illusory. 
Even if complete eradication is possible, CO! studies do not say anything 
about the costs of eradication itself, and will overestimate potential savings. 
Costs of prevention, for instance, can be become quite high for certain 
diseases. 
Prevention particular diseases will always result in an increase of other 
diseases. People get older and will likely suffer from 'substituting' diseases. 
Especially from a longitudinal perspective cost savings are at least uncertain 
and likely unattainable. It was shown, for instance, that the prevention of 
fatal diseases will induce higher health care costs [Bonneux 1998]. 
3. Cost-consciousness among policy-makers 
By focussing on diseases with high costs, CO! studies can implicitly divert the 
decision makers' attention from areas where important health gains can be 
made at low costs [Byford 2000]. A well-known example is phenylketonuria, 
which leads to severe intellectual disability but does not represent a 
substantial share in total cost of illness because incidence is low. However, 
this is not an argument against preventing the disease; it is, in fact, 
inexpensive to prevent while the health gain for the individual is great. Even 
so, costs of screening for this particular disease can become rather high if not 
performed in a joint screening programme. 
4. Identification of cost components and efficiency gains 
COl studies usually do not include the costs of informal care, while from a 
societal perspective it is an important category. Cost savings are 
overestimated if a reduction in formal care causes a shift to informal care. 
COI studies focus on costs and not on efficiency, and consequently may lead 
to incorrect decisions. High expenditure as such does not provide enough 
information to suggest (technical) inefficiency and waste. High expenditure, 
in other words, does not imply that efficiency gains can be attained. 
Resource allocation and its efficiency are usually matters of scale. Policy-
makers face questions about whether an existing program should be 
expanded or contracted. Decision-makers are interested in marginal analyses 
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that compare the expected change in benefits with the additional costs of the 
intervention that brings that change about [Shiell1987]. Policy-makers, in 
other words, need cost-effectiveness analyses instead of cost-of-illness studies. 
5. Justification of the health care budget or the amount on specific programs 
If inefficiencies and waste exist, the prioritising of programmes for diseases 
-with high costs can introduce some circularity, which means that policy 
decisions perpetuate and amplify the original irrational spending [Shiell 
1987, Koopmanschap 1998]. CO! studies, therefore, can not justify any 
allocation of health care resources [Davey 1992, Byford 2000]. 
6. Prioritising medical research 
COl figures do not provide sufficient information for decisions about the 
allocation of resources for medical research. COI can at most indicate 
important research areas from perspective of health expenditure, but always 
additional data on research opportunities are required. 
10. Projecting future health care costs 
CO! studies usually show a cross-sectional picture and fail to estimate the 
influence of technological change on health care costs [Hodgson 1989]. For 
instance, the developments in therapy had a substantial influence on costs 
coronary heart disease [Hodgson 1994]. As a result projections based on a 
'business as usual' assumption can be misleading. 
Discussion 
In the debate on the qualities of COl studies Hodgson argued that CO! studies are 
not aiming at policywmaking, but must be seen as policywrelevant by educating, 
informing and enlightening policy-makers [Hodgson 1989]. COl studies do not 
replace cost-effectiveness analyses (CEA) but can be seen as a baseline against 
which new, expensive clinical trials and CEAs can be performed [Drummond 
1992]. Policy-makers can use CO! studies in their considerations but mature 
decisions need more inputs. For decisions about the allocation of health care 
resources data on medical outcomes and cost-effectiveness is required. Equity 
arguments regarding distributive justice must also be considered [WHO 2000]. For 
decisions about the allocation of research funds, CO! studies can be used to 
indicate important fields, but additional information on promising research areas 
is always required. In summary, COl studies as such are no aid to decision-making 
or priority setting. Similar conclusions were made regarding the policy-relevance 
of the global burden of disease estimates. [Williams 1999, 2000, Mooney 2000, 
Murray 2000]. 
The other shortcomings have not been addressed extensively in the literature. 
It is clear, however, that most arguments more or less explicitly relate to the 
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efficiency argument. It is also clear that COl studies represent a different aspect of 
health economics than studies in Medical Technology Assessment (MTA). From 
the perspectives of decision-making, priority setting and resource allocation, the 
above mentioned criticisms regard relevant shoncomings of the COl approach. In 
our opinion, the 'opportunity cost' argument mentioned in the first point only 
confuses benefits (numerator) and costs (denumerator). In health economics 
opportunity costs are usually estimated by the value of invested resources since 
market prices are hardly available. 
It is true that COl studies do not estimate the whole burden of disease. 
Mortality, morbidity and quality of life are not included. CO! studies only estimate 
the expenditure burden of disease. Due to the disappointing cross-national 
comparability, however, the meaning of the expenditure burden is nearly limited 
to national levels. 
The issue of static descriptions in a dynamic sector is evident. This 
shortcoming, however, can at least partially be solved by repeating CO! studies for 
several years and describing the developments in that period. We were able to 
compare CO! studies for 1988 and 1994 and found interesting trends in health 
care costs by diagnosis and age (Chapter 3 and 5). 
What cost-ofillness studies can not tell 
The above mentioned limitations of COI studies can be summarised in four major 
points. COI studies can not tell us: 
1. the value for money invested in health care. 
2. whether or not more resources should be devoted to treating specific diseases; 
3. whether or not more resources should be devoted to particular areas of 
medical research; 
4. the total burden of disease. 
What cost-of-illness studies really can tell 
These shortcomings do not imply that COI studies do not have any value at all. 
They have their own worth as a numerator against which the dynamics of health 
status and health care can be described. While not appropriate for daily decision-
making, this information is policy-relevant and can be used in combination with 
other information for developing a strategic perspective on health care. So the 
Dutcb CO! study played a role in the debate on the furure of the health care 
system and the resources needed to comply with ageing [NZF 1997, Ministerie 
VWS 1998, 1998a, SER 1999]. 
According to Drummond, CO! studies can fulfil an important task in 
'highlighting the importance of diseases over and above the more usual 
epidemiological estimates' [Drummond 1992]. CO! estimates can offer a new 
perspective on the population's health status as a whole, as well as on specific 
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diseases in particular. One of the key messages of the Dutch CO! study on 1994 
was that the main health care costs were made for chronic disabling diseases and 
not for the major causes of death (Chapter 2). The expenditure burden, in other 
words, was different from the mortality burden. A similar conclusion can be made 
for disease rankings based on incidence. Some infectious diseases have high 
incidence rates, for instance influenza, while costs are low compared to disorders 
with low incidence rates such as intellectual disability, some psychiatric conditiOns 
and congenital malformations. 
In the Global Burden of Disease project (BOD) Murray and Lopez developed 
the DALY concept for the quantification of morbidity and mortality [Murray 
1996]. Disability Adjusted Life Years (DALYs) integrate reduced life expectancy 
and increased disability in a single figure, using disability weigbts. Disability 
weights and DALYs were published for the Netherlands in 1994 [Stouthard 1997, 
Ruwaard 1997]. In some cases, the ranking based on DALYs was comparable to a 
ranking based on expenditure burden as estimated in the Dutcb CO! study, sucb 
as, for instance, for infectious diseases (low DALYs and low costs), schizophrenia 
(moderate DALYs and moderate costs) and COPD, coronary heart disease, stroke, 
dementia and intellectual disability (higb DALYs and high costs). For other 
diseases, however, the rankings differed. Most cancers ranked high on a DALY-
scale, with relatively low costs. By contrast hip-fracture and Down's syndrome 
ranked low in DALYs, while the costs were high. 
We conclude that COI studies and other burden-of-disease estimates are 
complementary by focussing on different aspects of diseases: mortality, morbidity 
and costs. CO! studies do not say much about disease severity, but estimate the 
resources dedicated to the prevention and treatment of all diseases, severe or less 
severe. The advantage of CO! estimates is that they show how mucb society has 
invested in a particular disease compared to other diseases. In answer to the 
interpretation problems mentioned in the tenth shortcoming, we conclude that 
COl studies neither say whether one disease is a 'bigger problem' than another 
disease, nor indicate the resources society should invest in the specific disease. COl 
studies only disclose how much society has invested, given demography, 
epidemiology and medical technology. These insights, however, are worthwhile 
and complementary to the messages of the other burden of disease estimates. 
Especially when CO! data for several years are available and time trends can be 
studied. 
Another benefit of CO! studies is that projections of future health expenditure 
can be made, provided that expenditure has been allocated to age and sex. In this 
way the consequences of demographic and epidemiological developments for the 
health care budget can be explored. In sensitivity analyses, the boundaries of 
health care costs can be estimated, including status quo (current levels and 
technology of care provision) as well as alternative scenarios regarding new 
technologies and policy measures. 
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A last benefit mentioned by Drummond, and not disproved by the critics of COr 
studies, regards the possibility of crossMnational comparisons when estimates for 
different countries are available. An important condition here is that 'separate 
components of direct costs are identified'. 
Conclusion 
We conclude that cost-of-illness studies provide a suitable framework for the 
description, comparison and projection of health care expenditures from an 
epidemiological and demographic perspective, first of all as input for more 
detailed investigations. 
9.3 Descriptive qualities 
General cost-of-illness studies provide global descriptions of major patterns and 
trends. One of the key messages of the Dutch cor study was that most health 
expenditures relate to chronic disabling diseases rather than the major causes of 
death (Chapter 2). By including the whole health care system in the CO! estimates 
the resources invested in, for instance, mental disorders and intellectual disability 
become clear (Chapter 6). Another striking element in the global picture regards 
the costs of digestive diseases which were very high, for instance compared to 
costs of cancer, mainly due to dental care. General COI studies are less appropriate 
for detailed descriptions due to data problems and methodological aspects. 
Data problems 
General cor studies depend on numerous data sources (appendix A). Data on 
health care use is needed for each sector. For a number of sectors, national 
registries are available, while for other sectors, surveys must be used. Cost 
estimates for some diseases can be biased due to lacking data. The Dutch hospital 
registry (LMR), for example, which covered nearly all hospital care in 1994 
contained almost no specific data on renal dialysis provided in specialised hospital 
units. As a consequence, the costs of renal diseases were underestimated in the 
Dutch CO! study [Wit 2001]. 
Lacking data also made it necessary for assumptions to be made. In the Dutch 
study on 1994, we made several assumptions, some of which were weak, such as 
the assumption that survey data from one year were representative of another 
year, and others strong, such as the hypothesis that the costs of care in homes for 
the elderly were distributed among disease categories in the same way as in 
nursing homes. Another strong assumption regarded the distribution of hospital 
costs among inpatient and ambulatory care. Because of data problems and 
substituting assumptions, general CO! studies are suitable for broad descriptions 
rather than detailed analyses. 
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Top-down methodology 
General COl studies are based on a top-down methodology. For each sector, 
health expenditure is ascribed to diseases using key variables that represent equal 
units of health care consumption. For some sectors, the units of health care use are 
weighed by resource intensities, as was the case for hospital interventions and 
pharmaceutical care in the Dutch study on 1994. For other sectors, each unit per 
key variable is given the same weight, although there are indications that resource 
intensities differ per disease category. 
In Chapter 7, we described costs after hip ftacture as estimated in a bottom-up 
study. These estimates were based on detailed data on health care use. For each 
type of care, several components were distinguished. For hospital care, therefore, 
a distinction was made between the fixed costs of inpatient days and the variable 
costs of nursing, care by physicians and allied health professionals, laboratory 
analyses and radiology. Volume data per component were collected and multiplied 
by unit costs for each patient. The results were striking. First, the difference in 
total costs between a general hospital and an academic hospital on the one hand 
and between hospitals and nursing homes on the other hand were modest. 
Secondly, hospital costs declined steeply for nearly all patients in the post-
operative days and remained low until discharge. These results contradict the 
assumption of equal costs per hospital day as used in top-down COl studies. As a 
consequence, the costs of diseases that use considerable resources per inpatient 
day are systematically underestimated, while costs of other diseases are 
overestimated. General COl studies can be improved by distinguishing resource 
intensity weights for major care categories as inpatient day in hospitals and 
nursing homes. A first step would be to distinguish intensive care days from 
average inpatients days, which was not yet possible in the Dutch study on 1994. A 
second improvement would be to integrate care weights in the key variables. This, 
however, will only be possible if: 1) the registries contain information on the 
disnibution or care weights among people with a certain disease; and 2) the 
relation betvveen care weights and costs is clear. 
Prevalence-based 
General COI studies are cross-sectional, hence prevalence based. The estimated 
costs relate to all care for ill people in a certain year, irrespective whether people 
contracted the disease in that particular year or were already ill at the beginning 
of the year. As long as incidence is constant and costs are stable during the course 
of the disease, the cross-sectional approach will yield reliable cost-of-illness 
figures. In other cases, however, a bias might be introduced. Costs of cancer, for 
example, are high at onset of the disease, relatively low during the development of 
the disease, and high again in the final stage preceding death [Koopmanschap 
1994a]. Other examples regard aids and diabetes mellitus [Posttna 1998]. 
Cost estimates in general CO! studies, therefore, mirror the distribution of 
disease stages in a certain year's population. As a consequence, COI figures can 
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only be divided by incidence rates to calculate costs per incident case as long as 
incidence, stage distribution and duration are constant. 
Disease and comorbidity 
In general CO! studies, health expenditures are allocated to primary diagnoses 
only. A major advantage of this approach is that double counting is excluded by 
definition. Total cost of illness is equal to total health expenditure, and disease 
advocacy does not play a role, unlike some disease-specific cor studies. 
A shortcoming of this approach is that the costs of diseases, which are 
prevalent as comorbid conditions, are underestimated. In Chapter 7 it was 
calculated that hip fracture patients with comorbidities had substantially higher 
costs compared to people without comorbidiry. In general COl studies, these 
higher costs are all ascribed to the disease for which the patient was admitted to 
the hospital. For some diseases, this shortcoming can be corrected by specifying a 
separate axis for secondary diagnoses in hospital data. This will be the approach in 
the 1999 update of the Dutch cor study for sepsis and chronic ulcers of the skin. 
In the same way costs of causally related diseases are underestimated by the 
use of primary diagnoses only. Diabetes is a good example here. Costs for diabetes 
were relatively low in the cor study for the Netherlands in 1994, because patients 
were admitted to hospital for heart disease, eye disorders, renal insufficiency and 
other diseases caused by diabetes. Since diseases in this category experience more 
or less complex causal relations with other diseases, the underestimation can not 
be solved by simply specifying a secondary diagnosis. For this category of causally 
related diseases epidemiological models should be used to study the dynamics in 
epidemiology and costs [Barendregt 1998]. Such models, however, analyse 
specific diseases and do not comprise health care as a whole. Rather than as an 
improvement on COl studies, this modelling approach should be seen as an 
independent scientific discipline, in which COI studies can be p.sed as an input 
instead of the other way around [Barendregt 1997, Bonneux 1998]. 
9.4 Qualities of comparisons 
Comparisons over time 
The availability of COI estimates for tv-~o or more years allows for comparisons 
over time. Because the cor studies are based on the same population and the 
same health care system, the possibilities for comparison seem very good. Indeed 
the possibilities for comparison are nowhere better than here. However, there are 
some problems. 
In the first place, there are the data problems. Registries evolve and change over 
time. In 1988 the Dutch hospital registry, for example, contained almost no data 
on day care, while in 1994 the coverage was nearly 100%. As a result, the cor 
studies for 1988 and 1994 were compelled to employ different methods for the 
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allocation of hospital care. For the purpose of comparison. the 1994 study was 
adjusted to 1988 methods (Chapter 2), but the missing data on day care hampered 
the explanation of trends (Chapter 5). Other data problems concern the 
availability of surveys. In 1988, the data on care for the disabled were poor. In 
1994 the data were much better, but the data available for the 1999 update are 
again inferior in quality. Lacking data made allocation of pharmaceutical 
expenditure impossible for 1988, and hence no comparison could be made with 
1994. Another example regards home care for which in 1988 a survey was 
available, which was also used for the 1994 update because of the lack of data for 
that particular year. For the allocation of general practitioners' expenditure in 
1988 and 1994, two quite different surveys were used, which meant that this 
sector had to be excluded from comparisons. In conclusion, COI studies must be 
adjusted for differences in data and subsequent methods before comparisons can 
be made. 
The second category of problems regards the influence of health care policy. 
Two aspects are important here. First, the definitions of health care sectors change 
over time. In 1988, for example, the expenditure for psychiatrists was classified in 
the same category as for medical specialists, while in 1994 this expenditure was 
included in the figures for psychiatric care. Another example regards the 
vaccination program, which was classified as home care in 1988 and as preventive 
care in 1994. Before comparisons can be made, these administrative differences 
must be identified and eliminated. A second influence of health care policy regards 
investments in specific health care facilities and cost containment measures in 
others. In 1988 - 1994, the Dutch government invested in health services for the 
disabled. The COI comparison between the two years mirrors these investments. In 
other cases, however, the influence of health policy is less obvious. To contain 
pharmaceutical costs, for instance, some drugs were excluded from remuneration, 
while for others co-payments were introduced. Consequently not only expenditure 
changed, but also the numerator on which the expenditure was predicated. Costs 
for physical therapy were almost the same in 1994 and 1999, mainly due to a 
restriction of the allowed number of insured sessions per patient. Because in these 
examples all aspects changed, e.g. expenditure, sector definition and volume of 
care, it is very difficult to untangle the contributions of epidemiology and health 
policy. We conclude that CO! comparisons over time always include the effects of 
health care policy. In some cases the CO! figures can be adjusted for one year or 
the other. In other cases the influence is more implicit and can not be removed. In 
these cases, health policy might introduce a bias in the CO! comparisons. After all 
there was limited evidence for epidemiological causes of changes in CO! between 
1988 and 1994. The relatively shott period was also crucial here. 
Interesting time trends 
Some of the most interesting time trends were described in Chapter 5. We 
demonstrated that the average growth rate in per capita costs was almost stable 
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over age. Underlying this development quite different trends for acute care and 
long-term care were observed. The grov.rth rate for acute care costs increased with 
age, whereas the rate for long-term care decreased. The acute care trend took 
place within the fixed budget for hospital costs and was driven by technological 
innovations that caused an increase in day care, mainly among younger people, 
the broadening of indications for interventions among the elderly and an overall 
reduction in the average length of hospital stay. The trend in long-term care 
mainly resulted from specific invesonents in certain areas of health care, mainly 
facilities for disabled people. We conclude that from a societal perspective the 
developments in acute care are to a certain extent autonomous, while long-term 
care is more sensitive to policy measures. 
Comparisons over countries 
The availability of CO! studies for different countries allows for cross-national 
comparisons (Chapter 8). Here the problems associated with comparisons within 
one particular country are intensified, in addition to the new problems that arise. 
The first issue regards the definition of health care. Cross-national differences 
in per capita expenditure are quite large. The definition of total health care differs 
per country. In the Netherlands, for example, homes for the elderly are included in 
the health care system in contrast to all other countries. In Australia, institutions 
for people with intellectual disabilities are excluded from the health care system, 
while included in most other countries. Hence 100% of the health care budget has 
a different meaning for each country. Moreover, not all COI studies comprise 
100% of the health care budget. In many cases, however, it will be possible to 
adjust for these differences. 
The second issue concerns the scope and contents of health care institutions. 
Nursing homes are known to be quite different in the Netherlands and the United 
Kingdom. The definitions of hospitals also differ bet;v..reen countries, especially 
regarding psychiatric and rehabilitative care. Adjusting for these differences causes 
major problems that can not easily be solved. 
The third aspect has to do with differences in data and methods. Some studies 
use expert opinions while others are based on data from registries and surveys. 
Due to such differences pharmaceutical costs of illness could not be compared 
bet;v..reen England and the other countries. Another difference regards the use of 
resource intensity weights to adjust the number of inpatient days for the intensity 
of care. 
As a result of these problems, cross-national COI comparisons only reveal quite 
obvious epidemiological differences, such as, for instance, a high prevalence of 
skin diseases and diabetes in Australia (Chapter 8). Some indications of major 
differences in health care practice might also become evident. The hospital costs 
for childbirth in the Netherlands were low due to the Dutch practice of childbirth 
at home. High costs for digestive diseases in Germany were caused by the large 
number of dentists. In Canada, finally, pharmaceutical costs for circulatory 
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diseases were relatively low, probably due to a restrictive drug policy and 
substitution by hospital care. 
We conclude that the value of COl studies is primarily restricted to national 
levels. A true insight into cross-national differences is better obtained by studying 
either health care systems or epidemiology rather than their interaction. If, 
nevertheless, cross-national comparisons are to be made, we recommend that: 
1) uniform sector definitions be used; 2) many subsectors be distinguished to 
allow for detailed adjustments of national data to international definitions; 3) a 
distinction should be made between sectors with multiple diagnoses (mainly 
hospitals, physicians, pharmaceutical care and probably nursing homes) and 
sectors which costs can be attributed to only one diagnosis (dental care, care for 
people with intellectual disabilities or psychiatric conditions); and 4) methods be 
standardised. Furthermore, the inclusion of age and sex in the COl estimates 
would be very useful, as they provide a framework with borderline statistics for 
the interpretation of differences between health care sectors and disease 
categories and allow for adjusting COI estimates to demographic differences. 
Finally, it would be worthwhile to combine CO! estimates and other burden-of-
disease measures such as DALYs, in order to relate cost-differences to differences 
in health status. At this moment, this is unfortunately not yet possible. 
9.5 Power of projections 
Demographic projections 
The allocation of health care costs to age groups by sex allows for projections of 
future health care costs. The Dutch CO! figures were used in this way (Chapter 4) 
and the results were used by the government [Ministerie VWS 1998, 1998a]. 
Demographic projections, however, have some important shortcomings. 
The first shortcoming is that demographic projections only take into account 
changes in cohorts. The changing numbers of people in each age-sex group are 
multiplied by the fixed costs per age-sex group as estimated in the CO! study. The 
problem here is that population forecasts are not only based on birth rates, but 
also include some assumptions on ageing [Beer 1997].As life expectancy is 
increasing it is not appropriate to fix per capita costs at constant levels [Spillman 
2000]. This problem can be solved by estimating not only costs per age-sex group, 
but also the costs in the last year of life for all age and sex groups. There is some 
evidence of substantially higher costs in the year preceding death [Nord 1989, 
Lubitz 1993, WRR 1997], and therefore these costs will be specified in the 1999 
update of COl in the Netherlands. By analysing these costs separately the influence 
of longevity can be distinguished from the influence of changing cohorts and the 
projections become more reliable. 
A second shortcoming regards the assumption that costs per age and sex group 
are stable over time. Demographic projections extrapolate current medical practice 
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to the future and ignore the influence of epidemiological and technological 
change. In Chapter 4 and 5 we demonstrated a substantial impact of these 
variables. which was also the case for policy measures. The main advantage of 
demographic projections, therefore, is limited to a function as rough estimates of 
future costs and scenarios to which actual developments can be compared. 
Epidemiological and other projections 
Other projections can be used to deal with the shortcomings of demographic 
projections. If tvvo or more COl studies are available, time trends can be studied 
and extrapolated. In Chapter 4, we prolonged the combined trend for 
epidemiology, technology and health care policy irrespective of age. We concluded 
that projected health care costs will increase much more steeply compared to a 
simple demographic projection. In Chapter 5 we made a projection based on age-
specific trends. In this scenario, the total projected costs increase was even higher, 
but consisted of different projections for acute and long-term care. Both 
projections depended on the assumption that developments in the past are 
representative for the future, which is in fact a strong assumption. In 1988- 1994, 
for example, day care in hospitals emerged as an important health care service. 
Although it is likely that the importance of day care will increase in the near 
future, it is far from clear whether this trend will remain constant in the same 
magnitude or will curve downward. Similar conclusions can be made for the 
influence of health policy. In conclusion, projections of future costs based on past 
trends must be interpreted as rough scenarios of developments that will 
undoubtedly be different. 
Epidemiological models can be used to make more sophisticated projections 
for a particular disease or some related diseases. Unfortunately, integrated 
epidemiological models for the whole health care system and total health 
expenditure are not (yet) available. The Dutch cor studies were used to predict 
costs of cancer [Koopmanschap 1994a], smoking [Barendregt 1997] and 
circulatory diseases [Bonneux 1998]. In such studies cor estimates must be used 
with caution, as the estimates relate to all the costs of those with the disease in a 
certain year. We saw in the foregoing that the cost may vary during the course of 
the disease. Models based on the incidence-prevalence-mortality approach should 
take this aspect into account and in some cases should use adjusted COl figures, as 
Marc Koopmanschap did in the projection of the future costs of cancer 
[Koopmanschap 1994a]. Despite the sophisticated method of these models, it 
should be noted that they also assume that cor estimates per age and sex group 
are stable over time, which is still a strong assumption. 
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9.6 Conclusions: Are general cost-of-illness studies useful? 
General COl studies are used by researchers and politicians for several purposes, 
but are tbey realJy useful? Based on tbe observations and discussion in this tbesis 
we conclude tbat: 
1. COI studies have, first and foremost, national value. In the future, however, 
cross-national comparisons might be possible and will reveal interesting 
insights if methods are standardised and the estimates regard a common 
comparable package. 
2. CO! studies disclose interesting information complementary to burden-of-
disease estimates based on epidemiological criteria. The significance of COl 
figures mainly consists of tbe framework tbey provide for healtb care research 
and health care policy. They do not provide, however, simple criteria for 
decision making on the allocation of health care resources, research funds or 
whatever decisions can be made. They provide comprehensive insight into 
health care and must be seen as an input for cost-effectiveness analyses and 
policy measures, among many others. 
3. COl studies can contribute to tbe understanding of major trends in healtb 
expenditure and underlying developments. Until now, tbese insights have 
been limited, but this may improve if data also improve and remain constant 
during a longer period. 
4. CO! studies provide an essential input for projections of future healtb care 
costs. The value of these projections is limited since COI estimates are static, 
but, as tbe understanding of trends improves, it ntight be possible to develop 
more sophisticated scenarios. A first real improvement would be the 
introduction of health care costs in the last year of life. 
9.7 Recommendations 
This tbesis discussed tbe qualities of general CO! studies. We concluded tbat COl 
studies are wortbwhile but tbat tbeir value should not be overrated. We finish witb 
some general recommendations. 
1. CO! studies should distinguish between total healtb expenditure and a smaller 
definition of sectors in which multiple diagnoses are relevant, especially 
including physicians, hospitals, nursing homes and pharmaceutical care. This 
core sector must be defined in line with international standards for a common 
comparable package. As many subsectors as possible should be distinguished 
to allow for tbe adjustment of COl data to tbese standards. 
2. International standards for CO! methodology should be developed. Main 
aspects regard the use of registration data, surveys and expert opinions, as 
well as tbe metbods for weighing inpatient days and otber units of care to 
adjust for differences in resource use among disease categories. Because small 
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methodological differences can have a large impact, data and methods should 
be as similar as possible for the above mentioned core sectors. For other 
sectors, cross-national differences are less problematic. The definition of the 
common comparable package and the harmonisation of data and methods 
should be undertaken by international organisations such as the OECD and 
Eurostat. 
3. National data sources should be improved and a constant quality must be 
guaranteed. Some data sources, however, change their definitions in course of 
time due to changing applications. For other data sources, the quality and the 
coverage in tenns of included persons is not stable over time. Reliable 
comparisons call for constancy in definitions, quality and coverage of data 
constant over a longer period. A problem in this respect is the fact that COl 
studies make extensive use of administrative data, that are not primarily 
collected for scientific research in general, or COI studies in particular. As a 
consequence the data owners have no incentive to collect data for purposes 
beyond their O"wn business. As individual researchers are thus confronted with 
a prisoner's dilemma, we recommend that governments initiate the definition 
of responsibilities for the availability of data that are suitable for health care 
research. In addition governments should provide rules for the use of data at 
reasonable prices. 
4. In the Netherlands it is not possible to combine health care data from 
different sources on individual level, as is the case in, for instance, the 
Scandinavian countries. We recommend the introduction of a unique, 
identifying personal number in health care, comparable with the Dutch sofi~ 
number. Such a number will encourage health care research in general and 
cor studies in particular, and will contribute to a better understanding of 
health status and health care in the population. Of course the privacy of 
patients should be protected, but that is a minor issue regarding the 
technological possibilities. 
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Data and methods used in 
the cost-of-illness study 
for the Netherlands in 1994 A 
147 
This appendix describes the top-down mapping procedure by whicb health care 
costs were assigned to age, sex, and diagnostic group in the cost-of-illness study 
for the Netherlands in 1994 [Polder 1997]. The study was prevalence-based using 
cross-sectional data, and only included direct medical costs. Table A. I presents an 
overview of the data sources and the key variables used. 
Since health care provision is heterogeneous we split up most health care 
sectors into more homogeneous subsectors v.rith accompanying costs. 
Subsequently, total numbers of the key variables considered representative for 
health care use in any sector or subsector were mapped to all combinations of age, 
sex and diagnostic groups. The fraction of a key variable in eacb cell multiplied by 
the total costs of that sector or subsector, was considered to be a reliable estimate 
of the health care costs for that celL 
Hospital costs were split up into nursing costs, costs of medical procedures, 
and costs of outpatient care based on an analysis of Dutch hospital costs [Vrieze 
1995]. Inpatient costs were allocated by the number of bed days and day cases 
from the national hospital registry [LMR 1994]. We could not differentiate 
between (expensive) days in intensive care and other days in hospital. As a result, 
the hospital costs of diagnoses frequently often requiring intensive care vv:ill be 
somewhat underestimated, and vice versa. Distributed costs of medical procedures 
were obtained by national age-, sex- and diagnosis-specific production fignres for 
all interventions [LMR 1994], classified in about 1000 groups, that were weighed 
by the corresponding fees. The Netherlands has a refined fee system for 
remuneration of medical procedures. We combined data on diagnosis- and 
specialism-specific patient referrals in a large sample of general practitioners with 
data on the number of outpatient visits specified by specialism, to break down 
total outpatient hospital costs. 
Costs of psychiatric institutions were allocated by the number of bed days and 
day cases from a national registry [PIGGz 1994]. Costs ofresidencies for 
psychiatric patients were allocated using data on the number of occupants. We 
used contacts by diagnosis, sex and age to map the costs of outpatient psychiatric 
care. 
Costs of nursing homes and medical costs of homes for the elderly were 
allocated by bed days. The total number of bed days was available by age, sex and 
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diagnosis from the national registry of nursing homes, covering 88% of the 
Netherlands [SMS 1994]. 
Costs of several types of institutions for the intellectually disabled and 
physically handicapped were broken down by either days of residency or the 
number of occupants [LRZ 1994]. 
A regional primary care registry was used to allocate costs of general 
practitioners. Information on outpatient paramedical care was available from a 
sample registry of patient contacts. 
Costs of dental care were split into costs of procedures and costs of contacts, 
using data on dental care use from the National Health Survey and remuneration 
fees [CBS 1994]. 
For outpatient midwife and maternity care, an imponant sector in the 
Netherlands where about 30% of the deliveries are at home, age- and sex-specific 
budgets from the Sickness Fund Council were available. 
For ambulance services we used a regional registry of transports including 
diagnostic information. For household care sex- and age-specific national budgets 
from the Sickness Fund Council, the supervising agency of public health insurance, 
were used in combination with sample data on client contacts. Diagnosis-specific 
information was not available for this type of home care. Costs of home nursing 
care were allocated using diagnosis-specific contact data. 
To map outpatient medication costs, a database of prescriptions by a 
representative and large sample of general practitioners, containing both diagnosis 
and Anatomical Therapeutical Chemical (ATC) classification of the prescribed 
product, related national costs for outpatient medication, available by ATC-code, 
age and sex, to diagnostic groups [GIP 1994]. 
National costs for aids and appliances (including insulin injections and 
incontinence material) were related to the prevalence of diseases and disabilities 
for which these appliances are relevant. 
Costs for health care administration, of which only a small proportion could be 
attributed to diagnostic groups, were assumed to be proportionally distributed 
over age- and sex-categories. 
Table A.l Survey of used data sources and an assessment of their informative value, and of the key variables used to break down costs, 
by health care sector 
Health care sector Data source Type* Year Data availability ** Key variable 
Type of expenditure 
diagnosis age I sex 
Hospital care 
Nursing care National hospital registry (LMR), Health C, N 1994 + + bed days 
Care Information Centre (SIG) 
Day care LMR (SIG) C, N 1994 + + day cases 
Inpatient medical procedures L~1R (SIG) C,N 1994 + + medical procedures 
weighed by fees 
Outpatient treatment National Information system for hospital C,N 1994 + specialism-specific 
outpatient care (POLIS) (SIG) outpatient visits 
National Institute for Research on I, S 1987-88 + + specialism-specific 
Primary Care (NIVEL) referrals of general 
practitioners 
Specialised Institutions LMR (SIG) C,N 1994 ± + bed days 
National Information system for C,N 1994 + + bed days 
rehabilitative care (LIVRE), National 
Hospital Institute (NZI) 
Psychiatric care 
Inpatient psychiatric care National Information system for C,N 1994 + + days of stay and 
psychiatric care (PIGGz) (SIG) number of short stays 
National Association for Protective I, N 1994 + number of occupants 
Residencies (NVBW) 
Outpatient psychiatric care National Association of Outpatient Y, N 1994 + number of patients 
Psychiatric Care (NVAGG) 
IMTA{Trlmbos-lnstltute: research I, S 1992 -93 + ± patient visits 
survey 
Table A.l <continued> 
Health care sector Data source Type* Year Data availablllty ** Key variable 
Type of expenditure 
diagnosis age I sex 
Care for the addicted National Information system for care for C, N 1994 + + contact hours 
the addicted (LADIS) (SIG) 
Care for the elderly 
Nursing homes Nursing homes Information system c, y 1994 + + days of stay 
(SIVIS) (SIG) 
Homes for the elderly Statistics Netherlands (CBS) Y, N 1994 + number of occupants 
Nursing homes Information system C,Y 1994 + + days of stay 
(SIVIS) (SIG) 
Care for disabled people 
Institutions for mentally disabled National registration of services for C,N 1994 + + days of stay 
mentally retarded (LRZ) (NZI) 
Institutions for sensory disabled Central Accountancy for special health C,N 1994 ± + age/sex-specrnc total 
care costs (CAK/AWBZ) costs 
other care for people with Dutch Federation of care for physically Y, S 1994 ± + number of occupants 
disabilities handicapped (NFVLG) 
Fiadt-Wdt Y, S 1994 + + number of occupants 
Somma Y, S 1994 + ± number of clients 
Primary care 
General practitioners Regional Network Gronlngen (RNG) C,R 1994 + + patient complaints 
Consumer Safety Institute C,S 1994 + + emergency department 
visits 
Paramedical care (physical NIVEL I, S 1989 -94 + + consultations 
therapists, logopedians) 
Table A.l <continued> 
Health care sector Data source Type* Year Data availability ** Key variable 
Type of expenditure 
diagnosis age I sex 
Dental care Statistics Netherlands (CBS) Y, S 1994 + + consultations and 
procedures 
Midwives and maternity care Sickness Fund Council Y, N 1994 + + agejsex specific budgets 
Social services SYM8IOSE Y, S 1994 + consultations 
Ambulance transport Community health department (GGD), C,R 1994 + + transportations 
Dordrecht region 
other patient transport Sickness Fund Council Y, N 1994 + age/sex-specific budgets 
Home care Sickness Fund Council I, N 1995 + age/sex-specific budgets 
- household care Study survey I, S 1994 -95 + contact hours 
- home nursing care National Union home nursing (NKV) Y, S 1988 + + patient contacts 
- Intensive home nursing care Sickness Fund Council C,N 1994 ± + reimbursements 
Pharmaceuticals, appliances 
Pharmaceutical care Pharmaceuticals Information Project c,s 1994 + national costs per 
(GIP), Sickness Fund Council ATC-code 
NIVEL I, s 1987 -88 + + diagnosis-specific . 
prescriptions by general 
practitioners 
Appliances Sickness Fund Council C, N 1994 national costs by type of 
appliance 
Statistics Netherlands (CBS) I, S 1987 -88 ± + prevalence of disabilities, 
diabetes and chronic 
pulmonary disease 
TableA.l <continued> 
Health care sector 
Type of expenditure 
Public health 
Breast cancer screening 
programme 
Public health Institutions 
(a.o. child preventive care) 
Administration 
Health care administration and 
other costs 
• Datasource 
.. Data availability 
c 
I 
y 
N 
R 
s 
+ 
± 
Data source 
National evaluation team breast cancer 
screening (LETB) 
Statistics Netherlands (CBS) 
Statistics Netherlands (CBS} 
continuous registration 
incidental registration 
yearly registration 
national registration 
regional registration 
sample registration 
available 
partially available 
not available 
I!. a. 110t applicable 
Type* Year Data avallablllty ** 
diagnosis age I sex 
C, N 1994 + + 
C, N 1994 + 
C, N 1994 n.a. + 
Key variable 
·attendance rate 
population In young age 
groups and 
general population 
general population 
Table B.l 
Detailed results from the 
cost-of-illness study for 
the Netherlands in 1994 B 
Diagnostic groups in the Dutch cost-of-illness study for 1994. 
153 
Operationalisation in the International Classification of Diseases (9th edition~ 
ICD-9). Total costs in US$ and share of each group in total costs. Share of age 
and sex groups within each diagnostic group. 
ICD chapters !CD·9 Health care costs Share(%) Share(%) 
Disease categories US$ 1 min"' age groups men I 
(share ·m %) 0·24/·64/65+ women 
I. Infectious diseases 001-139 426 (1.3) 33/45/22 46/54 
AIDS en HIV-Infections 042-044 15 (0.0) 14/80/6 73/27 
Other Infectious diseases 411 (1.3) 33/77/23 45/55 
II. Neoplasms 140-239 1,283 (3.9) 3/42/55 44/56 
Oesophagus 150 24 (0.1) 0/32/68 64/36 
Stomach 151 43 (0.1) 0/25/75 57/43 
Colon and rectum 153·154 132 (0.4) 0/25/75 46/54 
Pancreas 157 26 (0.1) 0/28/72 42/58 
Trachea, bronchus & lung 162 123 (0.4) 0/36/64 79/21 
Female breast 174 139 (0.4) 0/51/49 0/100 
Prostate 185 66 (0.2) 0/15/85 100/0 
Lymphoma 200·208 85 (0.3) 11/40/49 50/50 
Benign neoplasms 173, 210-39 237 (0.7) 8/67/25 28/72 
Other neoplasms 408 (1.2) 3/40/57 44/56 
III. Endocrine diseases 240·279 609 (1.9) 5/35/60 33/67 
Diabetes mellitus 250 403 (1.2) 3/33/64 35/65 
Other endocrine diseases 206 (0.6) 9/37/54 27/73 
IV. Diseases of the blood 2$0·289 104 (0.3) 12/30/5$ 39/61 
V. Mental disorders 290·319 7,543 (23.1) 16/51/33 44/56 
Dementia 290 1,818 (5.6) 0/2/98 21/79 
Schizophrenia 295 460 (1.4) 18/77/6 60/40 
Affective psychoses 296,300 740 (2.3) 9/67/23 32/68 
Alcohol and drugs 291·2, 303·5 267 (0.8) 9/81/9 72/28 
Mental retardation 317·9, 758.0 2,632 (8.1) 26/68/6 56/44 
Other mental disorders 1,626 (5.0) 24/57/19 44/56 
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Table B.l <continued> 
ICD chapters !CD-9 Health care costs Share(%) Share(%) 
Disease categories US$ 1 min* age groups men I 
(share In %) 0-24/-64/65+ women 
VI. Nervous system 320-389 1,709 (5.2) 23/36/42 45/55 
Parkinson's disease 332 159 (0.5) 0/9/91 42/58 
Multiple sclerosis 340 86 (0.3) 1/67/32 37/63 
Ep!lepsy 345 167 (0.5) 52/37/11 53/47 
Disorders of the eye 360-379 547 (1. 7) 17/32/51 40/60 
Disorders of the ear 380-389 362 (1.1) 47/33/21 53/47 
Other nervous diseases 388 (1.2) 10/47/44 43/57 
VII. Circulatory system 390-459 3,414 (10.5) 1/31/69 47/53 
Hypertension 401-405 412 (1.3) 0/48/52 41/59 
Coronary heart disease 410-414 814 (2.5) 0/46/54 65/35 
Heart failure 428-429 355 (1.1) 0/9/91 40/60 
Stroke 430-438 1,054 (3.2) 0/13/87 38/62 
other circulatory diseases 779 (2.4) 2/39/59 49/51 
VIII. Respiratory system 460·519 1,320 (4.0) 23/35/42 54/46 
Acute respiratory infections 460-6, 480-7 395 (1.2) 32/39/30 52/48 
Asthma and COPD 490-496 568 (1. 7) 14/36/50 58/42 
Other respiratory diseases 357 (1.1) 27/30/43 49/51 
IX. Digestive system 520-579 2,559 (7.8) 14/59/27 47/53 
Dental abnormalities 520-529 1,385 (4.2) 19/67/15 47/53 
Gastric and peptic ulcer 531-534 207 (0.6) 1/55/44 51/49 
Appendicitis 540-543 58 (0.2) 45/45/11 47/53 
Inguinal hernia 550-553 133 (0.4) 12/46/41 67/33 
Other gastrointestinal dis. 555-569 229 (0.7) 12/45/43 42/58 
Diseases of liver and gall 570-576 154 (0.5) 3/55/42 39/61 
Other digestive diseases 393 (1.2) 8/46/46 44/56 
X. Genitourinary system 580-599 920 (2.8) 10/55/35 33/67 
Nephritis nephrotic 580-589 47 (0.1) 10/47/43 54/46 
syndrome 
Infections of kidney and 590,595, 104 (0.3) 14/36/50 30/70 
urinary tract 597,599.0 
Other genitourinary 287 (0.9) 9/43/47 42/58 
Hyperplasia of prostate 600 69 (0.2) 0/21/79 100/0 
Male genital organs 601-608 52 (0.2) 31/49/21 100/0 
Female genital organs 610-627, 629 330 (1.0) 10/76/14 0/100 
Infertility 628 32 (0.1) 7/93/0 8/92 
XI. Pregnancy, child birth 630-676 840 (2.6) 22/78/0 0/100 
XII. Diseases of the skin 680-709 535 (1.6) 20/50/30 41/59 
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Table B.1 <continued> 
ICD chapters ICD-9 Health care costs Share(%) Share(%) 
Disease categories US$ 1 min'* age groups men I 
(share In%) 0-24/-64/65+ women 
XIII. Musculoskeletal dis. 710-739 1,948 (6.0) 8/54/38 37/63 
Rheumatoid arthritis 714 177 (0.5) 2/39/59 23/77 
Diseases of back 720-724 618 (1.9) 6/74/20 45/55 
Other musculoskeletal 1,154 (3.5) 10/46/44 35/65 
XIV. Congenital 740-759 ui8 (O.S) 58/37/6 SO/SO 
abnormalities minus 758.0 
XV. Perinatal diseases 760-779 18S (0.6) 100/0/0 53/47 
XVI. Symptoms, 780-799 1,581 (4.8) 16/46/38 39/61 
ill-defined conditions 
XVII. Injury and E800-E999 1,384 (4.2) 16/32/S2 40/60 
poisoning 
Traffic accidents ES00-848, 222 (0.7) 32/43/25 57/43 
E929.0-l 
Other accidents E850-869, 185 (0.6) 31/46/22 59/41 
E890-928, 
E929.2/4-9 
E970-999 
Falls ESS0-888, 638 (2.0) 9/17/74 27/73 
E929.3 
Complications, violence E950-959, 339 (1.0) 10/46/44 41/59 
and suicide E960-969 
E870-879, 
E930-949 
Not allocated 2,661 (8.1) 20/3S/4S 36/64 
Non-specific 3A83 (10.7) 15/27/57 35/65 
Total health care costs 32,672 (100.0) 15/43/42 41/59 
*Exchange rate (1994): US$ 1 =f 1.82 (US$ =£0.83) 
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Summary 
Cost of illness in the Netherlands: 
description, comparison and projection 
Introduction 
157 
Health economics is an emerging discipline. Much attention has been paid to the 
economic evaluation of health care facilities, but cost~of-illness (COl) studies have 
also gained recognition since the pioneering work of Dorothy Rice. Several types 
of COI studies can be distinguished. Disease-specific studies estimate costs for a 
particular disease mosdy based on a bottom-up method and sometimes including 
indirect morbidity and mortality" costs. General COl studies focus on the national 
health care budget and how it is related to the prevalence of a~l diseases clustered 
in categories. This thesis deals with general COl studies. Our objectives are: 
L To explain the construction, application and interpretation of general cost-of-
illness studies; 
2. To discuss the advantages and limitations of general cost-of-illness studies 
"With respect to the objectives of description, comparison and projection. 
Cost ofiltness in the Netherlands 1994 
We performed a general CO! study for the Netherlands in 1994. Total health 
expenditure, amounting 60 billion Dutch guilders, was allocated to diagnostic 
groups and simultaneously to age and sex. A cross-sectional, top-down 
methodology was used in which key variables such as nursing days and 
ambulatory care visits represented equal units of care. Information on health care 
use was obtained from all health care sectors of the Netherlands, for the most 
important (hospitals, nursing homes, inpatient psychiatric care, institutions for the 
mentally disabled people) of which national registries were available. 
Health care costs were strongly age dependent. After the first year of life, costs 
per person for children were lowest. Costs rose slowly throughout adult life and 
increased exponentially from age 50 onwards till the oldest age group (95;,:). The 
top five areas of health care costs were mental retardation, musculoskeletal 
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disease (predominantly joint disease and dorsopathy), dementia, a heterogeneous 
group of other mental disorders, and ill-defined conditions. Stroke, all cancers 
combined, and coronary hean disease ranked 7, 8 and 10, respectively. Thus, old 
age and disabling conditions rather than the major causes of death were the main 
determinants of health expenditure in the Netherlands. 
Developments between 1988 and 1994 
Between 1988 and 1994, health care costs increased by an average rate of 5.2% 
per year. Wage and price developments were responsible for about a half of these 
rising costs; other causes were demographic changes (a quarter) and other factors 
including epidemiological cbange and technological innovations (another 
quaner). 
Health expenditure increased steeply for dementia, AIDS and HN infections, 
perinatal conditions, coronary heart diseases, diseases of the respiratory system, 
stroke and colorectal cancer. Relatively little to no increase, in some cases even a 
decline, was seen in the costs of diseases of the female genitals, blood diseases, 
appendicitis, traffic accidents, eye disorders and inguinal hernias. 
The cost development could be clarified for several diagnostic groups, e.g. the 
rising costs of dementia may be ascribed to the ageing population, of coronary 
hean diseases to the increased number of cardiac operations and coronary 
angioplasty procedures performed. In the case of other diagnostic groups, 
including that of diseases of the female genital tract and that of eye disorders, no 
clear explanation for the development in costs was available without further 
research. 
Trends in Dutch health care costs 
Health care costs have many determinants: demographic, epidemiological, 
teclmological and economic. Reliable detailed forecasts of future health care costs 
are not feasible. Using cost-of-illness data for the Netherlands, population 
forecasts and cost developments from the past, a rather robust projection of future 
healtb expenditure could be made. According to this projection Dutcb health care 
costs will increase in future decades by an annual rate of 2.4%, a pan from general 
inflation. This projected cost increase consists of increasing health care use due to 
demographic cbange (0.9 -1.0%) and developments in epidemiology and 
teclmology (1.1-1.2%) and of price and wage developments in health care which 
exceed general inflation by 0.3%. 
Age-specific increases in health care costs 
The distribution of health care costs per capita depends strongly on age. We 
demonstrated age·specific trends in health expenditure for the Netherlands. For 
1988-1994 we observed a growth rate for acute care that increased by age and 
was compensated by a decreasing rate for long-term care. A kind of balancing 
effect thus resulted in an average growth rate that was nearly stable for all ages. 
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These age-specific trends reflected the influence of technological change in 
surgery. Day-care treatment became increasingly common for younger people, 
while among the elderly the age boundaries for treatment shifted upwards. There 
was also an influence of governmental health care policies. During the observed 
period, large investments in institutionalised care for the elderly were withheld, 
while backlogs in psychiatric care and institutions for the disabled were eliminated 
by additional investments. Our analysis indicated that long-term care was more 
sensible for cost-containment policies than acute care. 
We concluded that ageing as well as technological and epidemiological 
changes reinforced the age pattern in health care costs. Health care costs not only 
expanded but also shifted from younger to older ages and from care to cure. 
Costs of intellectual disability 
Mental disorders in general and intellectual disability in particular represent a 
large share in the expenditure on health care in civilised countries. In the 
Netherlands, 25.8% of total disease-specific costs in 1994 could be ascribed to 
mental disorders (psychiatric conditions, intellectual disability, and dementia). 
There were large differences betvveen age~sex groups. Costs of intellectual 
disability and schizophrenia were higher among men; costs of dementia and 
depression were higher among women. The age pattern showed two peaks. The 
first at age 25- 35 (intellectual disability and psychiatric conditions), the second 
at age 75-85 (dementia). Demographic projections suggested a less than average 
cost increase for intellectual disability and psychiatric diseases (annual growth 
rate of 0.2% and 0.4% respectively) compared to the costs of dementia and total 
health care (annual rate of 1.6% and 0.9% respectively). Expenditure on 
intellectual disability, however, is likely to increase more sharply than 
demographic projections suggest because life expectancy of the disabled continues 
to rise. 
Costs after hip fracture 
It is widely assumed that health care costs can be reduced considerably by 
providing care in appropriate health care institutions without unnecessar:y 
technological overhead. This assumption has been tested in a prospective study. 
Conventional discharge after hip fracture surgery was compared with an early 
discharge policy in which patients were discharged to a nursing home with 
specialised facilities for rehabilitation. We compared costs for both strategies from 
a societal perspective, using comprehensive and detailed data on type of residence 
and all kinds of medical consumption during a 4-month follow-up period. 
As expected, early discharge reduced the length of hospital stay. More patients 
were discharged to a nursing home (76% versus 53%). Total medical costs during 
follow-up-were reduced by€ 1,057, representing small and not significant savings. 
There were two explanations for this unexpected result. First, hip fracture patients 
are relatively cheap whlle in hospital. Hence nursing home costs almost equalled 
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hospital costs per admission day. Second, compared to the conventionally 
discharged group, early discharged patients underwent more medical procedures 
during the first post-operative days. We concluded that: 1) early discharge shifted 
rather than reduced costs; 2) the details of costing have a major influence on the 
cost-effectiveness of alternative discharge policies. 
A cross-national perspective on cost of illness 
Since 1998, the OECD Health Data have included figures on cost of illness. The 
large differences between counnies are striking. We recalculated the CO! 
estimates for six countries using the original research reports in order to construct 
a comparable dataset and to explain some of the differences. The following 
countries were included: Australia, Canada, England, Germany, Netherlands and 
Sweden. The distribution of health care costs over major disease categories 
showed similar patterns for all countries as well as some remarkable differences-
that were mainly caused by health care systems. Comparisons for hospitals and 
pharmaceutical care showed differences that could in pan be related to 
epidemiological and methodological factors. 
At present, the scope of COr studies is virtually limited to national levels, 
because health care systems dominate the magnitude and distribution of health 
care costs. Cross-national comparisons might be possible if data and methods are 
standardised and CO! estimates are made for a common comparable package. 
Discussion 
In health economics literature the meaning and value of cost-of-illness studies 
have been debated. Opponents stated that CO! studies are based on a 
misunderstanding of economic cost and have no policy relevance since they do not 
study cost-benefit-ratios. Other critics have pointed at the scope for 
misunderstanding of CO! figures and the risk of high costs diverting the attention 
of policy-makers from diseases with low costs, which might have important aspects 
other than costs. 
Advocates of cor studies have argued that these studies are not aimed at 
policy-making, but must be seen as policy-relevant in that they can educate, 
inform and enlighten policy-makers. The major value of COl studies is that they 
provide a simple indication of the burden of disease (BOD) that covers the whole 
spectrum of diseases and is complementary to other BOD-estimates. The 
availability of more CO! studies will further allow for studying time-trends and 
cross-national differences. 
We concluded that CO! studies say nothing about: 1) the value of money 
invested in health care; 2) whether or not more resources should be devoted to 
treating specific diseases; 3) whether or not more resources should be devoted to 
particular areas of medical research; 4) the total burden of disease. Despite these 
shortcomings, CO! studies have their own worth and provide a suitable framework 
for studying health expenditure ftom an epidemiological and demographic 
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perspective. Obviously, improvements can be made. Methods must be refined and 
standardised. It is also important that the availability of good quality data is 
guaranteed for a longer period of time. From a cross-national perspective the 
harmonisation of CO! figures with a common comparable package should be 
recommended. 
Conclusions 
1. COI studies have, first and foremost, a national scope. In the future, however, 
cross-national comparisons might be possible and will reveal interesting 
insights if methods are standardised and the estimates regard a common 
comparable package. 
2. cor studies disclose interesting information complementary to burden-of-
disease estimates based on epidemiological criteria. The significance of COT 
figures mainly concerns the framework they provide for health care research 
and health care policy. They do not provide, however, simple criteria for 
decision making on the allocation of health care resources, research funds or 
whatever decisions can be made. They provide a comprehensive insight into 
health care and must be seen as input for cost-effectiveness analyses and policy 
measures among many others. 
3. cor studies can contribute to the understanding of major trends in health 
expenditure and underlying developments. Until now these insights have been 
limited but these might improve as data also improve and remain constant 
over a longer period. 
4. cor studies provide essential input for projections of future health care costs. 
The significance of these projections is limited since COl estimates are static, 
but, as the understanding of trends improves, it might be possible to develop 
more sophisticated scenarios. A first real improvement would be the 
introduction of health care costs in the last year of life. 
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Samenvatting 
Kosten van ziekten in Nederland: 
beschrijving, vergelijking en projectie 
Inleiding 
163 
De gezondheidseconomie is sterk in ontwikkeling. Veel aandacht wordt 
geschonken aan de econornische evaluatie van gezondheidszorgvoorzieningen 
binnen het vakgebied van de Medical Technology Assessment (MTA). Sinds het 
baanbrekende werk van Dorothy Rice in de jaren zestig zijn er binnen de 
gezondheidseconomie ook verschillende kosten-van-ziekten (KVZ) studies 
gepubliceerd. Er kan onderscheid worden gemaakt tussen studies die zich op een 
specifieke ziekte richten en studies die het gehele domein van alle ziekten 
beschrijven. Deze generieke KVZ studies nemen het nationale zorgbudget als 
uitgangspunt en beschrijven hoe de kosten zijn verdeeld over ziektecategorieen, 
leeftijd en geslacht. Dit proefschrift gaat over generieke KVZ studies en de manier 
waarop deze de kosten van de gezondheidszorg beschrijven, vergelijken en 
projecteren. Dit proefschrift beoogt: 
1. Toe te lichten hoe generieke kosten-van-ziekten studies worden gemaakt, 
toegepast en gelnterpreteerd; 
2. Inzicht te geven in de voordelen en beperkingen van generieke kosten-van-
ziekten studies gelet op de doelstellingen van beschrijving, vergelijking en 
projectie. 
Alle hoofdstukken in dit proefschrift zijn gebaseerd op het onderzoek 'Kosten van 
ziekten in Nederland 1994', met uitzondering van hoofdstuk 7 over de kosten van 
patienten met een heupfractuur. Dat hoofdstuk is gebaseerd op een MTA studie 
naar de kosten en effecten van alternatieve procedures voor ontslag uit het 
ziekenhuis na een heupoperatie. 
164 Cost of illness in the Netherlands 
Kosten van ziekten in Nederland 1994 
De kosten van de Nederlandse gezondheidszorg die in 1994 ongeveer 60 miljard 
gulden bedroegen, werden toegewezen aan een zestigtal diagnosegroepen met een 
simultane uitsplitsing naar leeftijd en geslacht. Deze toewijzing vond plaats 
volgens een top-down methode waarin een groot aantal sleutelvariabelen werd 
gebruikt die elk een vaste zorg- en kosteneenheid vertegenwoordigden. 
Voorbeelden hiervan zijn: verpleegdagen in ziekenhuizen en verpleeghuizen en 
consulten aan de huisarts, de fysiotherapeut en aile andere aanbieders van zorg. 
Gegevens over het zorggebruik werden per sector ingewonnen bij de houders van 
zorgregistraties. Voor de belangrijkste sectoren waren nati.onale gegevens 
beschikbaar met een hoge dekkingsgraad. 
De kosten van gezondheidszorg bleken sterk afhankelijk te zijn van de leeftijd. 
Na het eerste levensjaar waren de kosten laag voor kinderen en jongvolwassenen 
en narnen geleidelijk toe met de leeftijd. Vanaf de leeftijd van 50 jaar stegen de 
kosten steeds sneller tot zij hun maximum bereikten bij de 95-plussers. Het 
grootste deel van de kosten hield verband met zwakzinnigheid, aandoeningen van 
het bewegingsstelsel, dementie, psychiatrische stoornissen en een heterogene 
groep met symptomen en slecht omschreven ziektebeelden. Beroerte, kanker en 
coronaire hartziekten kwamen in rangorde van kosten pas op de zevende, achtste 
en tiende plaats. Uit deze gegevens blijkt dat de kosten van de Nederlandse 
gezondheidszorg vee! meer worden bepaald door ouderdom en chronische, 
invaliderende aandoeningen dan door de belangrijkste doodsoorzaken. 
Ontwikkelingen tussen 1988 en 1994 
In de petiode 1988-1994 stegen de kosten van de Nederlandse gezondheidszorg 
gemiddeld met 5,2% per jaar. De helft van deze stijging kwam voor rekening van 
loon- en prijsontwikkelingen. Daamaast droegen demografische veranderingen bij 
aan de stijging van de kosten, als ook de combinatie van epidemiologische, 
technologische en overige factoren. 
Voor de volgende diagnosegroepen stegen de kosten relatief sterk: dementie, 
AIDS en HIV-infecties, perinatale aandoeningen, coronaire hartziekten, 
aandoeningen van de luchtwegen, beroerte en darmkanker. Een geringe 
kostenstijging of zelfs een daling werd waargenomen voor aandoeningen van de 
vrouwelijke geslachtsorganen, bloedziekten, blindedannontsteking, 
verkeersongevallen, gezichtsstoomissen en buikbreuken. 
De meeste kostenstijgingen kunnen verklaard worden. De stijgende kosten van 
dementie hangen bijvoorbeeld samen met de vergrijzing van de bevolking. Verder 
zijn de kosten van hartziekten gestegen vanwege de toename van kostbare 
interventies als CABG en PTCA. Voor enkele andere diagnosegroepen is echter 
geen sluitende verklaring beschikbaar. Nader onderzoek zal moeten uitvvijzen wat 
de precieze reden van de kostenstijging of -<laling is geweest. Mogelijk hebben 
verschillen tussen databronnen hierbij een rol gespeeld. 
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Trends in de kosten van de Nederlandse gezondheidszorg 
De kosten van de gezondheidszorg worden door meerdere factoren be"invloed: 
demografische, epiderniologische, technologische eri econornische. Zeer 
nauwkeurige voorspellingen van toekornstige zorgkosten zijn niet mogelijk. Wel 
kunnen kosten-van-ziekten gegevens gebruikt worden om een tamelijk robuuste 
schatting te maken. Uitgaande van de bevolkingsprognose en de onrwikkelingen in 
de periode 1988-1994 is een projectie gemaakt voor de zorgkosten in de 
komende decennia. Volgens deze projectie zullen de kosten van de zorg in 
constante prijzen met gemiddeld 2,4% per jaar toenemen. Deze stijging is voor 
ongeveer 1% het gevolg van demografische veranderingen (bevolkingsgroei en 
vergrijzing). De combinatie van epiderniologische, technologische en overige 
factoren zal naar verwachting een groei van ruirn 1% veroorzaken. Het resterende 
dee! (0,3%) vloeit voort uit de Wet van Baumol die zegr dat de lonen en prijzen in 
de gezondheidszorg verhoudingsgewijs sterker stijgen dan in de rest van de 
economie. 
Leeftijdspeci.fieke kostertStijgingen in de gezondheidszorg 
Niet aileen de verdeling van de zorgkosten is sterk afhankelijk van de leeftijd, 
maar ook de kostenstijging. In de periode 1988-1994 stegen de gerniddelde 
kosten per inwoner van Nederland in absolute zin het meest voor de 
leeftijdsgroepen met de hoogste kosten. De groeivoet bleek echter voor alle 
leeftijden min of meer gelijk te zijn, waarbij zich een opmerkelijk verschil 
voordeed tussen de curatieve zorg en de chronische zorg. De groeivoet van de 
curatieve zorg was laag voor jongeren en nam met de leeftijd toe. Voor chronische 
zorg gold het omgekeerde. 
Deze trends waren onder meer het gevolg van veranderingen in het 
zorgaanbod. Gewezen kan worden op de toename van dagbehandeling vooral 
onder jongeren, en het oprekken van het indicatiegebied en van leeftijdsgrenzen 
voor bepaalde operaties bij ouderen. Daarnaast werden deze trends sterk 
be!nvloed door het gezondheidszorgbeleid. In deze periode hebben met name in 
de gehandicaptenzorg additionele investeringen plaatsgevonden, met als gevolg 
de hoge groeivoet voor chronische zorg bij de jongere leeftijdsgroepen. De 
verschillende trends suggereren dat vooral chronische zorg gevoelig is voor het 
overheidsbeleid, tervvijl de curatieve zorg zich meer volgens de relatief autonome 
ontwikkelingen van epidemiologie en medische technologie ontwikkelt. 
Wij concluderen dat het leeftijdspatroon in de kosten van de gezondheidszorg 
wordt versterkt door demografische, epidemiologische en technologische 
ontwikkelingen. A1s gevolg vindt er een absolute verschuiving plaats van jongeren 
naar ouderen en relatieve verschuiving van chronische naar curatieve zorg. 
Kosten van zwakzinnigheid 
Een groot dee! van de zorgkosten houdt verband met psychische stoornissen. Van 
alle kosten van de Nederlandse gezondheidszorg in 1994 die aan ziekten konden 
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worden toegerekend, had ruim een kvvart te maken met zwakzinnigheid, dementie 
en psychiatrische aandoeningen. Er waren grote verschillen tussen verschillende 
leeftijds- en geslachtsgroepen. De kosten van zwakzinnigheid en schizofrenie 
waren hoger voor mannen, terwijl voor vrouwen de kosten van depressie en 
dementie hoger waren. Het Ieeftijdspatroon venoonde twee pieken. De eerste 
deed zich voor bij de Ieeftijdsgroep 25 - 35 jaar en werd veroorzaakt door hoge 
kosten van zwakzinnigheid en psychiatrische aandoeningen. De tweede piek viel 
in de Ieeftijdsklasse 75- 85 jaar en was geheel het gevolg van hoge kosten voor 
dementie. 
Overeenkomstig demografische projecties zullen de kosten van zwakzinnigheid 
en psychiatrische stoornissen in de toekomst achterblijven bij de algemene 
kostenontwikkeling en de verwachte kostenstijging bij dementie. Dit komt door de 
vergrijzing en ontgroening van de bevolking. Omdat de levensvenvachting van 
mensen met een handicap nog steeds toeneemt, zal de feitelijke 
kostenontwikkeling waarschijnlijk hoger uitvallen dan in de demografische 
projectie wordt voorgesteld. 
Kosten na een heupfractuur 
In het algemeen wordt aangenomen dat de kosten van de gezondheidszorg 
gereduceerd kunnen worden door de juiste zorg op de juiste plaats aan te bieden. 
In een prospectief onderzoek hebben wij deze hypothese onderzocht voor 
patienten met een heupfractuur. De normale ontslagprocedure werd vergeleken 
met een versnelde procedure waarin patienten in een verpleeghuis werden 
gerevalideerd in plaats van in het ziekenhuis. Van beide patientengroepen werden 
de kosten gedetailleerd in kaan gebracht, uitgaande van het maatschappelijk 
perspectief. 
Zoals verwacht daalde de gemiddelde opnameduur aanzienlijk. De gemiddelde 
kosten per patient voor een periode van vier maanden daalden met € 1.057 
hetgeen veel minder was dan vooraf werd verwacht. Er zijn tvvee mogelijke 
verklaringen. In de eerste plaats bleken de ziekenhuiskosten van patienten met 
een heupfractuur verhoudingsgewijs laag te zijn ten opzichte van andere 
patientengroepen in het ziekenhuis. Mede als gevolg van de gedetailleerde 
berekeningsvvijze was er tussen ziekenhuis en verpleeghuis slechts een gering 
verschil in de kosten per verpleegdag. Ten tweede ontvingen de versneld 
ontslagen patienten aanzienlijk meer zorg in de eerste dagen na de operatie in 
vergelijking met de patienten die Ianger in het ziekenhuis bleven. 
Uit deze studie volgr: 1) dat vervroegd ontslag niet altijd tot 
kostenbesparingen hoeft te leiden maar ook een verschuiving in de kosten tot 
gevolg kan hebben; en 2) dat de mate van detail in de kostenschattingen een 
doorslaggevende rol kan spelen bij de beoordeling van de kosten-effectiviteit. 
Samenvatting 167 
Internationale vergelijking van kosten van ziekten 
Sinds 1998 staan er in de OECD Health Data schattingen over de kosten van 
ziekten. Het is opvallend hoezeer de cijfers tussen de verschillende landen 
verschillen. Uitgaande van de originele onderzoeksverslagen hebben wij de KVZ 
schattingen voor zes landen opnieuw berekend teneinde een vergelijkbare dataset 
te construeren en inzicht te krijgen in de belangrijkste internationale verschillen. 
De volgende landen werden in deze vergelijking betrokken: Australie, Canada, 
Duitsland, Engeland, Nederland en Zweden. De grate patronen in kosten van 
ziekten bleken voor de verschillende landen hetzelfde te zijn. Tegelijkertijd waren 
er grate verschillen die voor het grootste deel verband hielden met verschillen in 
de manier waarop de zorg werd georganiseerd en slechts in mindere -mare werden 
veroorzaakt door epiderniologische of demografische factoren. 
Vanwege al deze verschillen hebben KVZ-studie op dit moment vooral een 
nationale betekenis. Intemationale vergelijkingen kunnen zinvol zijn, maar een 
voorwaarde is dat de KVZ schattingen op exact hetzelfde zorgpakket betrekking 
hebben. Verder is standaardisatie van gegevens en methoden een noodzaak om tot 
vergelijkbare cijfers te komen. Verder verdient het aanbeveling om de 
sectorindeling van KVZ studies aan te laten sluiten op intemationale definities van 
een 'common comparable package'. 
Beschouwing 
De betekenis en waarde van KVZ studies zijn uitgebreid besproken in de 
gezondheidseconomische literatuur. Volgens de tegenstanders baseren KVZ studies 
zich op een verkeerd kostenbegrip en hebben zij geen praktische waarde omdat ze 
geen marginale analyse van kosten en effecten toepassen. Anderen hebben 
gewezen op de mogelijke verkeerde interpretaties en het gevaar dat de aandacht 
van beleidsmakers wordt afgeleid van ziekten met !age kosten waar mogelijk we! 
andere belangvvekkende aspecten aan vast zitten. 
Volgens de voorstanders zijn KVZ studies primair niet bedoeld voor concrete 
beleidsbeslissingen. Zij moeten veel meer gezien worden als studies met relevantie 
voor het beleid in de zin dat zij beleidsmakers informeren over belangrijke 
aspecten van volksgezondheid en gezondheidszorg. De belangrijkste betekenis van 
KVZ studies is dat zij een eenvoudige benadering van de ziektelast geven die het 
gehele spectrum van aandoeningen omvat, en die bovendien complementair is aan 
andere schattingen van ziektelast zoals incidentie, prevalentie en sterfte. Verder is 
gewezen op de mogelijkheden van vergelijking over de tijd en tussen Ianden 
indien er meerdere KVZ studies beschikbaar zijn. 
Wij concluderen dat KVZ studies: 1) geen inzicht geven in de opbrengst van 
het geld dat in de gezondheidszorg wordt geinvesteerd; 2) niet de informatie 
geven die nodig is voor beslissingen over de allocatie van het zorgbudget, of 3) het 
onderzoeksbudget; en 4) geen schatting geven van de totale ziektelast in de 
bevolking. Dit neemt niet weg dat KVZ studies hun eigen betekenis hebben, en een 
geschikt raamwerk bieden voor de bestudering van de zorgkosten vanuit een 
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epiderniologisch en demografisch gezichtspunt. Uiteraard zijn verbeteringen 
mogelijk. Methoden kunnen verder worden verfijnd en gestandaardiseerd. Ook is 
het van belang dat de benodigde gegevens over langere perioden beschikbaar zijn, 
zonder dat de kwaliteit al te veel flucrueen. Ten behoeve van internationale 
vergelijkingen is het verder wenselijk dat de sectorindelingen in KVZ studies 
worden geharmoniseerd met een intemationaal gestandaardiseerd zorgpakket. 
Conclusies 
1. KVZ studies hebben op dit moment in de eerste plaats een nationale betekenis. 
In de toekomst zullen internationale vergelijkingen ongetwijfeld mogelijk zijn 
en belangwekkende inzichten opleveren. Een vereiste daarvoor is wel dat de 
sectorafbakening en de methoden verder worden gestandaardiseerd. 
2. KVZ studies bieden interessante inzichten die complementair zijn aan andere 
benaderingen van de volksgezondheid die onder meer gebaseerd zijn op 
epiderniologische criteria. De betekenis van KVZ studies bestaat vooral in het 
raamwerk dat zij bieden voor onderzoekers en beleidsmakers binnen de 
gezondheidszorg. Zij bieden echter geen simpele criteria voor besluitvorming 
over de aanwending van het zorgbudget of van onderzoeksgelden. Zij geven 
wel een samenhangend en samenvattend inzicht in de volksgezondheidszorg 
en kunnen gezien worden als een 'input' voor onder meer economisch 
evaluatieonderzoek in de gezondheidszorg. 
3. KVZ studies kunnen inzicht geven in de belangrijke trends in de kosten van de 
gezondheidszorg en de achterliggende factoren. Op dit moment zijn deze 
inzichten beperkt, maar reele verbeteringen zijn mogelijk wanneer de kvvaliteit 
van de gegevens beter wordt en over een langere periode constant blijft. 
4. KVZ studies bieden essentiele informatie voor ramingen van toekomstige 
zorgkosten. De betekenis van deze ramingen moet echter niet worden 
overschat, omdat de KVZ gegevens een statisch karakter hebben. Wanneer het 
inzicht in de historische trends toeneemt moet het echter mogelijk zijn om 
meer realistische scenario's te ontwerpen. Een eerste belangrijke verbetering 
zou zijn om de kosten in het laatste levensjaar te onderscheiden van de kosten 
van de overige patienten en afzonderlijk mee te nemen in de projectie van de 
toekomstige zorgkosten. 
Sa men vatting 169 
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n; i 
In Western countries every year a lot of money is spent on health care. This 
thesis describes how health expenditure can be assigned to epidemiological 
and demographic variables. It is demonstrated that the main health care costs 
relate to old age and chronic disabling conditions, rather than the major 
causes of death. 
Comparisons over time reveal interesting trends, and more detailed analyses 
of specific diseases throw a new light on the cost-of-illness debate. From a 
cross-national perspective the meaning of cost-of-illness studies seems rather 
limited, but standardisation might improve the international comparability. 
It is concluded that cost-of-illness studies are worthwhile because they 
provide a single estimate of the burden of disease and offer a framework for 
more sophisticated analyses. Cost-of-illness studies can also be used for the 
assessment of major trends and for the projection of future health 
expenditure. 
